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ABSTRACT
The complete nucleotide sequence of four regions of DiGeorge Sydrome Critical 
Region in human chromosome 22, band ql 1, totally 482 kb, has been determined by 
sequencing an overlapping set of cosmid genomic clones that have been mapped to these 
regions. The sequencing strategy involved a modified diatomaceous earth-based large 
scale DNA isolation procedure to obtain the genomic cosmid clone, physical shearing of 
the clones by nebulization to generate randomly distributed DNA fragments, subcloning 
the end-repaired, kinased and size-selected DNA fragments into pUC-based vectors to 
get chimeric subclones. The chimeric subclones then were isolated using a modified 
alkaline lysis procedure manually or automatically on a Beckman® Biomek 2000 robotic 
workstation. Cycling Sequencing reactions were performed using dye-labeled primer or 
terminator chemistry, and loaded on an ABI® 377 DNA sequencer for automated sample 
electrophoresis, detection, data collection and base calling. The ABI-called shotgun 
sequences were transferred to Sun® SPARCstation and then edited, assembled and 
proofread by using several available editing and assembly programs. The final 
contiguous sequence in each regain was analyzed for features such as potential 
promoters, potential coding regions, repeated elements and database homology using 
XGrail and Powerblast.
From the data collected, part of the genomic sequence of the human clathrin 
heavy chain like gene (CLTCL), entire genomic sequence of the human homolog of yeast 
repressors of histone gene transcription HIRl and HIR2 (HIRA), the human ubiquitin- 
fusion degradation protein 1-like gene (UFDIL), the human homolog of mouse TIO 
gene, and a putative transmembrane gene were revealed. CLTCL may be involved in 
endocytosis. HIRA may be a negative regulator of core histone gene transcription. 
UFDIL may be involved in protein degradation. The TIO gene and the putative
XVII
transmembrane gene have no homoiog to any known functional genes in the database. 
The sequence of this approximate 0.5 mb of human genomic sequence reveals a gene 
density of slightly more than one gene per 100 kb with numerous ESTs and an extensive 
amoimt of repeat sequences. In addition, a ribosomal protein L34 pseudogene and a 
human Tigger 1-like transposon were reported. Different families of interspersed 
repetitive elements and their contents also were determined. The total content of these 
repetitive elements in these region is about 32%. The comparison of two 36 kb 
fragments of human genomic sequences fix>m two individuals revealed a overall 
difference of 0.2%. A fragment of 90 kb of mouse genomic sequence syntenic to human 
HIRA gene also was sequenced and compared with human sequence. Although the 
coding regions of the human and mouse HIRA gene are almost identical and the genomic 
sequence level similarity between these two genes is low, their genomic organization is 
similar.
xvm
Chapter I 
Introduction
1 .1  DiGeorge syndrome
1 .1 .1  History and nomenclature
The original description of DiGeorge syndrome was presented in a published 
discussion at an immunology meeting 1  ^and DiGeorge published a formal report 
three years later. A report by Strong PI predated this formal report and probably 
represented the same variable disorder and since DiGeorge syndrome overlaps clinically 
with the disorder described by the Japanese as "conotruncal anomaly face syndrome" 
[4.5.6] jt would be appropriate to use Takao syndrome for those cases with cardiac 
defects in contrast to the low T cell and hypocalcémie levels in DiGeorge syndrome and 
the craitiofacial and palatal abnormalities typical of Shprintzen syndrome. Because all 
three phenotypes have been shown to have a 22ql 1 deletion, Wilson et al. proposed 
the acronym CATCH22 (Cardiac Abnormality/abnormal facies, T cell deficit due to 
thymic hypoplasia. Cleft palate. Hypocalcemia due to hypoparathyroidism resulting 
from 22q 11 deletion) as a collective acronym for those with this common genetic 
etiology. Shprintzen 1*1 objected to lumping velocardiofacial syndrome with the 
DiGeorge anomaly, arguing that there was no valid evidence to suggest that 
velocardiofacial syndrome was etiologically heterogeneous whereas the DiGeorge 
anomaly was known to be so, but Hall 1^1 cited data of Driscoll et al. HOl indicating that 
velocardiofacial syndrome was etiologically heterogeneous.
1.1.2 Description and clinical features
The major symptoms of DiGeorge syndrome are hypocalcemia arising from 
parathyroid hypoplasia, thymic hypoplasia, and outflow tract defects of the heart, 
Disturbance of cervical neural crest migration into the derivatives of the pharyngeal 
arches and pouches has been proposed to account for the phenotype, which in most 
cases, results from a deletion of chromosome 22ql 1 . lo. 14. is, 22,24.25] "pyjs 
deletion also may have a variety of phenotypes; Shprintzen syndrome, conotruncal 
anomaly face (or Takao) syndrome, and isolated outflow tract defects of the heart,
A small number of cases of DiGeorge syndrome have defects in other chromosome, 
notably 10pl3 and in the mouse, a transgenic hox-1.5 knockout produces a phenotype 
similar to DiGeorge syndrome as do the tetratogens retinoic acid and alcohol. [^ 1
DiGeorge syndrome is clinically characterized by neonatal hypocalcemia, which 
may result in tetany or seisures, due to hypoplasia of the parathyroid glands, and 
susceptibility to infection due to a deficit of T cells. The immune deficit is caused by 
hypoplasia or aplasia of the thymus gland. A variety of cardiac malformations also are 
seen, in particular, those affecting the outflow tract. These include tetralogy of Fallot, 
type B interrupted aortic arch, truncus arteriosus, right aortic arch and aberrant right 
subclavian artery, in infancy, micrognathia may be present and the ears are typically 
low set and deficient in the vertical diameter with abnormal folding of the pinna. 
Telecanthus with short palpebral fissures also is seen and both upward and downward 
slanting eyes have been described. The philtrum is short and the mouth relatively 
small. In older children the features overlap Shprintzen syndrome with a rather 
bulbous nose and square nasal tip and hypemasal speech associated with submocous or 
overt palatal clefting. Cases presenting later tend to have a milder spectrum of cardiac 
defect with ventricular septal defect being common, 11-25]
Short stature and variable mfld-to-moderate learning difficulties are common in 
patients with DiGeorge syndrome and a variety of psychiatric disorders have been 
described in a small proportion of adult cases of velocardiofacial syndrome. These 
have included paranoid schizophrenia and major depressive illness. Clinical features 
seen more rarely include hypothyroidism, cleft lip, and deaffiess. 1^  23]
1.1 .3  Genetics of DiGeorge syndrome
1 .1 .3 .1  Inheritance
DiGeorge Syndrome is usually sporadic and results mainly from de novo 22 
deletion. A long series of reports has recognized the variable features resulting from 
this deletion in multiple family members with the variable phenotype behaving as an 
autosomal dominant trait H?» 22-26] Stevens et al. [26] suggested that such familial 
cases should be regarded as being velocardiofacial syndrome. The variable phenotype 
was described by Strong [31 prior to the recognition of DiGeorge syndrome. The 
mother of that family developed a psychotic illness. The first dominant pedigree in 
which marked clinical variability was associated with dominant transmission of a 22ql 1 
deletion was reported by Wilson et al. The mother bad the typical dysmorphic 
features and of her three affected children, one had coarctation of the aorta, one a 
ventricular septal defect, and one DiGeorge syndrome. Wilson et al. [22] also found 
five of nine families with familial outflow tract defects to have 22ql 1 deletion. Subtle 
dysmorphic features typical of those seen in DiGeorge syndrome were apparent in 
several of these affected family members.
1 .1 .3 .2  Cytogenetics
De la Chapelle et al. 1^ 1 suggested that DiGeorge syndrome may be due to a 
deletion within chromosome 22 or partial duplication of chromosome 20 p arm, based 
on finding the syndrome in members of a family with a 20;22 translocation. 
Specifically, they observed DiGeorge syndrome in four members of one family and 
demonstrated monosomy of 22pter-ql 1 and 20p duplication. They also mentioned a 
patient previously reported briefly by Rosenthal et al. l^ l^ with complete monosomy 22 
and DiGeorge syndrome. Their interpretation that DiGeorge syndrome might result 
from monosomy for 22qll was confirmed by Kelley et al. l^ o] in three patients with 
translocation of 22ql 1-qter to other chromosomes.
Greenberg et al. PH observed partial monosomy due to an unbalanced 4;22 
translocation in a two-month-old male with type I truncus arteriosus and features of 
DiGeorge syndrome. The asymptomatic mother showed partial T-cell deficiency and 
the same unbalanced translocation with deletion of proximal 22ql 1. Augusseau et al. 
[32] observed telecanthus, microretrognathia, severe aortic coarctation with hypoplastic 
left aortic arch, decreased E rosettes, and mild neonatal hypocalcemia in a patient with 
balanced translocation involved chromosome 2 and 22: t(2:22)(ql4:ql 1). The same 
translocation was present in the clinically normal mother and maternal aimt who had her 
fourth pregnancy aborted because of cardiac and other malformations detected on 
ultrasound and this translocation has proved important in analysis of the expressed 
sequences in the deleted segment.128.30.3i. 32]
The recognition of the importance of 22ql 1 deletion grew with improving 
techniques. Greenberg et al. 133] found chromosome abnormalities in 5 of 27 DiGeorge 
syndrome cases, 3 with 22ql 1 deletion though only one of these was an interstitial
deletion. Wilson et al. [^1 reported high resolution banding in 30 of 36 cases of 
DiGeorge syndrome and demonstrated 9 cases of interstitial deletion. All other cases 
were apparently normal. Use of molecular dosage analysis and fluorescence in situ 
hybridization with probe isolated Grom within the deleted area revealed deletion in 21 of 
22 cases with normal karyotypes giving pooled results of 33 deleted among the 
consecutive series of 35 cases 0^1. Driscoll et al. [36] also found deletions at the 
molecular level in all 14 cases studied.
Whereas 90% of cases of DiGeorge syndrome may now be attributed to a 
22ql 1 deletion, other chromosome defects have been identified. In the report of 
Greenberg et al. there was one case of DiGeorge syndrome with a deletion in 
10ql3 and one with a 18q21.33 deletion. Other chromosome defects also were 
reported to be associated with DiGeorge syndrome. A deletion of lOp was reported by 
Monaco et al. [371, Shapira et al. and Schuffenhauer et al. [391. Lindgren et al. 
reported that a chromosome duplication of 9q(2I.12-q22.1) was related to DiGeorge 
syndrome ['^I. Greenberg et al. reported that deletion 17pl3 was associated with DGS 
[411 and van Essen et al. reported a case with isochromosome 18q(46, XX, i( 18q)) who 
had combined manifestations of monosomy I8p and trisomy 18q and with DiGeorge 
syndrome [421. Lai et al. reported a DiGeorge syndrome case with simultaneous partial 
monosomy lOp and trisomy 5q [431. Fukushima et al. found a female infant with a 
deletion of 4q21.3-q25 and with DiGeorge syndrome [441. DiGeorge syndrome 
implicated with either of the two sex chromosomes, X or Y, has been reported. Most 
of them involved in a chromosomal translocation of 22, with either X or Y, resulting in 
a monosomy of 22q. The possibility of an unrecognized submicroscopic deletion of 
22ql I also was considered in these cases, although it is clear that the disturbance of 
neural crest migration presumed to underlie DiGeorge syndrome may be caused by 
several distinct defects at the molecular level. [45^ 9]
1 .1 .3 .3  Mapping
Cytogenetic studies support the presence of a DGS critical region in band 22ql I 
but a small number of cases with microdeletions were undetectable by cytogenetic 
analysis even with high-resolution banding techniques. Molecular analysis methods 
can detect deletions in those patients with normal karyotypes. RFLP (restriction 
fragment length polymorphism), gene dosage analysis and FISH (fluorescence in situ 
hybridization) have been used to smdy in mapping the critical region of DGS. [50-53] 
RFLP analysis, genomic DNA is digested by certain restriction enzymes and the 
resulting fragments are separated by electrophoresis. Radiolabeled probes are 
hybridized to appropriate bands by Southern blot. Normally, there are two bands for 
each probe, one is from maternal and the other is from paternal. If one of the probe- 
binding region is deleted, only one band can be seen. Gene dosage analysis is to 
determine the copy number of the DNA by quantitative analysis of Southern blots. A 
control probe binding to a region not involved in DGS is used simultaneously as a 
comparison. FISH analysis with a fluorescence labeled probe that can hybridize to 
metaphase chromosomes can be used to visualize the location of a large deletion. Since 
1989, the laboratories of Drs. Emanuel in Philadelphia, Desmaze in Paris and Scambler 
in London have been isolating probes from 22ql 1 to determine the smallest region of 
overlap in DGS patients. These different groups used different probes on different 
patients to locate the DiGeorge critical region [50-53]
Studies [36.50.54] conducted by Dr. Emanuel's group showed that loci D22S9 
(p22/34) and D22S43 (pH32) flank the critical region proximally. Loss of an allele at 
more distal locus, BCRL2, in one of the patient suggested that the distal boundary for 
DGCR might be in proximity to the BCRL2 locus. Other loci used as probes include
pH98 (D22S57), pHl I (D22S36), pR32 (D22S259), pHl60b (D22S66), pH 162 
(D22S68), N25 (D22S75), W21G (D22S24), and 22CI-18 (D22sI0). Probes N25, 
HI60b, pR32 and transiocation cell line GM5878 (a human -hamster hybrid carrying 
t(l0;22)(q26.3;ql 1.2) translocation and retaining ±e der(10) as the only relevant 
human chromosome) were detected in all patients studied. Desmaze et al. used 
many of same probes as well as additional probes such as 33-1 LTg (carrying a 
reciprocal t(x;22) translocation), 48F8, lOOCIO, NOT54, and ICB100 (carrying a 
recurrent t( 1 l;22)(q23.2;ql 1.2) translocation). They found the longest deletion region 
is flanked by probe D22S9 and ICB 100 and the smallest deletion region is between 
pHl 1 and GM5878. Scambler et al. 1^  ^on the other hand, detected shortest deletion 
region which is between pH 11 and GM5878. Maps of DGCR from these three groups 
are provided in Rgure I. The overlapping region of the three maps occurs from pHl I 
to GM5878. Because it is still possible that the disease may be caused by contiguous 
gene deletion, it is important to study the largest deleted region to understand the 
variable spectrum of phenotypes.
1.1.3.4 Molecular genetics
Augusseau et al. 1321 described a female patient (ADU) with DGS (see 1.3.2 
Cytogenetics) that had a balanced translocation involved chromosome 2 and 22; 
t(2;22)(ql4;ql 1). The same translocation also was present in her mother (VDU). The 
original paper reported that VDU had no features of DGS, but Budarf et al. later 
observed that subsequent publications cited VDU as mildly affected with VCFS and 
DGS. The DGS phenotype in ADU, the VCFS phenotype in VDU and a balanced 
translocation of chromosome in both led Budarf et al. t^ l^ to clone the translocation, 
sequence the region containing the breakpoint, and analyze the DNA sequence for
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transcript identification. A gene (DGCR3) disrupted by the rearrangement was 
identified. Their analysis suggested that there are at least two transcripts (DGCR3 and 
DGS-B) on opposite strands in the region of the t(2;22) breakpoint. The breakpoint 
disrupted a predicted open reading frame of one of these genes (DGS-B), deleting 11 
nucleotides at the translocation jimction. Additional fluorescence in situ hybridization 
studies and Southern blot analysis demonstrated that the deletions in chromosome 22 
deletion-positive patients with DGS/VCFS include both of the transcripts at the t(2;22) 
breakpoint. The answer to whether either of these two putative genes may be of 
significance in the etiology of DGS will lie in determining whether all deleted patients 
are hemizygous for these loci and whether mutations in these genes are detectable in 
non-deleted patients with DGS. Lacking such evidence, the possibility that the 
translocation separates a locus control region from its target gene or produces a position 
effect will still remain. Most recent research suggested that a common polymorphism 
in DGS-B may lead to a framesbift in this open reading frame (Holmes et al., 
unpublished). A transcription map of the DGS and VCFS minimal critical region on 
22ql 1 was published in 1996 by Gong et al. This study foimd transcription units 
such as DGS-A, LAN (DGS-C), DGS-D, DGS-E, DGS-F, DGS-G, DGS-H, DGS-I, 
CTP (DGS-J), CLTCL (DGS-K) in the minimal critical region. LAN gene, also named 
IDD gene, which is close to ADU breakpoint, was first isolated by Demczuk et al. 1^*1 
and Wadey et al. This is an integral membrane protein and is a putative adhesion 
receptor protein, which could play a important role in neural crest migration to the third 
and fourth pouch in embryogenesis, a process which has been proposed to be improper 
in the development of DGS. DGS-G is 94% identical in amino acid level to Mus 
musculus serine/threonine kinase gene CTP (citrate transport protein) is 98% 
similar in amino acid level to rat tricarboxylate transport protein gene
A patient named TOH has several features which also have been reported in 
individuals with DGS/VCFS. This patient carries a de novo constitutional balanced 
translocation (21;22)(pl2;ql 1) which has been identified within minimal DGCR 1^1. 
Budarf et al. cloned and sequenced the breakpoint of translocation and showed that 
it occurred in the CLTCL gene (result partially from the research of this dissertation). 
Because the breakpoint of the translocation on 21pl2 is in a repeated region telomeric to 
the rDNA cluster, it is unlikely that the patient's features are caused by interruption of 
sequences on 21pl2. The chromosome 22 breakpoint dismpts the 3' coding region of 
the CLTCL gene and leads to a truncated transcript
Halford et al. analyzed the extent of deletion in patients with DGS/VCFS 
phenotypes and refined the molecular cytogenetic map of the region. They found in no 
case was a deletion smaller than 300 kb and the boundary of the smallest deletion 
region is between scl 1.1a and Cl/79. Cl/79 is a probe about 275 kb telomeric to 
scFS. (see Figure 1). Probe scF5 was used to screen a human fetal brain cDNA library 
and a mouse embryo cDNA library and located a cDNA for a transcriptional regulator, 
TUPLE 1, which is similar to yeast TUPl gene. This gene contained WD40 repeat 
motifs, which were first described in the beta subunit of transducin, the GTP-binding 
protein. Two years later, the study of Lamour et al. showed that this gene is more 
similar to two yeast genes, HIRl and HIR2, that are repressors of histone gene 
transcription. Therefore the name of TUPLE 1 was changed to HIRA. This 
dissertation will reveal the whole context of the genomic organization of this gene.
Because the majority of the patients have larger deletions than the minimal 
DGCR, studies on neighboring regions also were carried out. Aubry et al. 
identified a zinc finger gene ZNF74 which has an open reading frame containing 12 
zinc finger motifs as well as N-terminal and C-terminal non-zinc finger domains. This
10
gene was found to be faemizygously deleted in 23 out of 24 DGS patients and 
expressed in human and mouse embryos but not in adult tissues. Hemizygous deletion 
of this gene may result in changes of the dosages of putative transcription factor. 
Halford et al. 1*^  isolated a cDNA at D22S134, which is distal to m inim al DGCR.
This gene, named TIO, is expressed during early embryogenesis in mouse and encodes 
a serine/threonine rich protein. The genomic organization of this gene was determined 
during part of this dissertation research and will be discussed later. Kurahashi et al.
[66] reported a gene, designated LZTR-1, which has an open reading frame encoding 
552 amino acids and has several characteristics of DNA-binding proteins. This gene is 
transcribed in several essential fetal organs. Their study showed that this gene is 
hemizygously deleted in 7 out of 8 DGS patients. Its stmctural characteristics 
identifying it as a transcriptional regulator suggest that it may play a role in 
embryogenesis and that haploinsufficiency of this gene may be partly related to the 
development of DGS. Pizzuti et al. 1®^ found a human cDNA homologous to the 
Drosophila's dishevelled (dsh) segment-polarity gene, a gene required for 
establishment of fly embryonic segments. The 3' UTR (untranslated region) of this 
transcript (DVL-22) was located in DGCR and was deleted in a DGS patient they 
studied. The pivotal role of dsh in fly development suggests an analogous key function 
in vertebrate embryogenesis of its homologue gene. Since DGS may be due to 
perturbation of differentiation mechanisms at decisive embryological stages, this gene 
also might be a candidate for the pathogenesis of DGS. Demczuk et al. [681 also found 
a gene, DGCR6 in DGS critical region. The putative gene encodes a protein similar to 
Drosophila's gonadal protein, which participates in gonadal and germ-line cells 
development, and the y-l chain of human laminin, which upon polymerization with a- 
and P- chains forms the laminin. Laminin binds to cells through interaction with a 
receptor and has functions in cell attachment, migration and tissue organization during 
development. COMT gene was first mapped to chromosome 22 by Brahe et al. [69l and
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further mapped to 22ql 1 by Winqvist et ai. Lachman et ai. associated this gene to 
DGS/VCFS in 1996 COMT (catechoi-O-methyitransferase) has two forms. One 
is soiubie and the other is membrane bound. Lachman et ai. identified a poiymorphism 
in membrane-bound form leads to a vaiine to methionine substitution at amino acid 158. 
Homozygotes for COMTiSSmet has a 3-4 fold of reduction in enzymatic activity 
compared with homozygotes for COMT158vai
Demczuk et al. pointed to the existence of a strong tendency for 22qi 1.2 
deletions in DGS, VCFS and isolated cormotmncal cardiac disease to be of maternal 
origin. With their experience of 22 cases in which parental origin could be determined, 
combined with recent results from literature, 24 cases were found to be of maternal 
origin and 8 of paternal origin, yielding a probability level lower than 0.01.
1 .1 .3 .5  Heterogeneity and population genetics
The association of the DiGeorge syndrome with at least 2 and possible more 
chromosomal locations suggests strongly that several genes are involved in control of 
migration of neural crest cells and their subsequent fixation and differentiation at 
different sites. In the mouse, Chisaka and Capecchi described a knockout of hox-
1.5 which produced a recessive phenocopy of DGS. Mice heterozygous at the hox-1.5 
locus appear normal, whereas hox-1.5'/hox-1.5~ mice die at or shortly after birth. The 
homozygous mice have deficiencies remarkably similar to the pathology of the human 
congenital disorder DGS but this gene maps to human chromosome 7, in an area not 
yet implicated in the cause of the human DiGeorge syndrome.
One explanation for the wide variation in phenotype would be the need of more 
than one gene defect to produce the severe version. Thus, for example, multiple
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signals and receptors should be effected to produce the full phenotype. Environmental 
factors also could play an additional role as features of DGS have been described in 
children with clinical evidence of fetal alcohol syndrome 174], x^e alcohol may have 
directly disrupted neural crest migration or have exposed a genetic predisposition. In 
addition Lammeret al. 1"^  ^studied a series of pregnancies exposed to the teratogen 
isotretinin (vitamin A) and several of the infants satisfied the diagnostic criteria of DGS. 
Thus, it is likely that these environmental changes are exposing the same susceptible 
pathways of development as are impaired by the 22ql 1 deletion although the possibility 
of an interaction between the insult and genotype remains open.
No formal population study has yet been completed, although a preliminary 
study in the Northern region of England, which has a birth population of 40,(KX) per 
annum, has revealed 9 cases bom in 1993 with 22ql 1 deletion who presented with 
neonatal DGS features. The overall birth prevalence of DGS therefore would appear to 
be approximately 1 in 4,(XX)
1.1.4. Sequencing analysis
The majority of patients with DGS/VCFS (about 90%) have a common large 
deletion, and a minority have smaller deletions, unbalanced translocations or no 
detectable abnormality of 22ql 1 . 2 Though the phenotype is highly variable, there 
is no apparent correlation between deletion size and phenotype The minimal 
DGS/VCFS critical region (MDGCR), defined as the region most likely to contain the 
gene or genes for DGS/VCFS, has been studied extensively. Different groups have 
their own definitions of MDGCR because of the different probands they used (see 
1.1.3.3. Mapping for detail). With the help of DNA sequencing, a transcription map of 
MDGCR has been published t^ T]. Combined with this transcription map and studying
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of balanced transiocation, three disrupted transcription units were found. One of them, 
DGCR3 1^ ,^ seems to be within another newly found transcription unit, DGCR5 I??!. 
The other transcription unit recently was found to be the functional gene for CLTCL, 
clathrin heavy chain-like gene The sequence data o f the genomic context of this 
gene revealed that the breakpoint is within intron 27 DGCR5 and CLTCL genes 
are the only two genes in MDGCR which span the balanced translocations. However, 
the relationship between genes and the features of DGS/VCFS still remains unknown. 
It is possible that the translocation breakpoints are exerting position effects on a gene or 
genes in the region or the neighboring region. To further understand the deletion 
mechanism and the genomic organization of the critical region of DGS/VCFS, Dr.
Roe's research group has been sequencing the entire 1.4 megabase DGCR. This 
sequence data has been proven to be a great help in establishing the transcription map, 
localizing known genes in the region, studying the genomic organization of genes, 
revealing the details of translocation breakpoint, and discovering new genes within the 
region 78] Thig sequence data in the DGCR is from numbers of overlapping
cosmids, fosmids, BACs, and PACs. A map of these cosmids, fosmids, BACs and 
FACs is provided in Figure 2. Database searches reveal the locations of several known 
genes and human homologs of known genes of other species. The presence of 
numerous STS's and EST’s also has aided the discovery of new genes in this region. 
Computational approaches, such as Xgrail, promoter scan, and signal scan programs, 
are used to predict the potential exons and promoter regions. Combining the locations 
of predicted exon cluster, potential promoter region and ESTs together can be very 
useful to discover new potential genes. A large number of interspersed repeat elements 
and single repeats also have been identified. The distribution of these repeats 
throughout the region can help to understand the clue of how the chromosome DNA is 
organized. After all known and potential genes are localized in the region and the 
genomic organization of all these genes are revealed, one can possibly answer the
14
1 0 3 a 2
bD3-6
e l  4 3
15A1 b 4 0 -
59C 10
72  FSq11.21 1 9 0 3
q11.22 49C 12
| l 0 2 G 9ES 
MOR 
NBFH 
NF2
129F8
RPoU 105A
100H
q13.31
q1 3.32
q1 3.33
g a p 2 l
72K21
P201
CES = Cat Eye Syndrome Region 
IQCL = Immunoglobulin Light Chain R< 
BCR = Breakpoint Cluster Region 
ES = Ewino's Sarcoma 
ÆR4 = Neurofilament Heavy Subunit
NF2 = Neurofibromatosis Region 2 
IfolJ = RNA Polymerase II subunit J 
MDR= Meningioma Deletion Region 
ACR = Acrosin BACs, Cosmids  
Fosmids, PACs
KeyL
Rnished to phase 3 
Rnished to  phase 2 
Orderd contigs 
Shotgun in progress
Figure 2: Map of cosmids, fosmid, BACs and PAG in DGCR
15
questions: Which gene or genes are responsible for DGS/VCFS or which regulatory 
factor or factors are responsible for DGS/VCFS? What causes the broad spectrum of 
severity observed in DGS/VCFS patients? How are the products of potentially 
responsible genes involved in early embryonic development which causes DGS/VCFS? 
What is the cause of deletions? What is the deletion mechanism?
1.2  DNA
1.2 .1  Inheritance and DNA
Far before DNA was discovered, the phenomenon of inheritance was observed
and attempts were made to understand its mechanism. As ancient Chinese put it:
"Dragon breeds dragonet, a phoenix breeds a little phoenix, and mice's son can surely
dig holes". Inheritance was defined as the ability of passing parental characteristics to
next generation. However, its physical basis was not understood until the first year of
the twentieth century, when, during a remarkable period of creative activity, the
chromosomal theory of heredity was established. Hereditary transmission through the
sperm and egg became known by 1860, and in 1868 Haeckel, noting that sperm
consisted largely of nuclear material, postulated that the nucleus was responsible for
heredity. When the theories of mitosis, meiosis and fertilization were accomplished, it
could be seen that unlike other cell constituents, the chromosomes were equally divided
between daughter cells. Moreover, the complicated chromosomal changes in meiosis
which reduced the number of chromosomes of sperm and egg in half became
understandable as necessary to keep the chromosome number consistent after
fertilization. These facts suggested that chromosomes carry the heredity information 
[79. 80. 81]
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It was not until 1900 that Gregor Mendel's basic rules of heredity were accepted 
by the scientific community. Although Mendel proposed bis basic rules of heredity in 
1865, they were completely ignored by prominent biologists of that time. After de 
Vries, Correns and Tschermak, all working independently, reached similar conclusions 
before ±ey knew of Mendel's work, the great importance of Mendel's forgotten work 
was realized. Mendel's work traced the results of breeding experiments between 
strains of garden peas (Pisum sativum) differing in well defined characteristics.
Mendel first related the physical appearance (phenoQrpe) with its genetic composition 
(genotype), and proposed that a pair of "particulate factors", one fix)m each parent, 
carried the information of heredity, passed unchanged fiom parent to progeny, and 
control the offspring's appearance. He also developed the concepts of dominance, 
recessivity, segregation and independent assortment. The dominance/recessivity 
concept discriminated two particulate factors carried by one individual. The dominant 
one will control the phenotype while the recessive one is in effect irrelevant. These two 
particulate factors have no permanent effect on one another when present in the same 
individual but segregate unchanged by passing into different gametes. When two 
different characteristics were reviewed, he concluded that the factor-pairs controlling 
different phenotypes will segregate independently, in modem word, nonhomologous 
chromosomes undergo independent segregation [79» 80.8i]_
Walter Sutton, in 1903, emphasized the importance of the factor that the diploid 
chromosome group consists of two morphologically similar sets and that, during 
meiosis, every gamete receives only one chromosome of each homologous pair. He 
used this fact to explain Mendel's results by relating "particulate factors " to 
chromosomes. Though Sutton's work didn't prove the chromosomal theory of 
heredity, it was very important in bringing together the independent disciplines of 
genetics and cytology *-1. In 1910, Johannsen called these "particulate factors"
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genes sii 1 9 1 0 , Morgan's work on Drosophila melanogaster proved that a 
specific gene always lies on a certain chromosome. It also was observed that if two 
genes are on the same chromosome (linked genes), they tended to be inherited together 
(linkage). Linkage is seldom complete because homologous chromosomes attach to 
each other during meiosis and often break at identical spots and rejoin crossways
80. 81. 83]
The relationship between the structiues of the genes and the biochemical 
mechanism by which they control the cellular characteristics was the next question. 
Each gene exists in a variety of different forms called alleles. Different alleles arise 
from inheritable changes called mutations. Smdies on large amount of spontaneous 
mutations in Drosophila led to the conclusion that many genes worked together to 
control one character such as eye color and wing shape 1^ *^ 80.8i. 84] Garrod was the 
first to propose the general hypothesis of a gene-enzyme relationship in 1909. In his 
studies of an hereditary disease affecting amino acid metabolism, he suggested that the 
illness was caused by a lack of a particular enzyme, which was required in the amino 
acid metabolism pathway, and proposed that the gene controlled the synthesis of the 
enzyme ®o. 85] ju 1 9 4 1 , Beadle and Tamm introduced a red bread mold 
(JNeurospora) as a genetic model system to study metabolism. Different mutants were 
generated by irradiation with X-ray and selected for their inability to grow on a medium 
that could allow the wild-type cell to grow. By adding additional nutritional 
compounds to the medium, the mutant's ability to grow was restored. They concluded 
that each mutation disrupted a certain gene whose product is involved in one of the 
metabolic steps and made the cell unable to use the nutrition the wild-type is able to use. 
Because each mutation blocked a particular step of metabolic pathway, adding the 
nutrients which appeared downstream of this step restored the cell growth. Based on 
this study, they proposed the "one gene-one enzyme " theory and confirmed Garrod’s
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hypothesis [81.86] more modem terms, considering some proteins consist of more 
than one kind of subunit, it is more precise to express "one gene-one enzyme" as "one 
gene-one polypeptide chain" [**1.
Studies by Fred Griffith in 1928 on bacterium Pneumococcus strains brought 
the first idea of DNA as the genetic material. Pneumococcus kills mice by causing 
pneumonia. The virulence of the bacteriiun is determined by the capsular 
polysaccharide, a component of the surface, which gives smooth appearance and 
protects the bacterium fiom destruction by the host. A wildtype strain of 
Pneumococcus (I S), which is able to synthesize a capsular polysaccharide and has the 
ability to kill the mouse, and a mutant strain of Pneumococcus (IIR), which has lost 
the ability to synthesize the capsular polysaccharide, has rough surface and can not kill 
the mouse, were used. Their results showed that coinjection of heat-killed smooth 
bacteria (I S) and live rough bacteria (IIR) into mice resulted in pneumonic infection 
and death, whereas injection of only Heat-killed IS  or live IIR  did not. Furthermore, 
the virulent bacteria recovered from the mixed infection had the smooth coat of type I. 
Based on these observations, Griffith presented his transformation hypothesis that 
some "transforming principle" fix)m dead type IS bacteria can transform the live 
avirulent H R bacteria so that they make the type I capsular polysaccharide, and as a 
result become virulent t8K87]_ Griffith’s "transforming principle" was chemically 
characterized by Avery, MacLeod and McCarty in 1944 after purifying the 
"transforming principle" fiom extracts. When the "transforming principle" was treated 
with deoxyribonuclease, an enzyme that specifically degrades DNA molecules to their 
nucleotides and has no eftect on the integrity of protein molecules or ribonucleic acid 
(RNA), transforming activity of the extract was destroyed. The addition of either 
enzyme ribonuclease, which degrades RNA, or various proteolytic enzymes, which 
destroy protein, had no influence on transforming activity. They then concluded that
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the "transforming principle" to be deoxyribonucleic acid (DNA) *^1. At that time, 
DNA was not even known to be a component of bacterium. However, it had been 
recognized for many decades that DNA was a major component of eukaryotic 
chromosomes. The results that showed that the genetic material of a prokaryote also is 
DNA indicated DNA is probably the genetic material in both prokaryote and eukaryote 
[81],
In 1952, Hershey and Chase confirmed that DNA also was the genetic material 
of a quite different system, T2 bacteriophage. When phages were labeled with 32p in 
DNA or with 3% in protein of phage coats, the label entered the infected bacteria
and can be recovered from progeny phages. The 3% label was found to be in empty 
phage coats but not inherited by the progeny [81.89] The similar observation also was 
obtained from studies in eukaryotes. When purified DNA containing information of 
particular phenotype mixed with single eukaryote cells which lack this particular 
phenotype, some of the cells could uptake the DNA and obtain this phenotype
These experiments showed directly that DNA is the genetic material. Now we 
know that all known organisms and many viruses use DNA as genetic material. 
However, some viruses use ribonucleic acid (RNA) as genetic material. In these 
circumstances, RNA serves the same role as DNA.
1.2 .2  DNA components
DNA is a polymer consisting of a chemically linked sequence of nucleotides. 
Each nucleotide contains three major components; a nitrogenous base, a five carbon 
sugar in ring form, and a phosphate group. DNA has four kinds of nitrogenous bases 
(Figure 3). They fall into two groups, pyrimidines and purines. DNA has adenine and
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Figure 3: Structures of bases, pentose and phosphate in DNA.
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guanine as purines and cytosine and thymine as pyrimidines. The five carbon sugar in 
DNA is 2-deoxyribose (Figure 3). The nitrogenous base is linked to position I on the 
pentose ring by a N-glycosidic bond from Ng of purines or Nj of pyrimidines. The 
phosphate group is linked to S' position of the pentose via phosphodiester bond. 
Nucleotides are building blocks from which DNA is constructed. The DNA 
polynucleotide is an unbranched polymer whose backbone consists of an alternating 
series of sugar and phosphate residues. The S' phosphate of one nucleotide is bound 
covalently to the 3' hydroxyl of the sugar on the adjacent nucleotide. The terminal 
nucleotide at one end of the chain has a free S' phosphate group and the other end has a 
free 3' hydroxyl group. Thus, the DNA chain has a direction. In 19S1, Chargaff, et 
al. found out that double stranded DNA consists of equal amounts of adenosine (A) and 
thymidine (T) and equal amounts of guanosine (G) and cytidine (C). The molar ratios 
of ([A]+[T]/[G]+[C]) differed among organisms, a finding which suggested that DNA 
molecules might be more complicated than originally considered. Chargaff 
hypothesized that the variable base compositions reflected differences in the base 
sequences among organisms, which somewhat revealed the complexity and diversity of 
genetic material 1^ -^ ^1.
1 .2 .3  DNA structure
Three major pieces of evidence helped Watson and Crick in 1953 conclude that 
DNA usually consists of two complementary polymeric strands that form a double 
helix. First, X-ray diffraction data showed that DNA has the form of a regular helix, 
making a complete turn every 34 Angstroms (3.4 nm), and with a constant diameter of 
20 angstroms (2 nm). Because the distance between adjacent nucleotides is 3.4 
angstroms, there are 10 bases per turn of the helix. Second, the density of DNA 
suggests that the helix must contain two polynucleotide chains. The constant diameter
of the helix can be explained only if the bases in each chain face inward and a purine is 
always opposite a pyrimidine, because purine-purine pairs are too large and pyrimidine- 
pyrimidine pairs are too small. The hydrophobicity of bases also suggests that bases 
face inward, making a hydrophilic backbone on the surface of the helix. Third, the 
proportion of G and C is always the same in DNA (G = C), and it also is true for the 
proportion of A and T (A = T). This indicated that A might pair with T and G might 
pair with C [79.80. si. 9I. 92.93].
Watson and Crick proposed that most of the time, hydrogen atoms in the bases
are found at precise locations instead of as was previously assumed, that they are
highly mobile, randomly moving from one ring nitrogen or oxygen to another. The
nitrogen atoms attached to the bases are almost always in the amino (NH2) form rather
than imino (NH) form and the C-6 atoms are keto (C=0) rather than enol (COH).
These structure features of the bases allow hydrogen bonds only between A and T, and
G and C (Figiue 4). Thus, the DNA molecule has two polynucleotide chains coiled
together in opposite direction (antiparallel) to form a right-handed double-helix. The
nitrogenous bases face inward and two hydrogen bonds between A and T in different
chains and three hydrogen bonds between G and C keep these two chains together.
Bases are flat structures lying in pairs perpendicular to the axis of the helix (base-
stacking). This base-stacking allows interaction of the aromatic 7C electron clouds and
diminishes the electrostatic repulsion expected between the negatively charged
phosphate backbones of two chain. Besides the hydrogen bonds, hydrophobic base-
stacking also keeps the DNA stmcture stable. The twisting of two strands around one
another gives two grooves on the surface of the helix, narrow and wide grooves. The
narrow groove is about 12 angstroms and the wide groove is about 22 angstroms [79.
80. 81]
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This stmcture represents a common form of DNA, B-form, existing in solution 
under physiological conditions, but there are other forms of DNA. The A-form DNA is 
very close to the conformation of double-stranded regions of RNA, where the presence 
of 2 -OH group prevents adoption of the B-form. In A-form DNA, there are 11 bases 
per turn and the diameter of the helix is about 23 angstroms and the bases are not lying 
perpendicular to the axis but tilted 95.96.97.98] -pijg Z-form DNA, is a left
handed double helix having only one deep groove with a greater density of negative 
charges than either groove in B-form (See Figure 5). Z DNA contains 12 base pairs 
per turn with a diameter of approximately 18 angstroms, making this structure much 
more compact than B-form DNA 1*°’ lOO. loi] The Z-form DNA double helix 
occurs in polymers with a sequence of alternating purines and pyrimidines as in CpG 
island which is seen in the promoter region of most house keeping genes. Besides the 
sequence of the nucleotides, negative supercoiling is another factor that determines 
which form DNA adopts. Negatively supercoiled DNA seems to have greater 
possibility of exiting in a Z-form than relaxed DNA. Since Z-form DNA has been 
reported in regions of SV40 virus that regulate transcription, Z-DNA is thought to have 
an effect on transcription proteins bound to DNA also may affect the ability of 
DNA to adopt different forms Méthylation of key cytosine residues also may 
influence gene functioning through its potentiation of the transition from B-form to Z- 
form [104,105] Miller, et al. reported that the conversion from B-form DNA to Z-form 
in nucleosomes could change the superhelical density of a DNA segment, and therefore 
alter gene expression
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Figure 5: Conçarison of A-form, B-form, and Z-fonn DNA.
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1 .2 .4  DNA and genetic information
How does the DNA structure relate to the genetic information it carries? How is 
this information coverted to biochemical metabolic functions? The central dogma 
proposed by Francis Crick may answer these questions The central dogma 
defined the paradigm of the molecular biology: genes are perpetuated as sequences of 
DNA (or in some cases, RNA), but the functions are carried out by being expressed in 
the form of proteins.
Central dogma contains two components (Figure 6): The first is DNA 
replication. Duplication of DNA to make an identical copy passes the genetic 
information from one generation to next. The second is gene expression which 
contains two stages. DNA replication provides a way for genetic information to pass 
from parent to offspring. Two major features should be mentioned here for DNA 
replication. First, DNA can only be synthesized firom 5'-end toward 3'-end. Second, 
no known DNA polymerase activity can initiate a DNA chain de novo, instead, it is 
extended from a pre-existing chain (primer), DNA or RNA, with a free 3 -OH end 
SI. 110,111.112,113] jn gene expression, transcription generates a single-stranded 
RNA identical in the sequence with one of the strands of the duplex DNA. Translation 
converts the sequence of RNA into the sequence of amino acids comprising a protein.
In eukaryotes, DNA is in the nucleus and protein synthesis occurs in the cytoplasm. 
RNA acts as a messenger to transfer the information DNA carries outside the nucleus 
into the cytoplasm. This RNA is called mRNA [I08,i09] Only one DNA strand is the 
template for mRNA synthesis. The template DNA strand which is copied and thus 
complementary to the mRNA is called the anticoding or negative strand. The other one 
which has the same sequence as mRNA (except in RNA a U is used instead of a T) is 
called the coding or positive strand so. si]
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Figure 6: Central dogma of molecular biology
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Transcription utilizes RNA polymerase. There are three RNA polymerases in 
eukaryotes. RNA polymerase I is responsible for synthesis of ribosomal RNA (rRNA) 
which is a constituent of ribosome t* ^ '*1, the factory of protein synthesis. RNA 
polymerase H is responsible for mRNA synthesis. RNA polymerase EH is responsible 
for synthesis of transfer RNA (tRNA), which recognizes a free amino acid and 
transfers it to a ribosome for protein synthesis Transcription is facilitated by the 
presence of specific promoters, containing specific consensus sequences, which are 
recognized by RNA polymerase. Promoters for RNA polymerase I, and most 
promoters for RNA polymerase H are located upstream of the transcription startpoint 
[116, 117.118, 119]^  and in most cases promoters for RNA polymerase HI lie downstream 
of the startpoint Because RNA polymerase II transcription results in mRNA, it 
will be emphasized here. RNA polymerase H usually requires specific consensus 
sequences in promoter region, such as the TATA box, with a consensus sequence of 
TATAA, which is located 25-30 base pairs upstream from the transcription start site. 
The TATA box is recognized by TFUD (transcription factor HD) and delineates the 
correct positioning of the RNA polymerase U for transcription initiation and specifies 
the 5' cap termini in the mature mRNA ^^ 2] Further upstream from TATA box is 
a region which can contain one or more upstream regulatory elements such as the 
CAAT box and the Spl (a transcription factor containing zinc-fingers) consensus 
binding site GGGCGG. The position of CAAT box can vary considerably from the 
transcription startpoint. It may also be present in either orientations. CAAT box may 
play a role in controlling the efficiency of the promoter. GGGCGG sequence (GC 
box) usually has multiple copies in different locations and can occur in either 
orientations 124. i25.126. 127] Bven though these regulatory elements are often 
described as promoters, none of them are essential, and a gene promoter region may 
lack any one of them and still be transcribed. In addition, several eukaryotic promoters
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have been shown to not necessarily function alone. Enhancers, which may be located 
at a variable distances from promoter, upstream or downstream, can increase the 
activity of promoter enormously. Enhancers also may not be specific for certain 
promoters, and can stimulate any promoter placed in its vicinity 1^28.129, 130]
Response elements are found either in promoters or enhancers, and are recognized by 
factors that coordinate the transcription of particular groups of genes. Response 
elements are switches that can tiun particular gene(s) on in the presence of certain 
factors, such as some metals, hormones (e.g. glucocorticoid) and serum. Such a factor 
binds to a receptor in cytoplasm, the complex then goes into the nucleus and binds to 
response elements that regulate the transcription ( i3 i ,  I32]
Little is known about the mechanism of termination of transcription of RNA 
polymerase H. A consensus sequence, known as poly(A) signal, is usually found near 
the end of transcription stop point. This sequence may not signal the termination of the 
transcription but rather signal the addition of poly(A) tail to mRNA. Actually, RNA 
polymerase H may continue elongating the RNA chain far beyond the polyadenylation 
signal site, but after it is somehow terminated, the nascent pre-mRNA then is cut by a 
specific endonuclease, which creates the correct 3' terminus for polyadenylation and 
releases downstream sequences for rapid degradation. The poly(A) tail is believed to 
control the stability and the lifetime of a mRNA 1(33' ^3 4 .135i
The coding regions, termed exons, usually are not continuous in eukaryote 
genes as they are separated by non-coding regions, termed introns. The size of the 
introns usually is much larger than the size of the exons 1®®* 136 .137 ,138. 139]
immediate product of RNA polymerase II is only a preciusor of mRNA because it 
contains large amount of non-coding regions. Before the mRNA precursor can be used 
as a template of protein synthesis, the introns must be removed by a process called
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splicing, which occurs in the nucleus 1^ 38. i40i During splicing the pre-mRNA is 
cleaved after a G residue (underlined in 3'-end of exon and 5'-end of intron consensus 
junction: (CyA)AQ/gt(a/g)agt, the bold is most conserved *^ 1^) at the end of the 
upstream exon. The resulting ftee guanosine at the end of the intron reacts with a 
residue (usually an A) in the middle of the intron (usually near the right end of the 
intron) to form a 5' to 2' phosphodiester bond After this lariat structure
is formed, the 3'-end of intron and S'-end of the down stream exon consensus junction 
((t/c)nn(c/t)ag/G) ‘^ 1^ is cleaved between two G's and the two exons are ligated. 
This process has been studied in detail and shown to require small nuclear 
ribonucleoprotein particles, termed snRNPs, which contain small nuclear RNAs and 
special proteins 1146. i47.148]
1 .2 .5  DNA packaging: genome and chromosome
The three billion base pairs of the human genomic nuclear DNA in a single cell 
is roughly one meter long and mainly B-form double helix. Human genomic DNA is 
organized and packaged into a set of 46 chromosomes in a haploid cell, two copies of 
chromosomes 1-22 and the sex chromosomes XX or XY. The shape of a typical 
chromosome in metaphase is provided in Rgure 7. A large number of proteins is 
bound to DNA. Some of these proteins, histone and non-histone proteins, help 
package the DNA into very dense form. The basic structural unit of a chromosome is 
chromatin. Chromatin consists of densely packed nucleosomes. A nucleosome 
contains a characteristic length of DNA, usually about 200 bp, wrapped two times 
around an histone octamer containing two of each histone: H2A, H2B, H3, and H4. 
Histone HI binds to the DNA between nucleosomes and facilitates chromatin 
packaging. Nucleosomes are organized into chromatin which is a helical fiber of 30 nm
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Figure 7: Typical human chromosomes in metaphase.
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diameter having six nucleosomes per turn. Without HI, the chromatin is 10 nm in 
diameter, in which nucleosomes are organized edge to edge and stacked along. 
Non-histone proteins are responsible for further packaging 0 4 9 . 150. isi. 152, 153] T h e  
chromatin packaging is regulated by phosphorylation of histone HI prior to mitosis, 
and dephosphorylation following mitosis. As a result of this covalent modification, 
chromatin has different densities. The very densely packed region, in a condition 
comparable to that of the chromosome at mitosis, is known as heterochromatin. 
Heterochromatin is a region of relatively inactive transcription [*^1 Two kinds of 
heterochromatin exists. Constitutive heterochromatin consists of particular regions that 
are not expressed, such as repetitive sequences. Facultative heterochromatin is regions 
inactive in one cell lineage but which may be expressed in other cell lineages [Sil. In 
most regions however, the chromatin is less densely packed than in the mitotic 
chromosome. These regions are called euchromatin. Euchromatin is actively 
transcribed 1^^ .^
1.3  Large scale DNA sequencing
1.3.1 History of DNA sequencing
The first approach to nucleic acid sequencing followed the same strategy of 
protein sequencing. The molecule was first broken into small overlapping pieces with 
different reagents and the composition of each small fragment were determined. By 
overlapping the small pieces, the exact sequence of the molecule was deduced. This 
method is practical for protein because twenty amino acids provide a large variety, but 
for DNA, there are only four different nucleotides and the composition hardly reflects 
the sequence. It was only possible for this initial approach to sequence very short DNA 
[156, 157]
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In 1978, two different methods of DNA sequencing were introduced. The first 
one, developed by Maxam and Gilbert in Cambridge, MA, is a chemical cleavage based 
approach [tS8] the second, developed by Sanger and Coulson in Cambridge, 
England, is an enzymatic synthesis based approach 1^ 59] jh e  two methods share the 
same general principle. Each method generates a series of single-stranded DNA 
molecules, each molecule is one nucleotide longer than the last This set of DNA 
molecules is separated on an acrylamide gel, because the acrylamide gel has the ability 
to separate DNA molecules only one nucleotide different in size. If there are four 
different reactions which can generate a series of DNA molecules with one of their ends 
known, upon separation on the gel in four parallel lanes with each lane containing only 
one specific ending, one can deduce the sequence according the ladder of bands on the 
gel. The difference between these two methods lies in the methods to generate the 
series of DNA molecules.
The Maxam and Gilbert technique involved chemical cleavage of a DNA strand 
by using different base-specific modifying chemicals. Two aspects must be 
emphasized. First, the cleavage must be specific. Because four distinct chemical 
agents were not available, combinations of chemicals were used. G cleavage 
(dimethylsulfate and heat) is very effective with guanine but it also has a weak effect on 
adenine. The difference of the reactivity is sufficient to distinguish on a gel. The 
reaction, dimethylsulfate and acid, cleaves at A, but also cleaves weakly at G. 
Hydrazine and salt together will cleave only at C, but hydrazine alone will react with C 
and T. Second, the cleavage should be partial at any susceptible position. Any site 
with appropriate base should only have a small possibility to be cleaved so that every 
sites will have the same opportunity. With only the 5' end labeled, if the cleavage is
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complete, only one band can been seen on the gel and the sizes of resulting fragments 
will not reflect the DNA sequence liSB]
Sanger and Coulson developed a sequencing method which utilized the 
polymerase activity of the Klenow fragment of £. coli DNA polymerase I. With the 
presence of small amoimt of 2',3'dideoxynucleotides, the chain elongation will be 
terminated if dideoxynucleotide is randomly incorporated because the ending 
dideoxynucleotide lacks the 3' hydroxyl group required for polymerization. If four 
dideoxynucleotides are used in four separated reaction, each reaction will give a set of 
DNA molecules in different length with the end according to the dideoxynucleotide 
used. DNA polymerization is from a defined site beginning with an oligonucleotide 
primer which is required for the enzyme and different labeling systems can be used for 
the detection of the resulting nested fragments. Primer, Dideoxynucleotides or building 
block deoxynucleotides can be labeled. Because initially, Sanger and Coulson used 
^-P-labeled deoxynucleotides and four separated terminator reactions, the resulting sets 
of DNA molecule fragments were loaded into separated parallel lanes on the gel and the 
DNA sequence could be deduced by the pattern of bands ladder on the gel. For 
example, in the A-specific lane, a band terminated with a dideoxyATP presents a T that 
occurred in the complementary template sequence. This method, dideoxy chain 
termination sequencing, is very simple and extremely accurate and today is preferred 
over the Maxam/GUbert chemical method 1^ 59]
1 .3 .2  Improvement of DNA sequencing
Since the original Sanger sequencing method was introduced, efforts have 
emerged that result in improvement in both its sensitivity and efficiency. Among these 
modifications, several are worthy of mention here.
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1 .3 .2 .1  Enzymes in DNA sequencing
Different enzymes have been used in DNA sequencing. In Sanger’s original 
method, the Klenow fragment of E. coli DNA polymerase I was used. The Klenow 
fragment is the large C-terminal fragment of the en^rme resulting from proteolysis of 
the enzyme. The Klenow fragment has both the DNA polymerization and 3" to 5' 
exonuclease activities but has the S' to 3' exonuclease activity domain removed because 
it will remove the common S' end Modified bacteriophage T7 DNA polymerase 
(Sequenase) is another enzyme often used in DNA sequencing. This enzyme's 3' to S' 
exonuclease activity is eliminated by in vitro mutagenesis in addition to already lacking 
S' to 3' exonuclease activity ft bas higher efficiency of polymerization and wider 
tolerance for nucleotide analogs than Klenow fragment. Sequenase also tolerates the 
fluorescent dye-labeled dideoxynucleotide terminators. More recently two thermal 
stable enzymes have been introduced: Bst {Bacillus stearothermophilus) DNA 
polymerase and Taq {Thermus aquaticus) DNA polymerase 1^ ^^ . The optimum 
reaction temperature for Bst DNA polymerase is 6S°C. This feature of the enzyme can 
help to reduce the DNA secondary structure and GC compression problem. The ability 
of polymerization even under low concentration of template of this enzyme because of 
high polymerization efficiency can significantly reduce the cost of sequencing.
Taq DNA polymerase has an even higher temperature tolerance and thus has an 
advantage over Bst DNA polymerase. The optimum temperature of Taq DNA 
polymerase is 72°C. Taq DNA polymerase as well as several mutant forms of this 
enzyme are the most widely used enzyme used in DNA sequencing today. The first 
mutant of original Taq DNA polymerase is AmpliTaq form ABI (Applied Biosystems 
Division of Perkin Elmer) AmpliTaq is formed by removal of 3' to 5'
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exonuclease activity domain from original Taq DNA polymerase. It can tolerate dNTP 
analogs and DMSO can be included in the reaction to reduce the secondary structure. It 
also can be used in both dye labeled primer and terminator chemistries. AmpliTaq 
exhibits a strong discrimination against incorporation of ddNTPs and requires high 
concentrations of expensive dye labeled terminators,
DNA polymerases differ in their ability to distinguish between dNTP and 
ddNTP. T7 DNA polymerase prefers dNTP by only several folds 167i 
Others prefer dNTP by several hundreds to several thousands folds 1^®^* *^ *1. The 
molecular basis of this lower discrimination against ddNTPS of T7 DNA polymerase 
was first recognized by Tabor and Richardson, and resided in a single hydroxyl group 
on the benzene ring of the residue tyrosine at position 526 P^ l^. At corresponding 
position of Taq DNA polymerase, position 667, it is a phenylalanine. When Phe667 is 
mutated to Tyr, the discrimination against ddNTPs of Taq DNA polymerase reduces 
250 to SOOO-fold The decreased discrimination against ddNTP not only reduces 
the cost of DNA sequencing but also improves the quality and read length of sequence 
data by giving more even signals and less background. KlenTaq-TR, developed by 
Barnes et. al., is a mutant form of Taq DNA polymerase 10^ ®* Actually, the 
precursor of KlenTaq-TR is KlenTaq, a Taq DNA polymerase 1 mutant without 5' to 3' 
exonuclease activity in addition to its already absence of 3' to 5' exonuclease activity 
(wildtype Taq DNA polymerase 1 lacks the 3' to 5' exonuclease activity already). 
KlenTaq DNA polymerase first was developed to increase the fidelity of PCR reaction 
[172] KlenTaq-TR, also named as Taquenase, contains the 3’ to 5’ exonuclease 
KlenTaq deletion but also carries the Phe667Tyr mutation. This mutation reduces the 
discrimination against incorporation of ddNTPS. ThermoSequenase, developed by 
Tabor and Richardson and marketed by Amersham, is similar to KlenTaq-TR but the 
deletion in N-terminal (responsible for removing exonuclease activity) in
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ThermoSequenase is shorter. AmpiiTaq-FS also has a similar Phe667Tyr 
mutation and is marketed by ABI, but the N-terminal mutation of this enzyme has not 
been revealed.
1 .3 .2 .2  Fluorescence labeling and cycle sequencing
DNA sequencing was improved dramatically by the introduction of fluorescent 
labeling methods to replace radioisotopic detection. Fluorescent S'-labeled primers 
were first used instead of radioisotope labeled primers One year later, 
fluorescent labeled ddNTP terminators were introduced These two labeling 
system were commercialized by ABI. In ABFs sequencing kits, fluorescein and 
rhodamine derivatives, FAM, JOE, TAMRA and ROX, each with a slightly different 
maximum emission wavelength, are used in dye-primer reactions. Four rhodamine 
derivative dyes, R110, R6G, TAMRA and ROX are used in dye-terminator reactions. 
Four different dyes in sequencing reaction allow loading four base-specific reactions 
into one lane and still can be distinguished. In dye-terminator chemistry, four base- 
specific reactions even can be done in the same single tube. Fluorescent labeled 
dideoxynucleotides also reduce compressions because the large fluorescent group 
attached to the ddNTP does not allow base stacking on the end of newly synthesized 
chain. Background also is reduced because abortive stops are undetected if they are not 
terminated with a labeled ddNTP. *®^1
With thermostable enzymes available, cycle sequencing was introduced to 
increase the amount of reaction product and thus improve its detection on fluorescence 
1*76.177] In cycle sequencing, all the reaction components are combined and incubated 
for several repeated temperature cycles of dénaturation, armealing and extension. Cycle 
sequencing can yield a large amount of fluorescent labeled DNA extension products by
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cycling Linear amplification. Furthermore, the use of thermostable enzyme elevates the 
extension temperature and reduces the secondary structure which interferes with the 
DNA sequencing and allows for lower template concentration. Cycle sequencing also 
is convenient for sequencing reactions using double-stranded template because no initial 
denaturing step is needed. For custom primer reactions in gap closure stage, dye 
labeled primers are impractical because the labeling of each primer increases the cost 
and time dramatically. In contrast, a dye labeled terminator reaction can use any 
primer, and therefore this approach is used exclusively in the gap closure stage.
1 .3 .2 .3  Nucleotide analogs
Deoxyguanosine triphosphate has been replaced by deoxyinosine triphosphate, 
a-thionucleotide triphosphate or deoxy-7-deaza guanosine triphosphate to eliminate the 
gel artifacts caused by short stretches of dyad symmetry, especially those regions 
containing a high proportion of G/C, that result in intrastrand secondary structure. 
Although dTTP can pair with dCTP, only two hydrogen bonds are formed and it, like 
a-thionucleotide, can reduce the possibility of secondary structure. 7-deaza-dGTP 
does not participate in base stacking thus also reduces the possibili^ of secondary 
structure l^^»
1 .3 .3  Large scale DNA sequencing strategy
Strategies for large DNA sequencing basically fall into two major categories: 
directed sequencing and random shotgun sequencing.
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1 .3 .3 .1  Directed sequencing strategy
Directed sequencing entails sequencing the target DNA directly &om both ends 
using a series of primers. Primers for the first set of sequencing reactions are based on 
the known sequencing data in the cloning vector. The primers for the next set of 
sequencing reactions are synthesized based on the data of previously sequenced 
regions. Every step uses the newly syn±esized primers and the same target DNA as 
template. The sequence data can be extended into the unknown region by this stepwise 
pattern. By sequencing 300-400 bp each time, all of the unknown region can be 
covered. This strategy is very straightforward and does not result in any assembling 
problems, because the exact locations of all newly sequenced data are known. This 
strategy is very useful and has been widely used to sequence relatively short cloned 
DNA fragments such as eukaryotic cDNAs. If the target DNA fragment is large, prior 
digestion with restriction enzymes is necessary. The resulting shorter DNA fragments 
then are cloned and directly sequenced. This strategy has shortcomings. First, it is 
slow as only two sequencing reactions can be performed at the same time and the next 
step can not be carried out until the sequence data is available. Second, it is expensive 
where every sequencing reaction requires a newly synthesized primer. Furthermore, 
dye labeled primer reactions are impractical for this strategy because of the expensive 
labeling process.
Another directed sequencing strategy eliminated the requirement of primer 
synthesis. Instead of walking along the target DNA into the unknown region, in this 
method the target cloned DNA is degraded unidirectionally by exonuclease EH, which 
digests the DNA from the 5' protruding or blunt end but the sequencing primer binding 
site is protected by having a 3’ overhang. The nested set of deletions from one end of
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the target DNA then are ligated back to the end with sequencing primer binding site. In 
this way, the unknown region of the target DNA is effectively moved closer to the 
sequencing primer site. Universal sequencing primer on the vector then is used to 
sequence the target DNA and the assembly is easy because the order of the nested set of 
DNA fragments is known based on the time of the exonuclease digestion i79i
1 .3 .3 .2  Random shotgun sequencing strategy
In the random shotgim sequencing strategy, the target DNA is not sequenced 
directly, but instead, various techniques are employed to generate a library of subclones 
which contain randomly distributed DNA fragments from the initial target DNA. These 
resulting subcloned DNAs then serve as templates for sequencing. Techniques 
involved in generation of randomly distributed DNA fragments are sonication l^ ^O.
181]^  nebulization 1^ *2,183]^  transposon insertion U84]^  and partial restriction 
digestion 1*^ 1. The random shotgun sequencing strategy can deal with a very 
large DNA project, and with new automation techniques, is efBciently applied to large 
sequencing projects such as large insert clones from the human genome project.
Because a large amount of sequence data from randomly distributed DNA fragments is 
generated, computer programs are needed to assemble the overlapping fragments into a 
single contiguous sequence.
The number of random subclones required depends on the length of the target 
DNA and accuracy demanded. The accuracy of the sequence depends largely on the 
redundancy, i. e., how many times a base has been sequenced with high redundancy 
yielding high accuracy. The accuracy also is improved when both strands of the DNA 
are sequenced. For example, a compression problem observed in one sequencing 
direction may not occur in the opposite direction. Because a very large number of
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subclones is needed to cover 100% of the target DNA by a totally random shotgun 
approach, after data from a certain number of sequencing reactions has been collected 
and the sequence of the most of the target DNA is known, a more directed approach 
then is used. This is because most of the gel readings collected after that time will fall 
into the known region and will not help to cover the gaps between known regions. 
When the redundancy reaches a certain level, which is practically determined to be 
enough to maintain the accuracy, random sequencing will be stopped. Directed 
sequencing then is engaged to close the remaining gaps. The redundancy only reflects 
the average number of times a base has been sequenced. If the subclone generation 
were absolutely random, every base would have same coverage, but in reality this 
process is not random. However, the randomness of subclone generation is sufficient 
if highly random cleavage approaches are employed and these more randomly generated 
subclones will require fewer gel readings to reach the same degree of accuracy. The 
question of how many gel readings needed to finish a project turns out in more of a 
question of when the shotgun sequencing should stop and the directed sequencing 
phase should start. A project can be finished by using a very large number of shotgun 
sequencing gel readings with only a few short gaps left, therefore using only a few 
directed sequencing gel readings, or it can be finished by using a minimum number of 
random sequencing gel readings and a large amount of directed sequencing data to ( 1) 
close large numbers of remaining gaps and (2) resequence large numbers of regions 
with less accuracy. The answer to this question lies in the answers to the following 
questions: How expensive is a shotgun random sequencing reaction? How expensive 
is a directed sequencing reaction? What accuracy is required for a project? Which, 
shotgun sequencing or directed sequencing, needs less time?
When random shotgun sequencing is stopped and all gel readings are 
assembled, we will get a series of contigs. The orientation of these contigs are
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important to know in the gap closure stage if PCR is used to generate the templates over 
the gap regions. In MIS-based single-stranded sequencing, the order of the contigs 
and their relative positions in the genomic target sequence are difficult to determine, 
although restriction map and some sequenced tags may be helpful. In plasmid-based 
double-stranded sequencing, because both ends of the insert are sequenced, the 
orientation of the matched forward and reverse sequence pair is known. This 
information is extremely useful to determine the orientation of the contigs as well as to 
assure the correcmess of final assembly.
Gap closure stage is one of the most challenging and time consuming steps in 
large scale DNA sequencing because various difficulties may be encountered. In this 
dissertation, a strategy of gap closure has been worked out. This strategy involved 
resequencing the ends with different chemistries, primer walking, PCR, and PCR 
product and subclone fragmentation (see Methods and Materials for detail).
1 .3 .3 .3  Cloning vectors in large scale DNA sequencing
DNA cloning is an extremely powerful way to amplify individual DNA 
sequences. Here, the target DNA is inserted into a carrier, called a vector, which then 
is transformed into the host cell where it can be replicated by host enzymes. The vector 
has the ability to replicate both itself and inserted DNA. The vectors used in this study 
include plasmids, bacteriophages, cosmids, forsmids, BACs and PACs.
Plasmids are double stranded, extrachromosomal DNA often naturally found in 
several bacterial strains. Naturally occurring plasmids typically contain important genes 
such as antibiotic resistance genes, bacterial conjugation gene for its transferring from 
one cell to another, and replication regulatory genes, Plasmids also have sequence
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representing the region for origin of replication, but the replication of plasmids usually 
relies on entirely on enzymes supplied by the host. 1*®®! In some instances, plasmid 
replication also is regulated by several proteins encoded by the plasmid itself. 1‘®^1 
Under normal growth condition, a few copies of the plasmids are maintained in a host 
cell. [190] To be used as a cloning vector, the negative regulation system of the 
replication is weakened by introducing mutation into the relevant gene, l^ ®®! therefore 
larger number of plasmids can be obtained from a single cell. pUC vectors are such 
kind of vector genetically engineered to have the copy number as high as 500-700. [*• 
The number and position of restriction enzyme cleavage sites where the foreign DNA 
insertion will take place are engineered. pUC vectors now have been engineered to 
contain over a dozen such sites. 092] The capacity to accept fragments of foreign DNA 
for a plasmid is limited in the transformation step, because the efSciency of 
transformation is inversely related to the size of the plasmid. Selectable markers are 
important characteristics of a plasmid vector. The most commonly used selectable 
markers are genes that confer resistance to antibiotics. 093] When plated on antibiotic- 
containing media, only those cells which uptake the plasmid upon transformation can 
survive. Other selectable markers are to distinguish host cells carrying nonrecombinant 
plasmids from those carrying an interesting DNA fragment. Here, a segment of DNA 
derived from the lac operon of E. coli was included in the original pUC vector system 
because it contains the regulatory sequences and the coding information for the first 146 
amino acids (Lac Z") of the enzyme ^-galactosidase which cleaves lactose. 1192] ^  
polycloning site is inside the p-galactosidase gene but does not dismpt the function of 
the gene. This kind of vector is used with host cells that code for the carboxyl-terminal 
portion of P-galactosidase. Although neither the host-encoded nor plasmid-encoded 
fragments are active, they can associate to form an enzymatically active protein. ['94] 
Thus, when foreign DNA is inserted into the polycloning site, the insert causes 
expression of a dysfunctional lac Z protein. In the presence of isopropyl-P-D-
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thiogalactopyranoside (IPTG), an inducer of the synthesis of Lac Z , and 5-bromo-4- 
chloro-3-indolyl-P-D-gaIactopyranoside (Xgal), a chromogenic substrate for P- 
galactosidase, cells carry a nonrecombinant plasmid will produce a functional P~ 
galactosidase protein which cleaves Xgal resulting in blue colonies, whereas those with 
inserted DNA will produce dysfunctional P-galactosidase and resulting colorless 
colonies. This color selection mechanism allows for differentiation between cells with 
only vector pUC DNA and those cells with pUC vector containing inserts.
A bacteriophage or phage is a virus that infects a bacterium. The infection of 
the host cell by phage involves injection of phage DNA into host cell. After replication 
and expression, a large amount of phage progeny will be released into the medium.
This feature of phage's life cycle makes the phage a suitable cloning vector, Major 
families of bacteriophage vectors are A, phage derivatives and M13-alike vectors. The X 
phage derivative vectors have linear double-stranded genome. Soon after entering the 
host cell, the cohesive termini of the linear DNA associate to form a circular molecule. 
Foreign DNA is inserted by cutting the linear phage genome into two pieces and 
integrating the foreign DNA into the X phage genome. The life cycle of this vector is 
relatively complex, The length of foreign DNA that can be cloned were
limited because the capacity of the phage head prevents genomes that are too long from 
being packaged. Thus, the nonessential portions of the phage genome were removed. 
However, the resulting genome itself is too short to be packaged into the phage head. 
Thus only those genomes with approximately 20 kb of foreign DNA fragments can 
generate phage progeny. The size of insert DNA depends on how much of the X phage 
genome is removed, because the X phage can pack the DNA from 78% to 105% of the 
size of wild-type X phage genome, MI3 bacteriophage is a quite different bacterial 
virus. It is one of the members of frlamentous bacteriophage. 199] contains
a single-stranded closed circular molecule of DNA and after entering the host cell, the
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single-stranded DNA (+ strand) is converted to double-stranded RF DNA where the (-) 
strand is used as templates for expression and replication. The replication mechanism 
is rolling-circle replication. The resulting (+) strand progenies are cleaved and 
circularized. [200-203] Another feature of M13 is the morphogenesis of phage particles. 
Unlike most other bacterial viruses, they do not assemble phage particles inside the cell. 
Instead, the DNA, bound with single-stranded DNA binding protein, moves to the host 
membrane where the binding protein is stripped and the DNA is extmded through the 
membrane and becomes covered with capsid. 205] xjjjs important feature gives 
this vector no strict limit to the size of foreign DNA to be cloned, For M13- 
cloning, the RF DNA of the M13 phage is isolated and used as vector because it is 
double-stranded. Like plasmid vectors, M13 vectors also contain genetically 
engineered polycloning sites, antibiotic resistance gene(s), and other selectable 
markers.
The attempt to combine some of the advantages of plasmids and phages led to 
the construction of cosmids. Cosmid vectors are modified plasmids that carry a copy 
of the DNA sequences, cos sequences, required for packaging DNA into bacteriophage 
X particles. Because cosmids carry an origin of replication and selectable markers as 
plasmids, cosmid vectors can be propagated as plasmids. Because they contain cos 
sequences, they can be packaged in vitro into X phages. By eliminating the large-sized 
phage genome, they can carry foreign DNA fiagments up to 40 kb. [^ 87.207-2101 y a C  
(yeast artificial chromosome) and recently developed BAG (bacterial artificial 
chromosome) fosmid and PAG vectors also are useful for cloning even larger DNA 
fragments. [211-214]
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1.3 .3 .4  Automated instruments for large scale DNA sequencing
The development of cycle sequence and fluorescent labeling systems opened the 
door for automated large scale DNA sequencing. Cycle sequencing was developed 
based on the same strategy as PCR but with only one primer used. 1^ 76. irr\ Cycles of 
dénaturation, primer annealing and extension allow the repeated use of the template 
resulting in very high signal intensity from a small amount of template. These two 
advantages of cycle sequencing made the automation feasible. The high signal intensity 
made the signal detection easier and with less template being required, template 
isolation was less expensive. The fluorescent labeling system brought a safer, quicker 
and more efficient way of signal detection. Several fluorescent DNA sequencing 
instruments were developed in about a decade. One DNA sequencer was developed by 
Ansorge et al. 216I the European Molecular Biology Laboratory (EMBL) and is 
marketed by Pharmacia. This instrument employs only a single dye, with the four 
base-specific reactions performed in four separate tubes and electrophoresed in four 
different wells of a denaturing polyacrylamide gel. The fluorescent dyes are excited by 
a laser beam directed into the gel and the detector is position perpendicular to the 
direction of laser excitation. Hitachi developed a similar fluorescent sequencer. The 
detection system differs from the EMBL system in that the emitted fluorescence is 
screened through bandpass filters, enhanced by an intensifier and detected by a camera 
before the data is communicated to an associated computer for analysis. Li-Cor 
introduced an automated DNA sequencer in 1992, which differs from Pharmacia and 
Hitachi as it uses infrared fluorescence technology. It also uses single dye labeling 
system and it can simultaneously detect two reactions in one four-lane set by using two 
different dyes and loaded together, 218]
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The DNA sequencer developed by Perkin Elmer's Applied Biosystems was the 
first commercially available fluorescent sequencer and today is most widely used. 1219. 
2201 All data in this dissertation research was collected from either of the two types of 
ABI’s instruments, ABI DNA sequencer 373A or the updated model ABI 377. Both 
instruments utilize a principle of four different fluorescent dyes which allows the four 
base specific reactions to be pooled and electrophoresed in a single lane of a 
polyacrylamide gel, thereby increasing the number of samples which can be processed 
per machine run by a factor of two or four with respect to the other instruments 
available. Both ABI instruments have a scanning argon laser, as in Pharmacia and 
Hitachi's machines, for excitation, but the ABI 377 uses a CCD (charged coupled 
device) camera instead of a PMT (photomultiplier tube), which is used in ABI 373, for 
detection. In the 373, the laser excites the fluorophores through a circular bandpass 
filter, one for each fluorophore. The emitted photons have characteristic wavelengths, 
depending on the fluorophore. The photons are detected, amplified by a PMT and the 
raw data stored by the associated computer. In contrast, the 377 detection system uses 
the same type of argon laser to excite the fluorophores but a series of lenses collect and 
focus the emitted light onto a spectrograph diffraction grating which separates the light 
based on wavelength into a predictably spaced pattern across a CCD camera. Using the 
collected light intensities from the CCD camera, the collection software records the 
amplified emission signals from the CCD camera and the raw data is stored by an 
associated computer. The CCD detection system is much more sensitive than the 373 
PMT detection system. Over the past few years, the sample loading capacity of ABI 
373A and ABI 377 has been increased from 24, to 36, to 48, and now to 64 samples 
per gel. The polyacrylamide gel thickness used in ABI 377 is 0.2 mm and 0.4 mm in 
the ABI 373A.
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Chapter II 
Methods and Materials
2 .1  Random shotgun sequencing strategy
Large scale DNA sequencing can be achieved by two strategies: one is directed 
sequencing and the other is random shotgun sequencing. In directed sequencing, the 
target DNA initially is sequenced directly from both ends to obtain the sequence at the 
vector-insert junction. From this data, sequence walking primers are synthesized and 
sequencing reactions once again are carried out using these newly synthesized primers 
and the target DNA as template. Thus, the sequencing data can be extended from the 
known into the unknown region. This procedure is repeated until all of the unknown 
region is sequenced. This method has several shortcomings. First, it is slow. Every 
time sequencing reactions are performed, only two ends of the target DNA are 
sequenced. Second, it is expensive. New unique primers are needed for every 
sequencing reaction. Random shotgun sequencing strategy in the other hand, does not 
use the target DNA directly as a template. Instead, the target DNA first is broken into 
small pieces and after sub-cloning, these small pieces are used as templates for the 
sequencing reaction. Because these small pieces are subcloned into the same kind of 
vector, the same universal primer, whose complementary sequence resides inside the 
vector, can be used to sequence different inserts. This approach solves the problems 
directed sequencing has. However, random shotgun sequencing also has its 
disadvantages. Because the random breaks in the target DNA are not truly random and 
because of the possible bias of subcloning, every base (or region) in the target DNA 
may not have the same chance to be sequenced. Some regions may be sequenced 
excessively while some regions may not be sequenced even once. The problem can be
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solved by applying the directed sequencing strategy once the initial data is collected by 
random shotgun sequencing.
Random shotgun sequencing strategy can be divided into two stages. The first 
stage is break down. Target DNA such as cosmid, PAC, or BAG usually is large. It 
has to be broken into small pieces about 3 kb in size. Such small pieces of DNA are 
subcloned into vectors such as M13 or pUC18. The end sequences of these small 
pieces are obtained and entered into a database. The second stage is assembling. The 
end sequences of these small pieces are assembled together into large contigs by the 
means of computer programs which find overlaps of small sequences and align them. 
Finally, all the sequences are joined to form a full length contig which represents the 
sequence of the original target DNA (Figure 8). However, even after several-fold 
coverage of shotgun clones have been sequenced, there still are regions for which 
sequence data has not been obtained and directed sequencing should be performed. 
Therefore the key consideration in any strategy is when to switch from random 
sequencing to directed sequencing. This depends on two things. One is how much 
coverage is needed for every base of the sequence and the second is the cost of directed 
sequencing. Usually, directed sequencing will cost more than shotgun sequencing, and 
if shotgun sequencing is stopped too early, it is difScult to reach the required coverage 
for every base without an excessive number of directed sequencing reactions, and the 
cost of a project will be extremely high. On the other hand, if too many shotgun 
sequencing reactions are performed, large amounts of unnecessary coverage occurs at 
many areas and this also increases the cost.
To obtain a final sequence accuracy of less than one error or uncertain base per
10,000 bases sequenced, it has been established that every base must have at least 
three-fold coverage and that the sequence from at least one opposite directioned clone
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i physical shearing and end-repairing
1 clone the fragments into pUC vectors
1 sequence the ends of subclones
computer assembling
gap closure
Figure 8: Shotgun sequencing strategy
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Figure 9: R u le  o f  three coverage:
u ,w Final
Note: The region labeled with "final" meets the criteria of rule of three. 
All other regions are considered as gaps.
spans each base. A diagram is provided to visualize this requirement (Figure 9). Thus, 
it has been established that, based on cost and efficiency, large numbers of shotgun 
clones should be sequenced until the average coverage reaches Gve to six fold and then, 
the directed sequencing phase should begin. Directed sequencing in this stage usually 
entails primer walking on existing subclones covering the region, or if there is no 
subclones covering the region, a PCR product covering the region is generated Grom the 
original target DNA. Because the shotgun stage is usually easy and routine, most 
difficulties will be encountered in this gap closure stage. A gap closure strategy will be 
discussed below.
At the early stage of this dissertation research, sonication was used as the 
physical force to shear the large-sized target DNA. Because of the possible 
unrandomness of sonication shearing and the difficulty of controlling of the sonic 
strength needed to produce desired size of products, nebulization was employed to 
overcome the shortcomings of sonication.
Single-stranded M13mpl8 vector also was used at the initial stage of this work 
because the single-stranded DNA sequencing method was sophisticated at that time. It 
was believed that single-stranded template was easier to sequence than the double- 
stranded ones. With the development of thermo-stable DNA polymerases, the cycling 
sequencing reaction with high denaturing temperature, and improved double-stranded 
template preparation, the double-stranded DNA sequencing became practical. Double­
stranded DNA sequencing has several advantages in large scale DNA sequencing. 
Obviously, template number required for Gnishing a project can be reduced by one-half 
by using double-stranded template comparing with using single-stranded template 
because double-stranded template allows one to sequence both ends of the insert with 
universal forward and reverse primers. Double-stranded DNA sequencing also has the
53
advantage of being helpful in assembling the gel readings and organizing the database. 
When two sequences from both ends of one template are present in the database, the 
information about the orientation of these two sequences is known. This information 
can be used as quality assurance that the final assembly is correct and thus a misjoint 
would be observed if the orientation of two sequences fi:om one template is not correct. 
It also is very useful to obtain the orientation information about two unjoined contigs if 
there are enough information of pairs of sequences fix>m same templates. When a 
large-sized repeat region is encountered, known orientation of two sequences from one 
template also can be very useful to determine where one sequence should be oriented 
when the position of the other one is known.
2 .2  Material preparation
2 .2 .1  Large scale DNA isolation
The method used for large scale cosmid DNA isolation is based on a 
modification of alkaline lysis procedure. 1221] After crude DNA was isolated, different 
methods were tested to further purify the DNA. At the early stage of the dissertation 
research, equilibrium ultracentrifugation in cesium chloride-ethidium bromide gradients 
was used. 1222] This method gave very pure DNA but the dealing with the carcinogen 
ethidium bromide was dangerous and the procedure was time consuming. A more 
recent method using diatomaceous earth to bind-elute DNA was less hazard and easy to 
do. 1223] The disadvantage of diatomaceous earth based method was that in some cases 
the yield of DNA was reduced. Recent results indicated that the diatomaceous earth 
purification step could be omitted if extreme care was taken during the cleared lysis 
phase, and the resulting DNA quality was sufficient to allow it to be used as a template 
for shotgun sequencing.
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2 .2 .1 .1  Large scale DNA isolation by diatomaceous earth
A smear of colonies of cosmid were picked and transferred into a 12X75 mm 
Falcon tube containing 3 ml of LB medium (10 g Bacto-Tryptone, 5 g Bacto-yeast 
extract, and 10 g NaCl in 1 L H2O, autoclaved) with appropriate antibiotic. After 
incubating at 37°C for 8 hours with 250 tpm shaking, the culture was transferred to a 
250 ml flask containing 50 ml of the same medium and incubated for 8 hour under the 
same conditions. Then, all 53 ml of the culture was transferred into a 2 liter flask 
containing 1 liter same medium and incubated for additional 8 hours. After harvesting 
the cells by centrifugation at 7000 rpm for 20 minutes in 500 ml bottles in the RC5-B 
using the GS3 rotor, cell pellets were frozen and stored at -70°C. Prior to use, the cells 
were thawed and resuspended in 35 ml of GET (50 mM glucose, 25 mM Tris-HCl, pH
8.0, and 10 mM of EDTA, pH 8.0) by gently teasing the pellet with a spatula and then 
70 mg of lysozyme was added to a final lysozyme concentration of 2 mg/ml. After 
mixing gently, to make sure lysozyme was dissolved completely, the solution was 
incubated at room temperature for ten minutes. Then 70 ml of alkaline lysis solution 
(0.2 N NaOH and 1% SDS) was added and after gently mixing until the solution was 
homogenous, it was incubated for 5 minutes in an ice-water bath. Then 70 ml of 3 M 
NaOAc, pH 4.8 was added and mixed gently by inverting the bottle several times and 
then the bottle was placed an in ice-water bath for 45-60 minutes. The lysate was 
cleared from precipitated SDS, proteins, membranes, and chromosomal DNA by 
pouring through a double-layer of cheesecloth, transferring the lysate into 250 ml 
centrifuge bottles and centrifuging at 10,000 rpm for 30 minutes at 4°C in the RC5-B 
using the GS A rotor. If necessary, an additional centrifugation was performed to 
ensure that all insolubles were removed. The supernatant then was transferred into a 
500 ml bottle and DNase-free RNase A (stock solution of 20 mg/ml of RNase A in I
tnM NaOAc, pH 4.5 is boiled for 10 minutes and cooled down in room temperature 
before using) was added to the final concentration of 100 ug/ml. After incubating in 
31°C water bath for 30 minutes, an equal volume of isopropanol was added and mixed 
well, the solution was held at room temperature for 5 minutes prior to centrifugation at
9,000 rpm for 30 minutes in RC5-B using GS3 rotor. The supernatant was decanted 
and the pellet drained. The DNA pellet then was dissolved in 20 ml of 10:1 TE ( 10 mM 
Tris-HCl, pH 7.6, 1 mM of EDTA, pH 8.0), divided into two 50 ml Coming 
centrifuge tubes and 40 ml of the defined diatomaceous earth (suspend 10 g of 
diatomaceous earth in 100 ml distilled water and let it settle down for 3 hours, decant 
the supernatant) in 6M Guanidine-HCl (100 mg defined diatomaceous earth/ml, 50 mM 
Tris-HCl, 20 mM EDTA, final pH 6.4) was added into each tube. After mixing well 
and setting at room temperature for 5 minutes with occasional mixing, and 
centrifugation in Beckman GS-6 R centrifuge at 3000 rpm for 10 minutes, the 
supernatant was decanted and 40 ml of wash buffer (equal volume of 10:1 TE and 
ethanol) was added to each tube to resuspend the diatomaceous earth. After 
centrifugation as before, and decanting the supernatant, the diatomaceous earth was 
suspended in 40 ml of acetone and centrifuged for 10 minutes, following by decanting 
the supernatant and drying in a vacuum oven. After the diatomaceous earth was dry,
20 ml of 10:1 TE buffer was added and after incubation at 65°C water bath for 10 
minutes, and centrifiigation in the GS-6 R for 15 minutes at 3000 rpm, the supernatant 
was collected. To improve the recovery, another 20 ml of 10:1 TE buffer was added to 
the diatomaceous earth, and after resuspending and incubating at 65°C, the supernatant 
was collected as before and pooled with the first supernatant prior to standard ethanol 
precipitation (2.5 volume of 95% ethanol with 0.12 M NaOAc, incubate in ice-water 
bath for 30-45 minute and precipitate). The final pellet was washed with 1 volume of 
70% ethanol and dried. The dried pellet usually was dissolved in 2 ml of ddH2Û and 
the DNA concentration was estimated by agarose gel electrophoresis.
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2 .2 . 1 .2  Large scale DNA isolation by CsCl gradient purification
The ceil growth and cell lysis procedure were the same as in the procedure 
given above, but once lysed and centrifuged, the clear lysate was mixed with one- 
fourth volume of 50% PEG/0.5 M NaCl by swirling and incubated in an ice-water bath 
for 1-2 hour. After collecting the PEG-precipitated DNA by centrifugation at 7000 rpm 
for 20 minutes at 4°C in the RC5-B using the GSA rotor, the pellets were dissolved in 
a combined total of 32 ml solution containing 100:10 TE buffer, 5 ml of 5 mg/ml 
ethidium bromide, and 37 g cesium chloride. After transferring the sample into 35 ml 
polyallomer centriftige tubes, removing all of the air bubbles, and sealing, the tubes 
were centrifuged at 60,000 rpm for 16-20 hours at 15-20°C in Sorvall OTD-75B 
ultracentrifuge using the T-865 rotor. The DNA bands were visualized under long­
wave UV light and the lower DNA band representing the supercoiled DNA was 
collected by puncturing the tubes with a 25 gauge needle on a 5 ml syringe. The 
ethidium bromide was removed from the DNA sample by passing through a previously 
equilibrated 1.5 ml Dowex AG column (the Dowex AG resin is treated with 1 M 
NaOH, water and then 1 M Tris-HCl, pH 7.6, until the Dowex solution has a pH of 
7.6) and 0.5 ml fractions were collected. Fractions with an A260 of 1.0 or higher were 
pooled into 35 ml Corex glass tubes and the DNA was precipitated, washed and 
quantitated as described above.
2 .2 .2  Minl'prep Isolation of subcloned DNA
The mini-prep DNA isolation methods for both single-stranded and double- 
stranded subclones are discussed below because even though the doubled-stranded
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pUC vector was used throughout most of this research, ml 3 single-stranded vector 
was used at the early stage.
2 .2 .2 .1  Double-stranded plasmid isolation
Double-stranded plasmid DNA was isolated in 1.5 ml eppendorf tubes during 
the initial stage of this research but more recently in a 96 well block format employing 
the same general strategy as the large scale DNA isolation described above. Here, 1.75 
ml of TB medium (12 g Bacto-Tryptone, 24 g Bacto-yeast extract, and 4 ml glycerol in 
9CX) ml ddH^O, autoclaved) with TB salt ( lOx TB salt stock solution; 2.31 g KH2PO4 , 
and 12.54 g K2HPO4  in 100 ml of ddH2 0 ) and 100 ug/ml of ampicilin was added to 
each well of a Beckman 96 well block. Individual white pUC plasmid colonies were 
picked with a toothpick from an LB plate and inoculated into separate wells on the 
block. The cells were incubated in a 37°C shaker at 350 rpm for 22 hours and then 
harvested by centrifugation in Beckman GS-6 R tabletop centrifuge at 1800 rpm for 5 
minutes. The supernatant was decanted and the cell pellets were drained by inverting 
on a paper towel. Cell pellets then either were frozen at -70“C for at least one hour 
before use or were stored at -70°C for later use. The following isolation steps were 
done either manually or on a Beckman's Biomek 20CX) workstation robot. The cells 
were resuspended in 200 ul of TE-RNase solution (50 mM Tris-HCl, pH 7.6, 10 mM 
EDTA, pH 8.0 and 100 ug/ml of DNase-free RNase A) by pipetting up and down 
several times with 12-channel P-200 pipette until all the cells were resuspended. Then, 
an equal volume (200 ul) of alkaline lysis buffer (0.2 N NaOH, 1% SDS) was added. 
The block was placed in a 350 rpm shaker for about 15 minutes to mix and then an 
equal volume (200 ul) of 3 M NaOAc (pH 4.8) was added to every well and the block 
was shaken again in a 350 rpm shaker for 10 minutes. The block then was sealed and 
set in a -20°C or -70°C freezer for at least half hour. The block then was removed
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from the freezer and the solution was thawed. After centrifugation at 3000 rpm in 
Beckman GS-6 R for 25 minutes to pellet the precipitated SDS, proteins membranes and 
E. coli genomic DNA, 400 ul of the clear supernatant from each well was transferred to 
another block containing I ml of 100% ethanol in each well. The block was incubated 
in an ice-water bath for 30-45 minutes, centrifuged at 3000 rpm for 25 minutes at 4°C 
in Beckman GS-6 R centrifuge and the solution was decanted. The pellet was washed 
with 1 ml 70% ethanol and after 5 minutes spinning at 3000 rpm, the solution was 
drained and the pelleted DNA was dried in a vacuum oven. Resulting pellet was 
resuspended in 50 ul of ddHiO.
2 .2 .2 .2  Single-stranded M13 DNA isolation
An early log phase culture of JMlOl was prepared by inoculating a glycerol 
stock of JMlOl into 50 ml of 2xTY medium (16 g Bacto-tryptone, 10 g Bacto-yeast 
extract, and 5 g NaCl in I L ddHiO, autoclaved) and pre-incubating the medium in a 
37°C water bath for one hour without shaking. Then 1 ml of early log phase JMlOl 
culture was aliquoted into 12x75 mm Falcon culture tubes and individual M13 plaques 
were picked into these tubes with sterile toothpicks. The infected cultures then were 
incubated in 3T°C 250 rpm shaker for 4-6 hours as incubation for more than 6  hours 
may result in cell lysis and contamination of the phage DNA with host genome DNA. 
The culture then was transferred to 1.5 ml microcentrifiige tubes and centrifuged for 15 
minutes at 12,000 rpm at 4°C to separate bacterial cells from the viral-containing 
supernatant. The microcentrifiige tubes then were placed in a special rack which fits 
into the Biomek 1000 workstation and the following pipetting and transferring steps 
were performed by Biomek 1000 robot. Two 250 ul of the supernatant of each sample 
were transferred into wells of 96-well flat-bottomed microtiter plate (Dynatech). Fifty 
ul of 20% PEG in 2.5 M NaCl solution was added to each well and mixed by pipetting
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up and down. The plate was covered with plate sealer and incubated at room 
temperature for 15 minutes. After centrifugation in the GS-6 R at 2400 rpm for 20 
minutes to pellet the precipitated phage, the PEG solution was decanted by gently 
draining the plate upside down on a Kimwipe. The plate was returned to Biomek 1000 
workstation and 200 ul of PEG:TE (1:3) was added to each well. After centrifugation 
and draining as above, 70 ul of TTE (10 mM Tris-HCl, pH 8.0,0.5% Triton X-100, 
and 0.1 mM EDTA, pH 8.0) were added to each well and gently tapped to resuspend. 
The solution from two paired wells were pooled into 1.5 ml microcentrifuge tubes and 
incubated in 80°C water bath for 10 minutes to denature the viral protein coat. The 
DNA was precipitated by standard ethanol precipitation and after drying was resuspend 
in 20 ul ofddHzO.
2 .3  Random shotgun DNA subclone library construction
Large-sized cosmid DNA was sheared initially by sonication and then at later 
stage of this research by nebulization. The size of the resulted DNA was controlled by 
adjusting the strength of the physical force and the viscosity of the solution. The 
resulting DNA fragments have different types of the ends, i. e., blunt, 3' protruding or 
5' protruding and in the later two instances, to subclone them into blunted-end vectors, 
the ends have to be repaired to become blunted-end. After end-repair and 
phosphorylation, the DNA fragments were size-selected by electrophoresis and elution 
from a low-melting temperature agarose gel with appropriate molecular weight marker. 
The excised DNA band was extracted with phenol-chloroform method and after ligation 
into blunted-end vector, was plated out. A diagram is provided to show the general 
procedure for the library construction (Figure 10).
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2.3 .1  DNA shearing
2 .3 .1 .1  DNA shearing by sonication
The generation of random DNA fragments by sonication was performed by 
placing a Microcentrifiige mbe containing the buffered DNA sample into an ice-water 
bath in a cup horn sonicator and sonicating for a varying number of 10  second bursts 
using maximum output and continuous power essentially as described by Bankier and 
Barren. 0**1 The optimal sonication conditions were determined for each given DNA 
sample as they varied from sample to sample. Approximately 100 ug of DNA sample 
was dissolved in 350 ul of Ix TM buffer (50 mM Tris-HCl, pH 8.0, 15 mM MgClz). 
This DNA solution was distributed into ten 1.5 ml microcentrifiige tubes. Five tubes 
were used to test and determine the optimal sonication conditions. Each of these five 
was placed in a Heat Systems Ultrasonics W-375 cup horn sonicator set on "HOLD", 
'CONTINUOUS', and Maximum OUTPUT CONTROL' =10. The DNA sample then 
was subjected to sonication for 10,20,30,40, and 50 seconds with at least one minute 
pause between every 10 second bursts to cool down the sample. This cooling down 
period was important because temperature increase will result in uneven fragment 
distribution patterns. After briefly centrifuging to collect the samples, 10 ul of each 
was loaded onto an agarose gel along with the appropriate molecular weight markers to 
determine which condition produced the desired DNA size distribution. The remaining 
5 tubes then were sonicated under the chosen conditions. All of the fragmented DNA 
samples were pooled and precipitated by adding 2.5 volumes of 95% ethanol 
containing 0.12 N NaOAc. After washing the sample with one volume of cold 70% 
ethanol, and drying in a speedy-vacuum, the DNA sample was dissolved in 35 ul of Ix 
TM buffer and ready for end-repair.
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DNA shearing by physical force
i
end repair of sheared DNA fragment
i
size selection of DNA fragment by electrophoresis
i
DNA extraction by phenol-chloroform method
cloning into pUC 18 vector
i
transformation and plate out
Figure 10: Shotgun DNA subclone library construction
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2 .3 .1 .2  DNA shearing by nebulization
A nebulizer is a small device which originally was designed for clinical use to 
break liquid samples containing either medication or nutrition, into fine droplets. A 
picture of the nebulizer used in this research is shown in Figure 11. After the DNA 
liquid sample was added to the bottom of the bowl, pressured nitrogen gas was 
introduced into the nebulizer fix>m the top. The nitrogen gas was guided into a small 
chamber that was connected to a tube that extended to the bottom into the liquid DNA 
sample. The flowing nitrogen gas created a vacuum in the chamber and the DNA 
sample traveled up the tube and out the hole in the bottom of the small upper chamber, 
where it formed small droplets after colliding with the protruding semi-spherical shaped 
hard plastic surface. The size of product DNA ftagment is inversely proportional to the 
pressure of the nitrogen (actually the flow rate of the nitrogen gas), and also is related 
to the temperature and viscosity of the liquid DNA sample. Glycerol was added to the 
DNA solution to increase the viscosity of the solution and to prevent the freezing of the 
DNA solution. 183]
Approximately 50 ug of DNA was added to the nebulizer to a final volume of
2.0 ml containing 500 ul of glycerol, 200 ul lOX TM buffer. The nebulization was 
carried out in a -20 °C alcohol-dry-ice bath. The nitrogen pressure was adjusted to 8  to 
12 psi and the nebulization time was 2.5 minutes. After nebulization, the sample was 
collected by briefly centrifuging the device in a Beckman tabletop centrifuge at 1500 
rpm. DNA sample then was divided into four microcentrifiige tubes and ethanol 
precipitated. The dried DNA was dissolved into 35 ul of IX TM buffer and ready for 
end-repair.
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pressured nitrogen gas
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chamber outlet
plas ic surfacebowl
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u ptaking tube
DMA sample
Figure II : A nebulizer (left) and a closer look of DNA
shearing parts (right).
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2 .3 .2  End-repair and phosphorylation
Since both sonication and nebulization generated DNA fragments contain a 
certain percentage of single-stranded ends, the fragments were end-repaired prior to 
ligation into blunt-ended vectors. E. coli DNA polymerase I, large (Klenow) fragment 
was used in end-repair. Klenow fragment is a proteolytic product of £. coli 
polymerase I which retains 5’ to 3' polymerization activity and 3' to 5' exonuclease 
activity, but has lost 5’ to 3' exonuclease activity. The 5' overhang of the DNA 
fragment was filled-in by the enzyme's 5' to 3’ polymerization activity and the 3' 
overhang of the DNA fragment was degraded by enzyme's 3' to 5' exonuclease 
activity. Because T4 DNA polymerase has a 3' to 5' exonuclease activity which is 
much more active than that found in the DNA polymerase I Klenow fragment, it also 
was useful to add T4 DNA polymerase as well. After the ends were repaired, T4 
polynucleotide kinase was used to add a phosphate group to 5’ hydroxyl terminus of 
the DNA fragment. T4 polynucleotide kinase also catalyzed the removal of 3'- 
phosphoryl group if any were present.
Here, 35 ul of DNA solution in IX TM buffer, 6  ul of lOX kinase buffer, 6  ul 
of 10 mM rATP, 10 ul of 0.25 mM dNTPs, 2 ul of T4 DNA polynucleotide kinase 
(New England Biolabs), 2 ul of T4 DNA polymerase, and 3 ul of Klenow DNA 
polymerase I fragment (New England Biolabs) were added and the reaction was 
incubated at 37°C water bath for 30 minutes. After stopping the reaction by incubating 
at 70°C water bath for 10 minutes and then cooling the sample on ice, 6  ul of agarose 
loading buffer was added to the solution, which then was loaded onto a low-melting 
temperature agarose gel for size selection.
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2 .3 .3  DNA size selection
DNA solutions from end-repair and phosphorylation reactions with about 10% 
of agarose loading buffer were loaded into separate lanes of a 0 .8 % low-melting 
temperature agarose gel with Hind EH digested X DNA and Hae HI digested ((>X-I74 
DNA size markers run in parallel. Afrer electrophoresing the gel at 120 mA for 60 
minutes, DNA bands in the size range fi»m 1.3 to 4 kb were quickly excised from the 
gel with sterile blazer while being visualized on a long wave UV light box in dark room 
because the duration of exposure of the DNA sample to the UV light should be 
minimized to prevent DNA damage. The gel slices then were placed into 1.5 ml 
microcentrifiige tubes and frozen in -20°C for at least 30 minutes. After melting the 
sample by incubating in a 70°C water bath, an equal volume of TE (10 mM Tris-HCl, 
pH 7.6, I mM EDTA, pH 8.0) saturated phenol was added and after a brief vortexing, 
was centrifuged for 5 minutes at room temperature to separate the phases. The upper 
aqueous layer was transferred to a clean tube and the lower organic phase was 
discarded. Half volume of TE saturated phenol and half volume of chloroform then 
were added to the aqueous phase, and after vortexing and centrifugation as above, the 
upper layer was transferred to a clean tube and an equal volume of chloroform was 
added. After again vortexing and centrifugation as above, the upper layer was 
transferred to a clean tube. An equal volume of water saturated ether was added, 
vortexed briefly and centrifuged for 5 minutes. The upper ether layer was removed and 
discarded and the DNA in the aqueous phase was concentrated by ethanol precipitation. 
After drying, each tube of DNA was resuspended into 20 ul of ddHiO and ready for 
ligation.
66
2 .3 .4  DNA ligation and transformation
The phosphorylated blunt-ended DNA was ligated into Smal linearized and 
dephosphorylated double stranded either M13 replicative form or pUC18 vector. The 
reaction, catalyzed by T4 DNA ligase (New England Biolabs), results in the formation 
of a phosphodiester bond between juxtaposed 5' phosphate and 3' hydroxyl termini in 
duplex DNA. It is also able to repair single stranded nicks in duplex DNA. For every 
set of DNA from different nebulizations, different amounts (usually from 0.1 to 1 ug) 
of DNA were used to determine the optimal ligation condition. The ligation reaction 
always was carried out with positive and negative controls. The positive control was 
the ligation reaction using the target DNA previously digested with Alu restriction 
enzyme. The purpose of this control was to insure the reaction was carried out 
correctly and that every ingredient functioned as they should. The negative control was 
the ligation reaction containing everything but insert DNA firagment. This was to 
determine the extent of any vector self-ligation background.
A typical ligation reaction was as follows: in a microcentrifuge tube, an optimal 
amount of DNA fragment (usually from 0.1 to 1 ug), 20 ng of vector (pUC18 Smal- 
linearized. Calf Intestinal Alkaline Phosphatase-dephosphorylated vector), 1 ul of lOX 
reaction buffer, 1 ul of T4 DNA ligase (400 U/ul), and ddHiO to bring the final 
reaction volume to 10 ul were mixed and the reaction was incubated at 4 °C over night. 
It then was ready for transformation.
DNA transformation is the process by which bacterial cells take up DNA 
molecules, in this case, pUCl8  plasmid containing a ligated insert. Because the 
plasmid DNA has an origin of replication recognized by the host cell DNA polymerase, 
the bacterial will replicate the plasmid DNA along with its genomic DNA. The plasmid
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also encodes the ampicilin (or any other antibiotic) resistant gene and the host bacterial 
genome does not. Thus when the host is subjected to an environment containing 
ampicilin (or other antibiotic), only those host containing such plasmid will survive. 
Because the object of transformation is to get the host cells containing foreign plasmids 
which carry insert DNA of interest, another selection is needed to discriminate host 
cells containing plasmid with and without an insert of interest. Plasmid such as pUC 18 
has lac Z spanning the polylinker region, lac Z operon, when induced by IPTG and 
when not interrupted, will express lac Z gene and the product of this gene is 
galactosidase. Galactosidase will metabolize X-Gal, a modified galactose, to produce 
blue-colored products. When the plasmid carries an insert at polylinker site, lac Z’ 
gene is interrupted and no blue color will be seen. It should be noted that both the M 13 
bacteriophage and pUClS used in this study contain similar poly linker cloning sites and 
the lac Z’ region.
The host bacterial cells usually have limited ability to take up foreign DNA.
Thus the cells need to be treated to increase this ability. The cells with increased 
efficiency of transformation are called competent cells. [224] Jq  prepare competent 
cells, a frozen glycerol stock of the appropriate strain of E. coli, JMlOl for M l3 based 
vector and XLl Blue for pUC based vector was thawed, transferred to 50 ml of 2xTY 
in 250 ml flask and incubated at 37°C water bath for 1 hour without shaking. Then, 
the cells were further incubated in a 37°C shaker at 250 rpm for about 2.5 hours to 
reach early log phase of growth. The cells then were transferred to a sterile 50 ml 
polypropylene centrifuge tube and collected by centrifugation at 2 0 0 0  rpm in a 
Beckman GPR centrifuge for 5 minutes. After decanting the supernatant, the cells were 
suspended in 25 ml of cold 50 mM CaCl] and incubated in an ice-water bath for 20 
minutes. For M13 transfection, 10 ml of original cells culture was saved in an ice-
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water bath for later use. The ceils were collected by centrifugation as above, 
resuspended in 5 ml cold 50 mM CaCl2 and then were ready for transformation.
For transformation, the ligation reaction was mixed with 200 ul of competent 
cell in a 12x75 Falcon tube. After incubating in an ice-water bath for 45-60 minutes, 
the cells were heat shocked by incubation at 42°C water bath for two minutes without 
any shaking. The cells then were chilled in ice-water bath for 5 minutes. For M13 
based transfection, 25 ul of 25 mg/ml IPTG in ddH20,25 ul of 20 mg/ml x-gal in 
dimethylformamide, 0.2 ml of non-competent cells, and 2.5 ml of 55°C lambda top 
agar (10 g Bacto-tryptone, 10 g Bacto-agar, and 5 g NaCl in 1 L of ddH20, autoclaved 
and kept warm) were added, briefly mixed and quickly poured onto a lambda agar plate 
(10 g Bacto-tryptone, 15 g Bacto-agar, and 2.5 g NaCl in 1 L ddH20, autoclaved and 
poured into petri dishes). After the top agar solidified, the plates were inverted and 
incubated at 37°C overnight. For pUC based transformation, 1 ml of 2xTY was added 
and the samples were incubated in a 37°C shaker for 25 minutes. The cells were 
collected by centrifugation at 1500 rpm for 2 minute, the supernatant was decanted and 
then the cells were suspended in 200 ul of 2xTY, to which 25 ul of IPTG and 25 ul of 
X-Gal were added. The samples then were plated onto an LB plate (10 g Bacto- 
tryptone, 5 g Bacto-yeast extract, 10 g NaCl, and 15 g Bacto-agar, autoclaved, cooled 
to 55°C to add antibiotic and poured to petri dishes) with an ampicilin concentration of 
100 ng/ml. The plates were inverted and incubated at 37°C overnight. White colonies 
containing DNA fragments of interest were picked and grown in TB medium as 
described above for plasmid DNA miniprep isolation. Positive and negative controls 
were performed in parallel where the positive control contained circular intact pUC 
plasmid to determine if the competent cells were viable and the transformation was 
carried out correctly, while for the negative control, only competent cells were plated to
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determine if the competent cells were contaminated by other antibiotic-resistant 
plasmids.
2 .4  Dideoxynucleotide DNA sequencing
Sequencing methods used in this research all were based on the Sanger’s 
dideoxynucleotide terminator sequencing procedure with detection exclusively using 
fluorescent dyes. The labeling methods included dye-labeled primers and dye-labeled 
dideoxynucleotide terminators and different DNA polymerases were used to achieve the 
optimal results for different sequencing templates.
Ruorescent dye labels instead of radioactive labels in the sequencing reaction 
are safer to handle, easier to automate and overall yield better quality sequencing 
results. The dye primer sequencing reaction, as will be discussed later, requires four 
separate reactions for four specific bases. In gap closure stage, dye primer chemistry is 
rarely used because every custom synthesized primer needs to be labeled. The dye 
terminator chemistry does not have these disadvantages but the difficulty with this 
chemistry is that the originally available DNA polymerases have very low affinity for 
then-existing dye labeled terminators. Dye terminator chemistry now is widely used 
since new enzymes with high affinity for dye terminators, such as KlenTaq-TR and 
AmpliTaq-FS DNA polymerase, are available. In the very early stage of this research, 
dye labeled primer was used, but for the majority of the research in this dissertation, 
dye labeled terminators were used. AmpUTaq DNA polymerase was the enzyme of 
choice for most of dye primer reactions and more recently was replaced by KlenTaq-TR 
or AmpliTaq-FS DNA polymerase in the dye terminator reactions. Sequenase was 
used for dye terminator reaction in gap closure stage before ABI introduced new dyes 
for terminator labeling. AmpliTaq-FS DNA polymerase was largely used in gap
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closure stage to resequence the contig ends and also used to resequence the regions 
difficult to sequence by other DNA polymerases. Automated sequencing instruments 
from Perkin Elmer’s Applied Biosystem Division were used throughout this work.
The ABI 373A initially was used and then was replaced by the more advanced ABI 
377. Both instruments use a laser to excite the fluorescent dye but the emission 
detection are different, as discussed above, and the ABI 373A uses a PMT but the ABI 
377 uses a CCD camera for detection.
2 .4 .1  AmpiiTaq catalyzed fluorescent labeled primer cycle sequencing
The fluorescent dyes used to label primers from PE's ABD were JOE (4’,5'- 
dichloro-2'7'-dimethoxy-6-carboxyfluorescein), PAM (5’-carboxyfluorescein), 
TAMRA (6-carboxytetramethyIrhodamine), and ROX (6-carboxy-X-rhodamine). The 
dyes were covalently attached to the 5' end of the primer by an amide linkage. Each 
base-specific fluorescent-labeled cycle sequencing reaction routinely included 
approximately 100 or 200 ng of single-stranded DNA or 200 or 400 ng of double­
stranded DNA for A and C or G and T reactions respectively, buffer, four deoxy- and 
one dideoxy-nucleotides, AmpiiTaq DNA polymerase and primer labeled with one of 
four fluorescent dyes. Sequencing reaction was carried out in four separate tubes, with 
the terminating dideoxynucleotide corresponding to the fluorescent labeled primer for 
that particular terminator. The flnal reaction volumes for A and C were 5 ul and G and 
T were 10 ul. Each ingredient in G and T tubes was doubled over that in A and C 
tubes. The final reaction contained 80 mM Tris-HCl, pH 9.0,20 mM (NH4)2S0 4 , pH
9.0, 5 mM of MgCla, pH 7.0, and 1% of DMSG as reaction buffer. The 
concentrations for dNTPs and ddNTP were as follows:
For A reaction: 12.5 uM dATP, 50 uM dCTP, 75 uM of c^dGTP, 50 uM 
dTTP, and 300 uM ddATP,
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For C reaction: 50 uM dATP, 12.5 uM dCTP, 75 uM c^dGTP, 50 uM dTTP, 
and 150 uM ddCTP,
For G reaction: 50 uM dATP, 50 iiM dCTP, 19 uM cMGTP, 50 uM dTTP, and 
25 uM ddGTP, and 
For T reaction: 50 uM dATP, 50 uM dCTP, 75 uM cMGTP, 12.5 uM dTTP, 
and 250 uM ddTTP.
The cycling conditions were 30 cycles of a seven temperature profile of 95°C 
for 4 seconds, 55°C 10 seconds, 72°C for 1 minutes, 95°C for 4 seconds, 72°C for 1 
minute, 95°C for 4 seconds, 72°C for 1 minute. This cycling profile was linked to a 
4°C soak file for storage. After cycling, four reactions for each template were pooled 
together and precipitated with 250 ul 95% ethanol. Dried samples were stored at -20°C 
prior to loading.
2 . 4 . 2  Sequenase catalyzed fluorescent dye terminator sequencing
Single-stranded template Sequenase dye-terminator reaction requires about 2 ug 
of template DNA. DNA template and 3.2 umol of primer in 12 ul of 40 mM MOPS, 
pH 7.5,50 mM NaCl, 10 mM MgClz, 5 mM MnCl2, 15 mM isocitrate and 2.5% 
glycerol solution were denatured at 65-70°C for 5 minutes. The primer was allowed to 
bind to the template by allowing the reaction to cool at room temperature for 15 
minutes. To each reaction, 7 ul of ABI terminator mix, 6.5 unit of Sequenase and 1 ul 
of 2 mM of a-S-dNTPs were added and the reaction was incubated for 10 minutes at 
37°C water bath. Then 20 ul 9.5 M ammonium acetate and 100 ul 95% of ethanol were 
added to the mixture to stop the reaction and precipitate the DNA, which then was 
washed with 300 ul of 70% ethanol twice to remove any unincorporated dye 
terminators. The sample was dried and stored at -20°C prior to loading.
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For double-stranded template, 5 ug of double-stranded template was denatured 
in 12 ul of 0.33 N NaOH solution at 65-70°C for 5 minutes. After denaturing, 3 ul of 
8 uM primer, 4  ul of MOPS-acid buffer (1.35 M acid form of MOPS and 1(X) mM 
MgCl2) and 8 ul ddHiO was added and after brief mixing, 4 ul of lOX Mn^+Zisocitrate 
buffer (50 mM MnCli, 150 mM isocitrate and 25% glycerol), 6 ul of ABI terminator 
mix, 2 ul (6.5 units) of Sequenase, and 1 ul of 2 mM a-S-dNTPs then were added. 
After incubating for 10 minutes at 37°C water bath, the reactions were stopped and 
precipitated as above mentioned.
2 .4 .3  AmpiiTaq catalyzed fluorescent labeled terminator cycle 
sequencing
About 0.5 ug of single-stranded or 1 ug of double stranded template, 0.8 or 3.2 
pmol of primer for single-stranded or double-stranded template respectively, and 8 ul of 
the reaction pre-mix were mixed in a total volume of 20 ul. Reaction pre-mix for ten 
reactions was pre-made by adding 40 ul of 5X TCAS buffer (400 mM Tris-HCl, 10 
mM MgCla, and 100 mM (NH4)2S0 4  pH 9.0), 10 ul of dNTPs mix (750 uM dTTP,
150 uM dATP, 150 uM dTTP, and 150 uM dCT'P), 10 ul of each dye-labeled ddNTP 
terminator (concentration of ddNTPs was not provided by the manufacturer), 5 ul of 
AmpiiTaq DNA polymerase (8 U/ul) together. The reaction was cycled for 25 cycles of 
a three temperatiure profile of 96°C for 15 seconds, 50°C for 1 second, and 60°C for 4 
minutes. This cycling profile was linked to a 4°C soak file. The reaction then was 
applied to a Sephadex G-50 spin column to remove any unincorporated dye 
terminators, dried and ready to load.
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2 .4 .4  KlenTaq-TR (Taquenase) catalyzed fluorescent labeled terminator
cycle sequencing
KlenTaq-TR DNA polymerase is a  mutant form of Taq DNA polymerase, in 
which the N-terminal 280 amino acids has been deleted to eliminate the activity of 5' to 
3' exonuclease, and a mutation of F667Y reduces the discrimination against 
dideoxynucleotides that is observed with the wild-type Taq DNA polymerase. About
0.5 ug of plasmid DNA was used for sequencing reaction and the reaction buffer 
contained 50 mM Tris-HCl, pH 9.2, 16 mM (NH4)2S0 4 , 3.5 mM MgClz, 1 mM 
MnS0 4 . The concentrations of the dNTPs were 150 uM for each of dATP, dCTP, and 
dTTP, and 450 uM of dTTP. The primer amount was 6.5 pmol. The dye labeled 
dideoxynucleotides were used as 0.01 ul of ddA, 0.02 ul of ddG, 0.004 ul of ddT and 
ddC from ABI (initial concentrations were not given by ABI and thus were unknown). 
If the pure dye labeled ddNTPs were not available, 0.01 ul of regular dideoxy 
terminator premix from ABI of unknown concentration were used. The final reaction 
volume was 20 ul. The reaction was cycled for 25 cycles of a three temperature profile 
of 96-98°C for 15 seconds, 50°C for 1 second, and 60°C for 4 minutes. This cycling 
profile was linked to a 4°C soak file. The post cycling treatment was the same as in the 
AmpiiTaq catalyzed dye terminator sequencing.
2 .4 .5  AmpliTaq-FS catalyzed fluorescent labeled terminator cycle
sequencing
AmpliTaq-FS DNA polymerase is similar to KlenTaq-TR and is commercially 
available from PE-ABD. As recommended by ABI, the amount of single-stranded 
template was from 50 to 100 ng and the amount of double-stranded template was from 
300 to 500 ng. For purified PCR product, about 30 to 180 ng was recommended. The
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template was mixed with 3.2 pmol of primer, 8 ul of reaction pre-mix (ddNTPS, dITP, 
dATP, dTTP, dCTP, Tris-HCl pH 9.0, MgCl2, thermal stable pyrophosphatase, and 
AmpliTaq-FS DNA polymerase, the concentrations of above mentioned reagents were 
not available fiom the supplier and the information of other probably used ingredients 
also was not provided by ABI) The cycle condition was 25 cycles of 96°C for 10 
seconds, 50°C for 5 seconds, 60°C for 4 minutes. The post cycling treatment was the 
same as in the AmpiiTaq catalyzed dye terminator sequencing.
2 .4 .6  Unincorporated dye terminator removal by Sephadex G-50 spin 
column
Sephadex G-50 was prepared by adding 20 g of Sephadex G-50 powder to 250 
ml ddH20 and allowed the G-50 to hydrate for several hours before using. The 
column was packed by adding 400 ul of hydrated Sephadex G-50 to each well of 
Millipore 96 well filter plate. The filter plate was placed on the top of a microtiter plate 
and centrifuged at 1600 rpm for 2 minutes in a GS-6R centrifuge. The water that was 
collected in the microtiter plate was discarded and the plate was placed back onto the 
bottom of the filter plate. Then, 200 ul of 1:5 diluted G-50 was added to each well of 
the filter plate and centrifuged for another 2 minutes at 1600 rpm as before. The water 
collected in the lower microtiter plate was discarded as before and a new clean 
microtiter plate was placed below to collect the sample. All 20 ul of terminator reaction 
was added to the center of the top surface of G-50 in each well of the filter plate. After 
centrifugation at 1600 rpm for 2.5 minutes to collect the DNA sample, the microtiter 
plate was covered with Kimwipe, the samples were dried under vacuum and stored in 
-20°C before loading.
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2 .4 .7  Sequencing gel preparation, sample loading and electrophoresis 
on ABI 377
The polyacrylamide gel used in automated DNA sequencing on the ABI 377 
instrument usually was 4.25% polyacrylamide gel containing 8 M of urea in TEE (10 X 
TEE buffer was made by dissolving 108 g Tris, 55 g boric acid, and 8.4 g EDTA in 1 
L solution) buffer. A stock of gel mix was prepared by adding appropriate amount of 
urea (360 g in 1 L solution) to 1 X TEE buffer and dissolving at 55°C with stirring. 
After the urea dissolved completely, the solution was cooled and the appropriate 
amount acrylamide and bisacrylamide (40% stock solution is made by dissolving 380 g 
of acrylamide and 20 g bisacrylamide in 1 L solution) were added. The solution was 
filtered to remove any undissolved particle and degassed by vacuum to remove any air 
dissolved in the solution. Before gel casting, 625 ul of 10% ammonium persulfate 
(APS) and 25 ul of TEMED were added into 50 ml gel mix to catalyze the 
polymerization. After mixing by swirling gently, the solution was immediately poured 
into a preassembled plate set. The thickness of the gel was 0.2 mm. The sharktooth 
comb was inserted backward and the glass plates were clamped tightly. The 
polymerization was at room temperature for usually more than 2 hours. If long time 
storage was needed, both ends of the plate are sealed with plastic wrap covering a moist 
paper towel to avoid gel drying.
After the gel had been polymerized, the glass plates were washed with warm 
water, rinsed with ddH20 and ethanol, and dried in a hood. The sharktooth comb was 
removed, inverted and inserted back to form the sample wells. The plates were 
assembled into the ABI 377 machine using the gel cassette, and a plate check using the 
PLATE CHECK option in the ABI data collection software was performed to assure 
the cleanness of plates. Then, 1 X TEE buffer was added to the upper and lower
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buffer chambers and the gel was pre-run by choosing the PRERUN option in the ABI 
data collection software until the gel temperature reached S 1°C.
Then, 1 ul of loading dye (10 mg/ml blue dextran and 5 mM EDTA in deionized 
formamide) was added to each dried sample, which was heated to 95°C for 4 minutes 
to denature. The samples were ready to load. However, before loading, the sharktooth 
well was cleaned with 1 X TEE buffer using a syringe. The odd number lanes were 
loaded first and after a 2-5 minutes prerun, the even number lanes were loaded and 
RUN option of the ABI data collection software was chosen to electrophoresis the 
sample and collect the data while for 48 lane loading, every third lane were loaded prior 
to the prerun followed by additional two cycles of loading and prerun. A typical ABI 
377 run took 3.5 hoins at 3 kV (limiting parameter) using a 4.25% polyacrylamide, 8 
M urea gel and a Long Ranger run on the ABI 377 took 7 hours at 1.68 kV (limiting 
parameter) using 5.3% Long Ranger polyacrylamide, 8 M urea gel.
The collected data was analyzed by the ABI analysis software. This analysis 
software required manual tracking because the tracking lines created by the software did 
not represent the actual lanes. Once the gel had been tracked, the software would 
extract the data hom each lane, correct the baseline, enhance the signal, correct the 
mobility shift from the fluorescent dyes, calculate base spacing, and finally, call the 
bases. The collected sequence data then was manually transferred to SUN 
SPARCstation for further analysis.
2 .5  Shotgun sequence data editing and assembling
In contrast to the directed sequencing approach, each gel reading of random 
shotgun sequencing has an unknown position relative to others. Thus the gel readings
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must be assembled by aligning them based on overlapping and for large scale random 
shotgun sequencing data assembling, various computer programs can be used. These 
include XGAP (X-window genome assembly program) FAKE (fragment 
assembly kernel), CAP2 (contig assembly program) and PHRAP (Phil's revised 
assembly program) 12271. XGAP, CAP2 and FAKE require pre-edited sequence data 
as input and TED (trace editing program) 1228] is used for editing purpose. PHRAP has 
it own editing program called PHRED1227] and these two programs are linked together 
as a package. All four of these assembly programs are based on Smith-Waterman's 
algorithm 1229].
XGAP was written by Roger Staden at the MRC in Cambridge, England and is 
based on basic Smith-Waterman algorithm. With this user friendly program, the user 
can view and edit the aligned sequence data at all the stages of assembly easily. The 
sample electrophoresis chromatogram can be easily viewed from within XGAP to 
verify the quality of the base calling. The parameters for the aligrunent can be set by the 
user and the assembled contig can be broken if the user considers the assembly has any 
problem. A "Find internal joins" option lets the user view the alignment before 
assembly under a looser stringency, and a "Join contigs " option lets the user join two 
contigs. XGAP also can calculate the consensus of a contig and put the resulting 
output into different formats. It also allows the comparison between the incoming 
sequence data and pre-assembled data already in the database and assembles the 
incoming data into the pre-existing database. Because XGAP does not have a base 
calling quality check function, the sequence data must be manually edited by TED 
before assembly. TED lets the user view the electrophoresis chromatogram and mask 
the 5' end cloning vector sequence and 3’ end ambiguous sequence. The sequences 
containing vector only or very short insert are screened out before the remaining data is 
entered into the database. The shortcomings of this program are that it is time
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consuming, requires significant manual interaction, and does not provide a measure of 
sequence data quality.
FAKE was written by Gene Myers and Susan Larson at the University of 
Arizona and based on an extended Smith-Waterman algorithm. This program also 
needs pre-edited (by TED) sequence data as input. It assembles all of the sequence data 
each time when a new data set is entered and the results can only be viewed and edited 
after converting the FAKH database into XGAP format No qualiQr measurements are 
provided with FAKE but it has the advantage of speed and is capable of handling large 
amounts of data.
CAP2 was written by Dr. Huang at the Michigan Technical University and used 
a further modified Smith-Waterman algorithm. As with FAKE, CAP2 needs pre-edited 
(by TED) sequence data as input and assembles all of the sequence data when new data 
is added. It has some degree of quality checking as certain regions arbitrarily defined 
by the user to have higher quality will be weighted heavier during assembling. The 
program does not have the capability to let the user define the better quality region for 
each individual gel reading. Instead, these numbers are pre-set for each project and the 
program considers that all of the gel readings have the same quality distribution pattern. 
The main advantage of CAP2 is that the initial data included in the assembly is weighted 
for accuracy and thus usually produces fewer contigs than FAKE. Like FAKE, the 
CAP2 database must be converted to XGAP format to be viewed and edited.
PHRED/PHRAP is a program package written by Phils Green at the University 
of Washington. It has a quality check method which gives a quality score to each base 
and thus is more precise than CAP2. PHRED, the editing part of the package, 
calculates the ratio of signal to noise for each base and the peak to peak spacing to
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produce the quality value which then is used in assembling. Because every base in the 
gel reading has a quality score, the 3' end ambiguous sequence does not need to be 
masked and can be used as low quality information in assembling. The result of 
PHRED/PHRAP can be viewed and edited by CONSED (consensus sequence editing 
program) or it can be converted to an XGAP viewable and editable database.
Because each assembly program has it own advantages and disadvantages, the 
research in this dissertation was assembled by different assembly programs and the 
results of each assembly program compared. Any discrepancies were resolved by 
additional sequencing.
2 .6  Final sequence data analysis
After the sequence project was finished, the consensus of the sequence was 
converted to fasta format for analysis. Generally speaking, the analysis contains two 
major parts. First, the sequence was used as a query to search all major DNA 
databases to identify any similarities of known features, which include known genes, 
EST's ( expressed sequence tags), STS's (sequenced tag sites), repeats and other 
sequences already in the databases. This part of the analysis was done using a 
computer program called BLAST (basic local alignment search tool). 1230] Several 
modified BLAST programs can be used. 123 U Basically, the repeat elements in the 
query sequence were filtered by searching the human repeat database. The unique 
nonrepeat regions then were compared with known sequences in the databases and the 
similarities were aligned with query sequences for reference. Second, any potential 
features of the sequence were predicted. These features include potential exons, 
promoters, CpG islands, and poly(A) signals. The structure feature prediction was 
done using GRAIL (gene recognition and analysis internet link) program. 1232] This
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program also gives a visualized pattern of C/G content. M i length repeat elements and 
single base repeats. Potential exon prediction was based on codon usage in open 
reading frame regions, hexanucleotide distribution and the occurrence of a consensus 
exon-intron splice site.
In addition to these two basic analysis tools, other programs were used to study 
selected regions of interest further. The following GCG (Genetic Computer Group) 
programs were used in this research 1233]. BESTFTT program for DNA alignment, 
the TRANSLATE program to translate DNA sequence to amino acid sequence, the 
COMPOSITION program to calculate the G/C content of the DNA sequence, the 
STEMLOOP program to view inverted repeats, the MAP, MAPSORT and MAPPLOT 
programs to display the position of restriction sites, the COMPARE and DOTPLOT 
programs to graphically display the homology comparison for two sequences. Des 
Higgin s Multiple Sequence Alignment program ClustalW [234] also was used for 
amino acid sequences aligiunent and the Cross-match program (developed by P. Green 
at Washington University, unpublished) also was used at the later phase of this study 
for homology comparison. In some cases, Staden's SIP (Sequence Identification 
Program) and NIP (Nucleotide Interpretation Program) were used as altemative 
analysis methods. [233] Dr. Dan Prestridge's SIGSCAN program [236] was used to 
frnd and list homologies of cis-acting regulatory elements and trans-acting factor 
binding sites in DNA sequence. Finally, an on-line protein secondary structure 
prediction program, TMpred [237], provided by Human Genome Center at Baylor 
College of Medicine (http://kiwi.imgen.bcm.tmc.edu: 8088/search-launcber/) was used 
to study protein secondary structure.
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2 .7  Gap closure
After 5-6 fold coverage of shotgun sequence data has been collected and 
assembled into a database, collecting more random shotgun sequences is not 
economical and thus a directed sequencing method was applied to close the remaining 
gaps. Gap closure stage is one of the most challenging stages in large scale sequencing 
because various difficulties may be encountered. In this dissertation research, the 
following gap closure strategy was developed (Figure 12):
I. All the contig ends were resequenced using the AmpliTaq-FS kit from ABI 
with 5-10% DMSO on a 48 cm, 5.3% Long Ranger gel with 8 M urea. Sometime the 
denature temperature of cycling reaction also was increased to eliminate the secondary 
structure of the templates. Usually, AmpliTaq-FS polymerase reaction products 
resolved on a Long Ranger gel will give longer reading in a single run than KlenTaq- 
TR. However, because AmpliTaq-FS kit is more expensive than KlenTaq-TR which 
was used in shotgun sequencing stage, a study performed as part of this dissertation 
research revealed that the sequencing reaction volume could be reduced from 20 ul 
recommended by ABI to 5 ul without any significant loss of signal. Typically, 70-80% 
of initial gaps and ambiguous region could be closed by this method.
n . Primer walking then was performed using custom synthesized primers on 
the template pUC-based clones covering the remaining gap. Before primer walking, 
the gap size was determined by PCR using universal forward and reverse primers. If 
the gap was very large (>2 kb), either the PCR product would be nebulized directly, or 
the clone would be digested by appropriate restriction endonuclease to extract the insert 
and the insert would be nebulized. The nebulized DNA fragment then were subcloned
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Figure 12: Gap closure strategy
and sequenced. If there was no clone covering the gap, PCR reaction would be 
performed as described below.
m . For any gaps with no clone coverage, the gap usually could be obtained by 
PCR using synthesized flanking primers and cosmid DNA as template. The size of the 
PCR product could be estimated by determining the size of the PCR product on agarose 
gels and then, either primer walking or nebulization would be used to close the gap. 
Usually, all the gaps could be closed by one of the above mentioned three alternative 
methods.
IV. In the rare cases that there was no clone covering the gap and attempts to 
PCR the gap failed, the first choice was to re-nebulize the entire cosmid using a low 
pressure (4-6 psi) and low temperature (-20°C) to generate larger DNA fragment, i.e. 
approximately 4-8 kb. These fragments were subcloned and end-sequenced to find a 
clone covering the gap. In other instance, larger DNA fragments could be generated by 
appropriate restriction endonucleases. The resulting restriction digested fragments then 
were gel purified, cloned and end-sequenced to find the clone covering the gap. The 
restriction endonucleases chosen were selected by mapping the available sequence of 
contigs of the cosmid with GCG's MAPPLOT program.
2 .7 .1  Oligonucleotide primer synthesis and PCR
Oligonucleotide primers, either used in primer walking or PCR, were chosen by 
computer programs using the following criteria. First, the primer must be unique i.e., 
it must bind only to the one desired site. Second, it must have about 40-50% of G/C 
with no obvious inverted repeat motifs and the melting temperature (Tm) of the primer 
should be between 50-55°C. Third, when possible, the 3' end of the primer should be
8 4
either a G or a C. The computer programs used in this research to select primers were 
the primer selection function in XGAP, the DSP (oligonucleotide selection program) 
from Washington University, the PRIMER program from Whitehead Institute for 
Biomedical Research, and in the later stages of this research, the Primo program from 
Southwest Medical Center, Dallas.
Oligonucleotides were synthesized according to manufacturer's procedures on 
either the Beckman Oligo lOOOM DNA synthesizer or ABI 392 DNA/RNA synthesizer 
using the phosphoramidite chemistry. Post-synthesis treatment of oligonucleotide 
entailed ammonium hydroxide cleavage of oligonucleotide from the solid support, 
removal of protection group by heating the ammonium hydroxide solution, 
concentration by butanol precipitation and measurement of the final primer yield. Here 
one ml of ammonium hydroxide was used to cleave the oligonucleotide from the 
column at room temperature for 1.5 hours. The solution then was incubated in 70°C 
water bath for at least 2 hours. Four 100 ul aliquots were removed and each was mixed 
with 1.25 ml of butanol. After vortexing to mix and centrifugation at 4°C for 10 
minutes at 13,000 rpm in a microcentrifuge, the oligonucleotides were dried in vacuum, 
and dissolved in 100 ul of ddH20. The amount was estimated in a spectrometer by 
reading the 260 run absorption and assuming one A26O unit in 1 ml solution in a 1 cm 
path is 37 ug of single-stranded DNA.
PCR (Polymerase chain reaction) 1238] typically was performed by mixing 10- 
20 ng of template DNA, 100 pmole of each primer, 20 nmole of each deoxynucleotide,
5 units of AmpliTaq DNA polymerase and 10 ul of lOX PCR buffer (500 mM KCl,
100 mM Tris-HCl, pH 8.5, 15 mM MgCl2) in 100 ul reaction volume. The solution 
was denatured in 95°C for 5 minutes before thermal-cycling begins. The reaction was 
cycled for 25 cycles of a three temperature profile of 96°C for 1 minute, 55°C for 1
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minute, and 72°C for 2 minutes. This cycling profile was linked to a 4°C soak file. 
After the cycling, 10 ul of the reaction was loaded on a 0.8% agarose gel to estimate the 
size and amotmt of PCR product The PCR product then was purified by low-melting 
agarose gel electrophoresis followed by phenol-chloroform-ether extraction.
For the templates difGcult to PCR, 5% to 10% of DMSO 1239.240] was added, 
the dénaturation temperature was increased, or a new primer corresponding to a nearby 
region was synthesized. For long PCR (5 to more than 40 kb), the GeneAmp XL PCR 
kit from Perkin Elmer was used according to the protocol provided by the 
manufacturer.
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Chapter III 
Results and Discussion
3 .1  Summary
Totally 13 cosmids and one PCR product that form four contigs from the 
DGCR region of human chromosome 22 and one BAG clone syntenic to this region 
have been sequenced. Cosmid 59c 10 makes one contig in the proximal portion of the 
DiGeorge Critical Region. Cosmid 19d3,98c4,49c 12,102g9,83c5, and 129f8 form 
the second contig more distal to the first with the mouse b264nl BAG syntenic to a 
portion of this second contig. Cosmid 105a, 81h, 3le, Gapl (the PCR product) and 
lOOh form the third more distal to the DiGeorge Critical Region contig. Cosmid 68f 
and 24b form the fourth contig in the most distal portion of the DiGeorge Critical 
Region. A cosmid map is provided in Figure 13. The size, the number of gel readings 
used, and the redundancy of the coverage of each cosmid are listed in Table 1.
The accuracy of the sequence data was estimated by three methods: observing 
the discrepancies in overlapping regions between cosmids, observing the discrepancies 
between genomic sequence data and published cDNA sequences in the region, and 
comparing the sequenced cosmid vector sequence with the known sequence of the same 
vector. In this dissertation research, there was no discrepancy between any two 
overlapping cosmids and the sequence of the cosmid vector agreed exactly with known 
sequence of the cloning vector. There were some discrepancies between the genomic 
sequence data and published cDNA sequences in the same region and all these 
discrepancies were examined carefully and evaluated. Because of polymorphism
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Table 1: S um m ary o f  c o sm id s  seq u en ced
Concig name cosm id name s iz e  o f  i n s e r t # o f  g e l  read in g s co v erag e
c o n t ig l
59cl0 43995 682 3.35
concig2
19d3 39706 795 4.74
S8c4 38712 851 4.05
49cl2 39546 949 4.47
102g9 43945 979 6.27
83c5 42074 780 5.36
129f8 43699 492 2.15
concigS
105a 38478 1285 5.13
81h 43481 1011 5.39
3 l e 35711 591 4.57
gap l 4717 164 11.14
lOOh 40646 727 5.56
concig4
68f 39573 748 5.69
24b 38987 1085 3.91
Total=533276
mouse BAC b264nl 89500 1905 5.46
Grand tocal=622776
Note: Gap I is a PCR product covering the physical gap between cosmid 3 le and 
lOOh
8 8
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Cosmids and 
Bacs included in 
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Figure 13: Map of clones completed in this research.
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between different individuals, these discrepancies may not reflect sequencing errors in 
either the genomic or cDNA sequence.
Ambiguity of the sequence data was calculated by dividing the total number of 
bases in all contigs by the total numbers of N in the sequence. Overall, the ambiguity 
was less than 0.0027% in the four human genomic regions of over 533.27 kb.
3 .2  Comparison of 36 kb of genomic sequences from two individuais
Cosmid 19d3 contains 36172 bp and overlaps with BAC 72f which was 
sequenced by Axin Hua in the lab. Because this cosmid and BAC come from two 
different individuals, comparison of these two sequences revealed the allelic variations 
in this region. After aligning the two sequences with the GCG BESTFTT program, the 
results shown in Figure 14 were obtained. As also shown in Figure 14, this region 
contains the 3' end of human HIRA gene and the adjacent 3' region of the gene. The 
position of exons and introns of the human HIRA gene in this region also are given in 
this figure.
There are 73 (0.20%) differences between these two sequences. Among the 73 
allelic variations, 34 (46.58%) are transitions (nucleotide substitutions of a purine by a 
purine, or a pyrimidine by a pyrimidine), 15 (20.55%) are transversions (nucleotide 
substitutions of a purine by a pyrimidine, or a pyrimidine by a purine), and the 
remaining 24 (32.88%) are nucleotide insertions or deletions. The frequencies of 
transitions, transversions, and insertions/deletions observed in this study are different 
from previous report. P4i. 242] ju the factor DC gene, 1241] the frequencies of 
transition, transversion and indels (insertions/deletiotis) are 62%, 23% and 14.6% 
respectively. In human immunoglobulin X gene, 1242] the three frequencies are 58%,
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F igure 14: A lle lic  varialion  m ap
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30% and 12% respectively. In this region, transitions occur more frequently than 
transversions which agrees with those reported previously. However, the 
insertions/deletions in this region is much higher than those observed before. Most of 
the insertions/deletions (22 out of 24) occur inside repetitive elements. Considering all 
the variations, more than half (49,67.12%) occur inside repetitive elements which 
include Alu, LI and MLT. Only one variation occurs inside a human HIRA gene exon 
and that is in the last exon, in the 3' untranslated region.
The variation is not equally distributed throughout the region. There are two 
"clusters" of variations in this region. In position 11529-11597, there are 8 variations 
and in position 18533-18647, there are 8 variations. A map of all variations is 
provided in Figure 14.
3 .3  Analysis of contig 1
Contig 1 consists only one cosmid, 59c 10, which is located within the 250 kb 
region of DiGeorge minimal critical region (MDGCR). 157] ft is 43996 bp and overlaps 
the proximal cosmid 15c 10 and the distal BAC 72f. The database similarity search was 
performed with Powerblast program and the functional regions were predicted by 
Xgrail program. Figure 15 shows the results of Powerblast and Xgrail analysis. The 
sequence shown is in the direction &om centromere to telomere and reveals 18 exons of 
the clathrin heavy chain-like gene (CLTCL). In position 29955 to 30250, which is 
within intron 5 of CLTCL, there is an EST with homology to 60S ribosomal protein 
L34 that probably represents a non-functional pseudogene fragment.
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Figure 15: Result of Powerblast and Xgrail analysis of contig 1
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Human CLTCL g e n e  exon lO , 12 and  I 6 , b l a s t  f a i l e d  t o  f in d  exon 5 , g r a i l  f a i l e d  t o  p r e d i c t
N o te : X g ra i l  r e s u l t  i s  on th e  to p ,  I t ie  g ra y  l i n e  i s  DNA se q u e n c e . The p e a k s  a r e  p r e d i c t e d  ex o n s . The sm a ll
c o lo r  b a r s  above o r  be low  th e  p e a k s  i n d i c a t e  th e  q u a l i t y  o f  ex o n s , G reen f o r  e x c e l l e n t ,  b lu e  f o r  good 
and  r e d  f o r  m a rg in a l .  Peak above th e  g ra y  l i n e  m eans th e  exon i s  on fo rw a rd  s t r a n d  w h ile  p e a k  u n d e r  th e  
l i n e ,  r e v e r s e .  The i n t e n s i t y  o f  th e  g ra y  l i n e  m eans th e  GC c o n te n t s .  The l i g h t e r  th e  r e g io n  i s ,  th e  
h ig h e r  th e  GC c o n te n t s .
P o w e rb la s t r e s u l t  i s  on th e  b o tto m . The b la c k - g r a y  l i n e  i s  DNA se q u e n c e . The g ra y  r e g io n s  a r e  r e p e a t  
s e q u e n c e . The sm a ll  c o lo r e d  b a r s  a r e  m a tch es  found  in  G enBank. The num bers u n d e r r e d  b a r s  a r e  exon 
num bers o f  CLTCL.
3 .3 .1  Clathrin heavy chain-like gene
Exons 4 to 21 of the clathrin heavy chain-like gene are within this contig. The 
alignment of the genomic sequence and the cDNA sequence of CLTCL is provided in 
Figure 16. Clathrin heavy chain-like gene is present in various species. The 
function of CLTCL is unknown except its homology to clathrin heavy chain (CLTC). 
[243.244] The similarity of CLTCL and CLTC in human is 85% at amino acid level but 
the expression of CLTCL is more restricted to adult. It was revealed that CLTCL is 
expressed highly in human skeleton muscle but lowly in heart and other adult tissues. 
[611 Because velopharyngeal insufficiency which presents in more than 90% of VCFS 
and DGS patients results firom hypoplasia of the lateral pharyngeal wall musculature, it 
suggests CLTCL may play a role in the etiology of these syndromes [60.
A DGS patient (TOH) who shows some but not all of the common features 
associated with DGS carries a de novo t(21;22)(pl2;ql 1) balanced translocation which 
disrupts the CLTCL. [60 Clathrin is known to form triskelion stmctures composed of 
three heavy chains and three light chains. The triskelions form a lattice that line coated 
pits and vesicles and the carboxy terminus of the heavy chain is believed to important 
for trimerization. 2^ 51 The translocation in patient TOH disrupts CLTCL product 
at C-terminus. [60 If the product of CLTCL is like CLTC to form triskelion, the 
disruption of the gene in TOH will clearly disrupt endocytosis and membrane receptor 
trafficking. Further more, it was detected that CLTCL is expressed in early (9-12 
week) fetal tissues. If CLTCL is involved in receptor-mediated endocytosis like CLTC 
does, it may play an important role in intercellular signaling processes in early 
developmental stage when DGS evokes. [60
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In another report. Northern and Southern blot analysis of meningiomas 
suggested that CLTCL also may be involved in the tumorigenesis and can be 
considered as a candidate tumor suppressor gene,
Comparing the CLTCL exons with both Xgrail predicted and Powerblast found 
exons, one can see that Xgrail missed exon 5 and Powerblast failed to find exons 10, 
12 and 16. In addition, four exons predicted by Xgrail in this region are not present in 
CLTCL mRNA (see Figure 15 for detail).
The CLTCL DNA sequence fix>m genomic clone agrees perfectly with the 
mRNA sequences in GenBank, except for two bases. The first discrepancy locates at 
base 1907 of contigl which is a "T" but in mRNA sequences it is a "C". This 
discrepancy results in a change of codon from GCG to GCA both of which are for 
alanine. The genomic sequence of this site has four-fold coverage with one forward 
and three reverse gel readings. It is possible that this discrepancy is a result of 
sequence polymorphism. The second disagreement is located at base 17026 which is a 
"C". The five mRNA sequences in GenBank differ in this position too, namely 
HSCLH22AS (X95486), HSU411763 (U41763) and HUMEX23G (L42356) agree 
with contigl but HSU60803 (U60803) and HSU60802 (U60802) have a "T" at this 
position. The "T" to "C" change results in a difference of codon from AAG to GAG 
which code for lysine and glutamic acid respectively. The genomic sequence of this 
base has seven coverage with three forward and four reverse gel readings and clearly is 
a "C" in this cosmid.
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F igure 16: A lign m en t o f  g en o m ic  se q u e n c e  and C L T C L
59C10 > 401 a tc a g tg a g a tg cag ag ccc tag g g ag ag g g g ac tcacc t
59C10 > 441 a c lc g c c c c c g c c g g c tg a c tg a a c a a c ttc c a g g ta a g a g
U60803 < 3486.................... ....................................................................................
c l a t h r i n  h  < 1136 S R S A S Q V V E L Y S
59C10 > 481 g a a g g g tc g tc c c c tc tg a c a ta g g a g ttg a tg g c c c c c c
U60803 < 3448 ........................................................................................
c l a t h r i n  h  < 1122 S P D D G R I Y S N I A E K
59C10 > 521 tc a c c a a a tc t t tc tg g a g c tg g g c t tg g g c c a g c tg a c t
U60803 < 3408 ........................................................................................
c l a t h r i n  h  < 1109 V L D K Q L Q A Q A L Q S
59C10 > 561 c c a c a c a g c a g g c tc a t tg c a tc tc tc c g c a a a c tc a ta t
U60803 < 3368 ........................................................................................
c l a t h r i n  h < 1096 W V A P E N C R E A F E Y
59C10 > 601 g c c c g g tc c a g g tt tc c a a tg tg c tc g a tc a g g a c  I c ta g g
U60803 < 3328 ....................................................................................
c l a t h r i n  h  < 1083 A R D L N G I H E I L V  Q
59C10 > 641 g g t ta tg a g a g g a c t tc c a t tc tc tg c a a c a tc ta g tc a g
in t r o n  20, sequence 681-1800 n o t shown
59C10 > 1801 g tg g c a g a a g g c g c ta g g tc c g a c a tg c tta c a c tc a g c a
59C10 > 1841 g c c c a c Ic tg g a t tg c tg a g g c a t tc a ta tc a a a c t tg tg g
U60803 < 3295 ..................................................................................
c l a t h r i n  h < 1073 V Q I A S A N M D F K H
59C10 > 1881 a a a a c g g tg a a g g c c tc c tc a ta c a g tg c g c tg c tg a c a g
U60803 < 3259  c ..
c l a t h r i n  h < 1059 F V T F A E E Y L A S S V A
59C10 > 1921 c g a tg c tc g c g a tg tc c a g tg c g tc a ta g ttg tc c a g g c g
U60803 < 3219 ........................................................................................
c l a t h r i n  h < 1046 I S A I D L A D Y N D L R
59C10 > 1961 g c tg a tg ta c tc c a tg a c c c g tg tg c g g tc tg c c t tg a tg
U60803 < 3179 ........................................................................................
c l a t h r i n  h < 1033 S I Y E M V R T R D A K I
59C10 > 2001 g c a g tc a g g a tc a a c a g a t tc tg ta g a t tc  I c tgaggagag
U60803 < 3139 ...........................................................................
c l a t h r i n  h < 1022 A T L I L L N Q L N  R
59C10 > 2041 aggg tg g tcag cacg g ca tcccag g aacg aag g c tg caca
in t r o n  19, sequence 2081-7560 n o t shown 
59C10 > 7561 c a g a a g a tg a g ta tc a a g c a g a tg t t t tg a a tc tg c c tg t
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59C10 > 7601
U60803 < 3110
c l a t h r i n  h  < 1019
59C10 > 7641
U60803 < 3098
c l a t h r i n  h  < 1006
59C10 > 7681
U60803 < 3058
c l a t h r i n  h  < 992
59C10 > 7721
060803 < 3018
c l a t h r i n  h  < 979
59C10 > 7761
U60803 < 2978
c l a t h r i n  h < 972
59C10 > 7801
g tc c a c a g c ta c c c c tg g c a ta g c c tc a c 1c tg tg c tc g c t
R H E S 
g a a g a c a g a g c ta tc c a g a a c ta c c c tc tc c a g c a g c tc a  
F V S N D L V I K E L L E  
a tc a g t tc a t ta g g c a g g tc g g c c g tc a ta a a g g c t t tg a  
I L E N P L D A T M F A K V  
c a g tg a c c g a a a c c tc c tc a g g a tc c c g tg t t tc tg a c a a  
T V S I E E P D R T E S L  
t g c tg t c tg ta c c a c I c tg g t t t t a a a a a g c a t t tg a a a g a  
A T Q V V Q D 
a c c tg a tc a a a g tc a a tc c a a g a c tg ta tc t t tg a a g c ta
in t r o n  18. sequence 7841-11360 n o t shown 
59C10 > 11361 g g c a a a a tg c a g g tg tg c a g a c a ta c c c a tc tc tg tg c c t
c a c I c tg g tc a a t ta g c tg tc tc c tg g a tg g g t tg g tc tc c  
V Q D I L Q R R S P N T E  
tc a a g g a c g tg a g c c c a g a g c tc c g g a tc c tt tc tg c a ta  
E L V H A W L E P D K R C V  
c c a g g ta g c g g g c c tc g c t t t tg a a c a g a g a a t tc tc a t t  
L Y R A E S K F L S N E N  
g c a c a c Ic tg a a a tg a g c a c a c tc a tg tg tg tg a c a c a g c a  
C V K
59C10 > 11561 g c c a a cc a g c g g a a g c tg c ttg g g a g g a ca c a c c c c a a tt
59C10 > 11401
U60803 < 2966
c l a t h r i n  h  < 962
59C10 > 11441
U60803 < 2926
c l a t h r i n  h < 948
59C10 > 11481
U60803 < 2886
c l a t h r i n  h < 935
59C10 > 11521
U60803 < 2846
c l a t h r i n  h  < 932
in t r o n
59C10 > 12841
59C10 > 12881
U60803 < 2843
c l a t h r i n  h  < 925
59C10 > 12921
U60803 < 2815
c l a t h r i n  h  < 911
59C10 > 12961
U60803 < 2775
c l a t h r i n  h  < 898
17, sequence 11601-12840 n o t shown 
a a g c ttc cc tg g g a g c c c a g g g tta c a tg g g c a g c tc a g c  
a c a tc tg c ta c c c a c Ic t tg a tg a g c tc a a g g tc a c a c tg c  
V K I L E L D C Q  
c c c c g c tc a ta g g c a a c a c ag g c c a g a tg g g g g tc tc g c t 
G R E Y A V C A L H P D R K  
tc tc a c a g ta g c g g c c c a c c a c g c tg c tg tc a ta g ta g g c  
E C Y R G V V S S D Y Y A
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59C1Q > 13001 acccccccccaggaagcacccggggccgccg tcgccg tcg
U60803 < 2735 ........................................................................................
c la c h r in  h  < 885 N E R L F C E P S N N S D
59C10 > 13041 a tg tag a ttC tag ccag tg caccg tg ag cg g cag g c tccC
U60803 < 2695 .......................................................................................
c la c h r in  h  < 871 l Y I K A L A N H T A P E E
59C10 > 13081 cacagccCCccCgaacctgggactccagccagggêiagcag
U60803 < 2655 .......................................................................................
c l a c h r in  h  < 858 C G E Q I Q S E L W P L L
59C10 > 13121 cagcccgagc I ccccgaaagaaggaaggcgccgcaaagccc
U60803 < 2615 ...........................
c la c h r in  h  < 854 L K L R
59C10 > 13161 caaggccaccaccggaagccC cgagggcaaccccagggcc
in c ro n  16, sequence 13201-13400 noc shown
59C10 > 13401 accagacagaaacaacaacagacaccagaacccaggggca
59C10 > 13441 agagaaaacaccaagcaaggacaccccac I CTATTrCTTTT
R N R K
59C10 > 13481 TTCTACTTCAGCCACCAACTCATCAGTAGAGAACrGTCCT
E V E A V L E D T S F Q G
59C10 > 13521 CTCACTGCCATGAOTAAGTXnTTAATCACTTCCTCAGAAC
R V A M I L H K I V E E S C
59C10 > 13561 AATCCACATCAAGCaGCCCTCCAATCACAGCTGGGGTCCG
D V D L L G G  r V A P T R
59C10 > 13601 GCTAGGGTTGAClcCagggCagCcaaggccaagcaacccca
S P N V
59C10 > 13641 gcgccgcaaacacaagccaccgccagaagccccccacgac
in c ro n  15, sequence 13681-14160 noc shown
59C10 > 14161 gcccagaggcagccgggcgCcacCccagggagccagcagC
59C10 > 14201 acIcccccgcacgcagaccccaacgcacccccgcaggccgc
U60803 < 2464 ..........................................................................................
C lachrin h < 794 V K Q V Y I E I Y R Q L N N
59C10 > 14241 C gcggcacaaacacaggacaaggccacggacaaagccaaa
U60803 < 2424 .......................................................................................
c la c h r in  h  < 781 R Y L Y L V L D H V F G F
59C10 > 14281 acgaccacacacgacgacgaggggaagcCggCccgCgagc
U60803 < 2384 .......................................................................................
c la c h r in  h < 768 R D C V I I L P L Q D T L
59C10 > 14321 CcggccCcIccgaggaccagaacgcacagaacaagccaggg
U60803 < 2344 .......................
c la c h r in  h < 764 K A E K
59C10 > 14361 agcggagaaaccagacagccagaccccggacccaccgcac
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in tro n . 14, sequence  14401-15360 n o t shown
59C10 > 15361 cca tcag caagggcagc tca tggaaggaggcagcac tgga
59C10 > 15401 a c a c a c lc t tc a g g a a g t tc t tc a c a c g c tc tg g g t tg ta g
U60803 < 2337 ...............................................................................
c l a th r in  h < 754 K L F N K V R E P N Y
59C10 > 15441 c a g c tg c tc tc tc g g c a ta tc c tc tc c a c c tc c t tg a tc t
U60803 < 2302 ........................................................................................
c l a th r in  h  < 740 C S S E R C I R E V E K I Q
59C10 > 15481 g c c c tg tc t ta c a g g c a g c c tg a a tg ta t t tc a g a tg c a c
U60803 < 2262 ........................................................................................
c l a th r in  h < 727 G T K C A A Q I Y K L H V
59C10 > 15521 a tc tg g g tc ttg g c tg a a g ttc a c g a ttg a g c c c a g g a a g
U60803 < 2222 ........................................................................................
c l a th r in  h < 714 D P D Q S F N V I S G L F
59C10 > 15561 ta g a a g a g g c Ic ta tg a a g a g a g a c c a t tc c a t t t t tg tc c
U60803 < 2182 ............................
c l a th r in  h < 710 Y F L G
59C10 > 15601 t tg ta a c a c c tg c c tg tc tc c tc c g ta g c tg c tg c c c a c c
in t r o n  13, sequence  15641-16920 n o t shown 
59C10 > 16921 ag g ag g tg tag tcaca tg g tg g g g tcg g cg ag ag g c tg ca
59C10 > 16961 tg g t t ta c I c t t tg ta a c tc t tg a a g g a t tc a a a g a g c tc c
U60803 < 2173 ..........................................................................
c l a th r in  h < 700 G K Y S K F S E F L E
59C10 > 17001 a c c a g g g c c tg c g tg c c c a g c tg c tc g tg g ta c tta g a g g
U60803 < 2140  t .............................
c l a th r in  h  < 686 V L A Q T G L Q K H Y K S A
59C10 > 17041 c c a c c tg c a c a c a c a g c tg a a g g ttc tg tc tg a tg tta g c
U60803 < 2100 ........................................................................................
c l a th r in  h <  673 V Q V C L Q L N Q R I N A
59C10 > 17081 a g a c a g ca tg g c a tg c a g a c a c tcc a c a g a a tc c tcc a c c
U60803 < 2060 ........................................................................................
c l a th r in  h < 660 S L M A H L C E V S D E V
59C10 > 17121 g a taag g ag ccaaag aaa ttg acaag cca Ic tg g g aacaag
U60803 < 2020 ...............................................................................
c l a th r in  h  < 649 S L S G F F N V L W  E P
\
I
c
c la th r in  h < 649
59C10 > 17161 g e ia g a g tc tg tc c a c a a c g a tg c a c c a c tc ta a a g a ttg c
in tro n  12, sequence  17201-17680 n o t shown
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59C10 > 17681 acac taaccg cacagacaacagccacaacaggagcgccca
59C10 > 17721 ggggtuicacagtacICTCGGGMTGflGGAGGTGAGTGTGGA,
E P N L L H T H V
59C10 > 17761 CCacaCCXXrrcriXaTGTXaaaGflGGTCGGTGTAGTGCTC
V A R K I D Y L D T Y H E
59C10 > 17801 CAGlXXnTGCTGCftGGftGGCCTGCCTrCTCaCftGflGCTGG
L A Q Q L L G A K E C L Q
59C10 > 17841 GCAATGTGGGCCaSGTCGTaAIGAGTAAACArTTTArrTC
A I H A R D Y H T F M K N G
59C10 > 17881 CAAGGftTGGCATCTGCAAC I c ta c g a aa c a g g g a g ttc g g t
L I  A D A V
59C10 > 17921 gagciagccccgaccaa tggcaacaaccc tc taagaccagc
incron 11, sequence 17961-21280 not shewn 
59C10 > 21281 gcCcaagtccgcaaacccagagaggCgccacaggtgccct
gcctctcggtgctagcctacaagtcactgacIctggggtgc
V Q P A
atgaacaaggttcatctccaacagccatgtcCgcaggagt 
H V L N M E L L W T Q L L  
ccctcagccgggcgatcactccccéiaggcatccéiacaaga 
G E A P R N N K L A D L L F  
aggaagcacactgccgaactaaaccgtcctccacgaaeiac 
S T C Q Q I L S N E M F I  
gtccacaacIctgaaacacaCccaiagccacaccttcaccca 
D V I  Q
59C10 > 21521 gcacgttctcactcagtgtttcatcctcctatcgaaatag
59C10 > 21321
U60803 < 1828
c l a t h r i n  h  < 592
59C10 > 21361
U60803 < 1817
c l a t h r i n  h  < 579
59C10 > 21401
U60803 < 1777
c l a t h r i n  h  < 565
59C10 > 21441
U60803 < 1737
c l a t h r i n  h  < 552
59C10 > 21481
U60803 < 1697
c l a t h r i n  h  < 548
59C10
59C10
59C10
59C10
59C10
59C10
in t r o n  10, sequence 21561-23920 n o t  shown
> 23921 c g a a tc a a a g a a a tc t tc ta g a tg g c tc ta a a a a g c c a c a
> 23961 aaaagttgtccaaaactgcctacgctcacICTGGCTAATGT
Q S I  N
> 24001 TGGCCAGCGGCTCXTCGTCCrGCACTAGCATTCGAGAAAA
A L P E E D Q V L M R S F
> 24041 CTGCASGCCCTGTTCCGGACTGArCTTCATTACACCCCTC
Q L G Q E P S I K M V G R
> 24081 AGCAGAAAGATCCAGTCTGGGGTGTACCCAACIctagaagc
L L F I W D P T Y G V
> 24121 aag g g ag caccaa tcag g aaaa tcaa tg aaaaaccc tg g g
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i n t r o n  9 ,  s e q u e n c e  2 4 1 6 1 - 2 4 6 4 0  n o c  sh o w n
59C10 > 24641 g a g ta a tc cg tg a g a c g c c a g tg g ttc a a ca c a c g tC a c l
U60803 < 1566
c la c h r in  h < 508
59C10 > 24681 ccccccggcacagagcacaaccccccggaaccggcccgcc
U60803 < 1565 ........................................................................................
c l a c h r in  h  < 495 K K A Y L V I K Q F Q G T
59C10 > 24721 ccCgcaaaacacCggaCcaccccgcCCggcacacccgccc
U60803 < 1525 ........................................................................................
c l a c h r i n  h  < 481 E A F C Q I V K S P V N A R
59C10 > 24761 gaaggcacacacccagagcgagcacggggccagcggcccc
U60803 < 1485 ........................................................................................
c l a c h r in  h  < 468 L Y V S L A L M P D T T K
59C10 > 24801 aaccaagcccccgagcCccCccgeigcacCccagIccgcggc
U60803 < 1445 g ........................................................................
c l a c h r in  h  < 457 V L D G L E E S C E L
59C10 > 24841 aCgccaagggacaaggcaaagccaggaggcaggcagggag
in c ro n  8
59C10 > 24881 cccggaccaagcccccaagccgcgcgggggggccacgagc
59C10 > 24921 ccacaag cg cccccacIcccacccccccccag ccacccccc
U60803 < 1412 ....................................................
c l a c h r in  h  < 449 K D E K L W K E
59C10 > 24961 caggagccgcccacgcccccgccgaagaaccagacggcaa
U60803 < 1388 ........................................................................................
c l a c h r in  h  < 436 L L Q K R G Q Q L V L H C
59C10 > 25001 agccccaaggacccaagcccaccgagccgaccccggccga
U60803 < 1348 ........................................................................................
c l a c h r in  h < 422 L E L S E L K N L Q G Q D L
59C10 > 25041 gcaggaccccgaagcaccgcagcaacggagaagcccggcc
U60803 < 1308 ........................................................................................
c l a c h r in  h  < 409 L I G F Y Q L L P S A Q G
59C10 > 25081 agaccgagcgggcacaccccggaacccccggaccgccccc
U60803 < 1268 ........................................................................................
c l a c h r in  h  < 396 S Q A P I S Q F K Q V T E
59C10 > 25121 ccggcacgcaggaccccIccaacaacaaacggaaaaacagg
U60803 < 1228 ...........................................
c l a c h r in  h  < 389 R T R L I G  K
59C10 > 25161 ccaccgcgccgcaaccacaggggacccccccacccaaccc
in t r o n  7 , sequence 25201-25960 n o t shown 
59C10 > 25961 accccccccccaaggccggcccccaacacccagaacaccc
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59C10 > 26001
U60803 < 1212
clachrin h < 384
59C10 > 26041
U60803 < 1194
clachrin h < 371
59C10 > 26081
U60803 < 1154
clachrin h < 358
59C10 > 26121
U60803 < 1114
clachrin h < 344
59C10 > 26161
U60803 < 1074
clachrin h < 331
59C10 > 26201
U60803 < 1034
clachrin h < 323
59C10 > 26241
gaacagcacccaaggcccaccacIccccggngcagacgccg
K ? A S A A 
c a a c ttc g g c g g c ttc a g c a ta g c tg c c c tg tg c a a a g a g  
V K A A E A Y S G Q A F L  
g g ta ttg a a c tc tc tc a c a a a c a a c c tc C c tg c c c c a g c c  
T N F K R V F L K E A G A  
ag g ttac tacg aacg g ccaaacg cag accaag g tccg g a t 
L N S R V A L R L G L D P N  
tc tg a a g c a c g c tg g c tg c a ta a t tc a c a a tg c ta c c tc c  
Q L V N T A Y N V I N D E  
c ccaacacaaac tg acag cac  I c tgcciaggacacaacaag t 
E V C V S L V  Q 
g ag ag cag cccggcccagaagag tgccccaccacccctcc
in c ro n
59C10 > 27161
59C10 > 27201
U60803 < 1006
c la c h r in h < 314
59C10 > 27241
060803 < 983
c la c h r in h < 301
59C10 > 27281
060803 < 943
c la c h r in h < 287
59C10 > 27321
060803 < 903
c la c h r in h < 274
59C10 > 27361
060803 < 863
c la c h r in h < 265
59C10 > 27401
5, sequence 26281-27160 n o t shown 
ag tccc taacg aacg g aaaag g tC cg caaacg aacg tcag  
a g tc a c a c a c Ic tg g c c c tc tc tg c c g a c a c c a a ta a tc c c  
Q G K K N V G X I G  
ag ag g c tg g cccg cg tg g ag cag cg acaaacac tg cg tca  
S T P K H P A T V F I T D  
g c a c ta a ta c g g ttc a tg c a g a C g c a c a c g c c a g a c tc ta  
A S l R N M C r c V G S E L  
g g tcg ta c a g ac g a a g a ta g c c a ta c tc c g c g a c c a a g ca  
D Y L H L Y G Y K T I L Y  
a a ta a ca c c a tg tc ta g c C c c aa tIc C a ta a g a a g a c ag a g  
I V G H K A G I  Q 
agcaagaggtcggaaagtaaggaggagaagccaC gcgggt
59C10
in c ro n  5, sequence 27441-30720 n o t shown 
> 30721 cccg catccg g g g ag g tg c tag ag cag ac ttag g acacg a
59C10 > 30761
U60803 < 854
c la c h r in  h < 268
agacgc C cagagagcagcacaC CcgcacIcC gcacagccac 
• C • » C^l *c **»*»»»«»*#»
H K A  G I Q M A V
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59C10 > 30801 cggaaaaccaccccgcgcccccggaggaaaaaacacaccc
U60803 < 827 ....
c l a t h r i n  h <  249 P F D N Q A E P P F F V D
59C10 > 30841 a c tg c tt tc t tc a c a a a a g g tc g g tc tc c c g c tg c a g g c t
Q60803 < 787 .......................................................................................
c l a t h r i n  h <  235 V A K K V F P Q N G A A P Q
59C10 > 30881 g tc c a a c tc c a a tg a tg tg c a a I  c ta g a a g a g a g a tt t ta g
U60803 < 7 4 7  ......................................................
c l a t h r i n  h < 227 G V E I I H L  K
59C10 > 30921 g tcaa tcaag g g g a c c g c c tg tg g tg g tg g g c a a g tg c ta
in t r o n  4 , sequence 30961-34240 n o t shown
59C10 > 34241 c c a g c tca tg a c a c ttttc tc a g g g a g e ia g a c a g ta g a g t
59C10 > 34281 g g g a tc t ta c  I c t tg c c tc c tg tg g g a tta c g ta c a g c a a a
U60803 < 7 2 5  .................................................................
c l a t h r i n  h < 218 K G G T P N R V A F
59C10 > 34321 g c a g a a a a g g g tg g c a g g c ttg g c a ttc c c c tc c a tc ttg
U60803 < 695 .......................................................................................
c l a t h r i n  h < 205 C F L T A P K A N G E M K
59C10 > 34361 a a c tc tg c a a a a g c c g c a g c a tg g c c ttc ta tg g g ttg tg
U60803 < 655 .......................................................................................
c l a t h r i n  h  < 191 F E A F A A A H G E I P Q S
59C10 > 34401 a a a c c ttc c ta tc c a c a g a g ta g a g c tg c a ttg c tc c a a c
U60803 < 615 .......................................................................................
c l a t h r i n  h < 178 V K R D V S Y L Q M A G V
59C10 > 34441 c a c a c g g t t t t g  I c ta a g a a aa g a ta tta tg c a a tg a a a g g
U60803 < 5 7 5  ................................
c l a t h r i n  h < 173 V R N Q Q
59C10 > 34481 g a g a g a a a a g a g a g g a a ta ta a a g a a a c a a ttc tta a a a t
Note: Not all sequences are shown. The transcription direction of CLTCL is 
from telomere to centromere on the complementary strand of 59c 10. 
indicates the identity. Discrepancies are bold. "I" indicates the splice site. 
Capitalized sequences represent the exons 10,12 and 16 which the Powerblast 
program failed to find.
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T a b le  2: S p lic e  s ite s  o f  C L T C L  com paring  w ith  the c o n se n su s  seq u en ce .
exon in t r o n  exon
3 . . .cttttcttaglCAAAACCGTG.. . 4
4 — AGGAGGCAAG1g c a a g a tc c c . . . 4 . . .tctcttctaglTTGCACATCA.. . 5
5 . . . GGCTATGCAG1g ta c g a a c g t . . . 5 . . .cttCttacaglATTGGAGCTA.. . 6
6 — AAAGGGCCAG1g tg tg t a a c t . . . 6 __ g tc c t t a c a g 1GTACTGTCAG— 7
7 . . .TGCACCAAAGIgtgaCaaacc.. . 7 . . . ttatcattagIGGAATCCTGC. . . 8
8 __ AGAAGATAAG1g ta g a a a c a c . . . 8 — cacaccacagICTGGAGTGCT — 9
9 — TGCCAAAAAGIgtaacgtgtg.. . 9 . . .ttgcttctaglGTTGGGTACA.. . 10
10 — CATTAGCCAG1 g tg ag cg cag . . . 10 . . . t a t g t t t c a g 1ATTGTGGACA. . . 11
11 . . .TGCACCCCAGIgtcagtgact.. . 11 . .  -tgCCtcataglGTTGCAGATG.. . 12
12 . . .CAATCCCGAGIgtaccgtgta.. . 12 —  t t g t t c c c a g 1TGGCTTGTCA— 13
13 — AGTTACAAAG1g ta a a c c a tg . . . 13 . . .ctcctcataglGCCTCTTCTA— 14
14 — CTTCCTGAAGIgtgCgtCcca.. . 14 . . . t a a c c c tc a g 1GAGGCCAAGC. . . 15
15 — CGTGCAGAAGIgtactgccgg. . . 15 . . . a c ta c c c ta g 1GTCAACCCTA— 16
16 — AAAGAAATAG1g ta a g g tg tc . . . 16 __ tctctcaaagIGCTCAAGCTG___ 17
17 — GCTCATCAAG1 g tg g g ta g c a . . . 17 __ ctcatttcagIGTGTGCAATG— 18
18 — AATTGACCAG1g tg a g g c a c a .. . 18 __ ttê iaaaccag  IGTGGTACAGA— 19
19 . . .GCGAGCACAG!gtgaggcCaC. . . 19 __ ctctcctcagIGAATCTACAG — 20
20 — AGCAATCCAG1g tg g g c c g c t. . . 20 __ CaacccctagIGTCCTGATCG— 21
21 — AGCAGGAGCA. 1 g ta a g c g a g t. . . 21
con sen su s (C /A )A G Ig t(a /g )ag t..
Note: Upper case letters are exons while lower case letters, introns. The bold 
letters are those do not match with the consensus.
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The splice sites for exons 4 through 21 are listed in Table 2. The sequences of 
these sites were located by comparison with the consensus splice site sequences and 
analyzing the amino acid codons at the terminals of each exon. It is shown that most of 
the splice sites are conservative with one exon end and several exon beginnings as 
exceptions. The study of the splice sites of the gene is important because it is possible 
that there exists alternatively spliced transcript forms of CLTCL gene,
Determining the entire genomic context of this gene now makes it possible to 
understand the proteins produced by these splice variants that may reflect differences in 
the resulting protein function.
3 .3 .2  Ribosomal protein L34 pseudogene
In region 29881 to 30320 of this condg, Powerblast found a homology to 
putative human ribosomal protein L34. However, it is more likely that this region 
contains a non-functional pseudogene similar to ribosomal protein L34. This region 
contains almost all the mRNA sequence without any intron. It lacks an ATG start 
codon and there is no putative promoter within 7 kb of the 5’ end based on Xgrail 
prediction. Previous studies showed that it is likely that there are several copies of L34 
genes in the mammalian genome, but in no instance has it been shown that more than 
one of the genes is functional [247-250] T h e  presumption is that for each ribosomal 
protein the genome contains only one gene that is expressed, and the other copies are 
non-fiinctional pseudogenes [2511. There is a putative ribosomal protein L34 gene 
proximal to BRCAl at 17q21. [252] Aligmnent of the cDNA sequence and genomic 
sequence shows only 82% identity. In position 30229 and 30230, an "A" to "T" and a 
"G" to "A" changes occur respectively, making a stop codon UAG instead of CUG for 
leucine in the mRNA sequence. The alignment is shown in Figure 17.
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Figure 17: Alignment of region 29881 to 30320 of contigl and human ribosomal
protein L34 cDNA.
59C10
59C10
L38941
59C10
> 29881
> 29921 
< 365
rib o so m a l < 114
> 29961
L33941 < 359
rib o so m a l < 109
aggtgtgagccaacgcgcccggccaagatttcttatatat
cctacatccaaccggtttatctacagaggaatgttctctg
K Q
accccgtgcctttgacacctccacaacêiaCaccccgcccc
....... t.g.......C....Cg..t......
S Q A Q A V K V I I K Q E
rib o so m a l < 107
ccCtca 
K L
59C10
L38941
> 30001 
< 313
r ib o so m a l < 85
Ccaataaggaaagcacacttgatcctgtcacgaacacact
- - g ....................................g ............................................................c .
E I L F A R K I R D R V C K
59C10
L38941
> 30041 
< 273
rib o so m a l < 72
tagcacacacggaaccaccacaggccccgctgacatgcgt
........................ t ............................ t ................................................ c .
A C M S G G Y A R S V H K
59C10
L38941
> 30081 
< 233
rib o so m a l < 59
ccccgtcctagggaaccccacaagaaccccaggtctcata
c.t g.ac..C c...... t.....c.c.
K T K S L R M L V K P R V
59C10
L38941
> 30121 
< 193
rib o so m a l < 4 5
gcacgaactccccgaagcctggctaggcacacgccacatg
-g c....... c. -c. .g.....ca.....
P R V G R L K G P C V G C A
59C10
L38941
> 30161 
< 153
r ib o so m a l < 32
caggcccaggtgttcccccaacctccttgacgtaaaggtg
 a. -Ct c............. g.a......a
S K P A K G V K K T Y L Y
59C10 > 30201 C iace iaccc tcccaccag g g g cttg g g ac tacc tag tc tca
L38941 < 113 . . c  a r c .................c . c .......... a g ................. eg
r ib o so m a l < 1 9  V I R N G P T R S L R T K
59C10
L38941
> 30241 
< 73
r ib o so m a l < 15
ctagaggctgcgcgtcaaaggctgggccaCCctgaatgcc
c ........................
N S A T
59C10 > 30281 agcccaaaggacCgtccctgggagctctaggctccctcaa
Note: A indicates where a stop codon occurs instead of leucine.
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3 .3 .3  Repetitive elements in contig 1
DNA sequences containing interspersed repetitive elements and simple repeating 
units were identified using both Xgrail and Powerblast programs with a library of 
human repeat sequences. Alu is the most commonly occurring repetitive element found 
in the human genome. It is believed that Alu is a pseudogene derived ftom 7SL RNA. 
Previous studies estimated that one Alu sequence appeared in about every 2 kb of 
genomic DNA. A typical Alu is about 300 bp in size and consists two homologous 
halves, each of which has an A-rich tail. Alu sequences found in the human genome 
can be whole length, half length or quarter length. [253-256] There are other 
interspersed repetitive elements in contigl, LI, MER and MLT, which occur at much 
lower frequencies. Powerblast identified 33 individual Alu elements, 11 L i’s, I MLT 
and 1 MER. Besides these interspersed repeat elements, Xgrail identified 21 single 
repeat units within this contig, all present in intron regions. The interspersed repetitive 
elements are summarized in Table 3.
Table 3: Interspersed repetitive elements in contig 1.
Family number bases % of region
Alu 33 8579 19.5
LI 11 4150 9.4
Mer 3 297 0.7
Mit 2 809 1.8
Total non-Alu 16 5256 11.9
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3 .4  Analysis of contig 2
Contig 2 contains 6 cosmids, namely &om centromere to telomere, they are 
I9d3,98c4,49cI2,102g9, 83c5 and I29f8. They form a contig of 211,386 bp in 
length. For the convenience of analysis with Xgrail, this contig has been divided into 
two contigs. The first contig, called contig2.1, has 118,000 bp and contains the entire 
human HIRA gene. This contig is presented as the reverse and complement here 
because human HIRA gene is expressed in the telomere to centromere direction. The 
second contig, named contig2.2, has the remainder of this 211,386 bp sequence.
3 .4 .1  Contig 2.1
The total length of contig2.1 is 118,000 bp. Database homology search reveals 
that this region contains the human HIRA gene. The results of Xgrail and Powerblast 
are provided in Figure 18. Comparing the results of Xgrail and Powerblast, 
Powerblast failed to identify only two of the known exons of the human HIRA gene. 
Both of the exons are relatively small, 71 bp and 59 bp, and are very close to 
neighboring exons. In contrast, Xgrail failed to predict five of the 25 HIRA exons and 
instead predicted several exons which are not found in the hiunan HIRA cDNA 
sequence. Most of the additional predicted exons lie in three large introns of the HIRA 
gene, namely intron 1,21 kb, intron 15, 14 kb and intron 24, 20 kb (see below for 
detail). Powerblast results showed that those additional exons were homologues to 
widely expressed EST's in the GenBank but the similarities were low. These 
additional exons may belong to a family of pseudogenes that appear to be the result of 
tandem reiterations of DNA segments during evolution. The structural similarities of
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Figure 18: Result of Powerblast and Xgrail analysis on contig 2.1
g I
SDK aOK 70K 80K 90K
10, 20 m isse d  by  pow b lg g t
nil nil III II 1 II III I
2 3 4 5 67 8 9  11-13 1415 16-19, 21-24
I
25
N ote !
#4, 6, 13, 17, 21 n o t  p r e d i c t e d  by x g r a i l '  Human HIRA gene
X g ra i l  r e s u l t  i s  on th e  to p . The g ra y  l i n e  i s  DNA se q u e n c e . The p e a k s  a r e  p r e d i c t e d  ex o n s , The sm a ll
c o lo r  b a r s  above o r  below  th e  p e a k s  i n d i c a t e  th e  q u a l i t y  o£ ex o n s . G reen  f o r  e x c e l l e n t ,  b lu e  f o r  good 
and r e d  f o r  m a r g in a l . Peak above th e  g ra y  l i n e  means th e  exon i s  on fo rw a rd  s t r a n d  w h ile  p e a k  u n d e r th e  
l i n e ,  r e v e r s e .  The i n t e n s i t y  o f  th e  g ra y  l i n e  m eans th e  GO c o n te n t s .  The l i g h t e r  th e  r e g io n  i s ,  th e
h ig h e r  th e  GC c o n te n t s .  The p in k  b o x es  on th e  g ra y  l i n e  a r e  CpG i s l a n d s .
P o w e rb la s t  r e s u l t  i s  on th e  b o tto m . The b la c k - g r a y  l i n e  i s  DNA se q u e n c e . The g ra y  r e g io n s  a r e  r e p e a t  
se q u e n c e s . The sm a ll  c o lo r e d  b a r s  a r e  m a tc h e s  found  in  GenBank. The num bers u n d e r  g re e n  b a r s  a r e  exon 
num bers o f  human HIRA g en e .
these DNA segments to specific functional genes are the reason why Xgrail predicted 
these regions as exons, tso-sij
3 .4 .1 .1  Human HIRA gene
Analysis of contigl. 1 reveals the genomic organization of the human HIRA 
gene. The transcription direction of this gene is fiom telomere to centromere. The 
human HIRA gene contains 25 exons. Comparative analysis of the genomic sequence 
and the cDNA sequence reveals the position and the size of all 25 exons (Table 4).
The HIRA cDNA sequence originally reported contained only 61 nucleotides upstream 
of the initiation codon which later was shown not to be correct since RNase 
protection experiments indicated that the 5' end of the cDNA sequence should extend 
further 159 nucleotides. 12571 The full-length HIRA transcription therefore consists of 
4018 nucleotides and a poly(A) tail. The boundaries of exon/intron are determined with 
the available genomic data to preserve the nearly invariant consensus 5' GT and 3' AG 
dinucleotides of intron boundaries. The comparison of all splice sites and the 
consensus is provided in Table 5.
The aligmnent of genomic DNA and HIRA cDNA is provided in Figure 19. A 
poly(A) signal at position 110194-110199 indicates the end of the last exon. These two 
sequences match perfectly except in their 3' UTR as here there are five mismatches 
(including three "n "s in cDNA sequence) and five indels. All discrepancies were 
checked carefully. In all cases, there was more than six-fold redundancy in genomic 
DNA sequence. The aligmnent of human (X89887) and mouse (X92590) cDNA 
shows great similarity (87.53% identity by cross_match). Approximately 40% of the 
discrepancies are observed in the 5' and 3' UTR. The identity at amino acid level is 
about 97%.
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Table 4; Position and size of exons and size of introns of human HIRA gene in 
contig 2.1
Exons Introns
Exon Start End Size Intron Size
1 9232 9488 257 1 20662
2 30150 30212 63 2 2122
3 32335 32445 111 3 1208
4 33654 33744 91 4 1303
5 35048 35142 95 5 7699
6 42842 42937 96 6 1044
7 43982 44142 161 7 2277
8 46420 46587 168 8 2127
9 48715 48828 114 9 3545
10 52374 52444 71 10 666
11 53111 53216 106 11 1974
12 55191 55406 216 12 1814
13 57221 57306 86 13 5552
14 62859 63056 198 14 2075
15 65132 65293 162 15 13697
16 78991 79195 205 16 385
17 79581 79685 105 17 1752
18 81438 81586 149 18 2284
19 83871 84032 162 19 601
20 84634 84692 59 20 364
21 85055 85160 106 21 1640
22 86801 86923 123 22 476
23 87400 87563 164 23 1909
24 89473 89561 89 24 19799
25 109361 110221 861
Note: Exon I contains 5' untranslated region. Start codon ATG begins at position 
231 of the first exon. Exon 25 contains 3' untranslated region. Stop codon 
TAG begins at position 115 of the last exon.
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T able 5: ExonÆ itron boundary o f  hum an H IR A  g e n e
exon in c ro n  exon
1 — AACCACAATGIgtgagCgcgc.. .  1 . .  .tCgctCCcaglGCAAGCCGKT—  2
2 ...GGAGGACflAGIgtatgtCtac... 2 . .  .ttCgtCccaglQGCAGGATTC.. .  3
 3 __AATCACTTAGI g ta t t a c a g a  3  t t c t t c c c a g  I CATüTGTGAÀ—  4
 4 __AGCGGGCTACI g ta a g c a tc a  4  CcCcacacag IGTACATCGGC—  5
5 — CATTCftGGCGIgtgagtggga.. .  5 . .  .ctCctCCcaglATGTGATGGA—  6
6 — AAGTTCCCAGIgtctggggcc.. .  6 . .  .ttcttcacaglAAM TCTAGC—  7
 7 __TTTTGATGAGIgtaagtgggg 7 . . .  c tC c tC tcag  ITGTGGAGGAA—  8
 8 __GflCTGTCGTGIgtgagtgccc.. .  8 . .  .ttggccccaglAAATTCAACC—  9
9 ...TTCTGTCrGGIgCgagcctgc... 9 . . .  C tc c ttc c a g  I CTCACaTGTC. . .  10
1 0 __ATATTTCCTGIgtaaggtgga.. .10 . .  .tgcctttcaglGACTCTGAAT—  11
1 1 __GGAGGAGAAGI g ta g g c tg a c  1 1  gcCtccccaglAGCCGCATTC—  12
1 2 __TATCAGGAAGI g tg ag ag ccc . . .  12 . . .  gcC ttg ccag  IAATCTTTTGA —  13
13...TG G A CA CTQ G Igtactggttc...l3 . . . ttgatgacagIGGACTTCTCC. . .  14
1 4 __ATAAAGACAGI g tcag cg g g c . . .  14 . . .  C tcaccccag  ITA3X3AATGCT —  15
1 5 __CTGTGGAAAGIgtaggtggta.. .15 . .  .tCCtgtgcaglGTTAAAAGAG—  16
1 6 __GTCTGTCCAGI g tg ag g ccag . . .  16 . . .  g cC c ttccag  ITCTCCAGCTG —  17
1 7 . . .CACCCTCCAGIgtaagCtcta.. .1 7  . . .cttcatccaglGTCAGCTCCG.. .  18
1 8 __CGGGCAGCTGIgtaagggtgg.. .18 . .  .gccttctcaglTGACGTGGTG—  19
1 9 __TCTCTGTCTGIgtgagaggca.. .19 . . . tccctcctagIGGATGTTCAC—  20
2 0  ATCCIGGCAGlgtaatgcagg.. .20 . .  .ctgtcctcaglGAAGTGATAT—  21
2 1  TTTCCACATGIgCaagcaagc. . . 2 1  . .  .gcctccccaglGAACCTGGTT—  22
2 2 . . .GCACCTCCAAIgCacgtgacc.. .2 2  . . .gtctctgcaglCTCGGGAAGG.. .  23
2 3 __GTAAACGAAGIgtgaggctcc.. .23 . . . ccgtaaCtagIGGTTTGAATA—  24
2 4 __AACAGTAGTGlgcaggcgctt.. .24 . .  .gtgtccacaglGGTCTGCGGA—  25
co n sen su s : (C /A )A G ig t(a /g )ag t ( t /c ) „ n ( c / t ) a g lG
Note: Upper case letters are exons and lower case letters, introns. The bold letters are 
those do not match with the consensus.
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F igu re 19: A lign m en t o f  g en o m ic  D N A  and hum an H IR A  cD N A
c o n c ig 2 .1  > 9213 gaggaggagcggcgcaggggatgcggctgtggtggcggcg
human > 1  .............................................
c o n t ig 2 .1  > 9253 gcggcggccgagcgcgggtggcggctgtggcggcggaggg
human > 22 ........................................................................................
c o n c ig 2 .1  > 9293 gggcgcgggccggcgacggcgcggcggccctgagggcgcg
human > 62 ........................................................................................
c o n c ig 2 .1  > 9333 gggcgggcggcggccggagggcgggcggcgcgggaggaag
human > 102 .....
c o n c ig 2 .1  > 9373 cggcggcgg tggctccatggcccgggcgcgctgagggacc
human > 142 .....
c o n t ig 2 .1  > 9413 cggcgctcgcctcagcccggcggcggcggcggccgaacaa
human > 182 .....
c o n t ig 2 .1  > 9453 tg a a g c tc c tg a a g c c g a c c tg g g tc a a c c a c a a tg Ig tg a
human > 222 ...........
HIRA > 1  M K L L K P T W V N H N G
c o n c ig 2 .1  > 9493 g tgcgcgcaggggtcgcgggaggccgagcccggagtcggg
------------------------- in t r o n  1, sequence 9533-30092 n o t show----------------------
c o n t ig 2 .1  > 30093 a c a c t t c a a tg a a ta a a a g c c a a t t t a g a ta c tg ta t t t t
c o n t ig 2 .1  > 30133 t t t t t c t t t g t t t c c a g I g c a a g c c g a t t t t t t c a g t t g a t
human > 257 ......................................................
HIRA > 1 3  G K P I F S V D
c o n tig 2 .1  > 30173 a ttcaccc tg acg g g accaag ttcg cê iac tg g ag g acaag l
human > 281 .....
HIRA > 2 1  I H P D G T K F A T G G Q
c o n tig 2 .1  > 30213 g ta tg ttta tg g a a tc ta a g a a a g g g a a a g c tta a c a g c c c
human > 321
HIRA > 3 4  G
c o n t ig 2 .1  > 30253 tg c c a c c t tg c tc t t c t c c tg c tg tc c a t t t a g c tg ta g a
------------------------- in t r o n  2, sequence 30293-32292 n o t  shown-------------------
c o n t ig 2 .1  > 32293 c t a c t c c t t g c a c a t t c a g c c a t t t c t g c t c c t t t g t t c c
c o n t ig 2 .1  > 32333 a g Ig g c a g g a t tc tg g g a a g g t tg tg a tc tg g a a ta tg tc t
human > 319 .....
HIRA > 3 4  G Q D S G K V V I W N M S
c o n tig 2 .1  > 32373 c c a g tc c tc c a g g a g g a tg a c g a g a a g g a tg a a a a ta ttc
human > 359 .....
HIRA > 4 7  P V L Q E D D E K D E N I
c o n tig 2 .1  > 32413 c c a a g a tg c t t tg c c a g a tg g a c a a tc a c t ta g Ig ta t ta c
human > 399 ....
HIRA > 6 0  P K M L C Q M D N H L
c o n tig 2 .1  > 32453 a g a g tg g c c c tt tg c a g g c tt tg c g tg ttg g c a g a g tg c c
------------------------- in t r o n  3, sequence 32493-33612 n o t shown-------------------
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c o n c i g 2 .1
h um an
HIRA
c o n t ig 2 .1  
human 
HIRA
c o n t ig 2 .1  
hunan 
HIRA
conC ig2 .1  
human 
HIRA
> 33613
> 430
> 70
> 33653
> 431
> 71
> 33693
> 471
> 84
> 33733
> 511
> 98
c o n t ig 2 .1  > 33773
------------------------- in c ro n
conC ig2 .1  > 34973
g accaccg g a c c c c c a tc ac c c c a c c c cc c c c tc c c c cc a
g  I cacg tg cg aac tg tg tg cg g tg g ccaaacag cg g g acg c  
A C V N C V R W S N S G M  
a c c ta g c c c c tg g g g g a g a tg a c a a ac c g a tc a c g g tg tg  
Y L A S G G D D K L I M V W  
g aag cg g g c tac  I g c a a g c a tc a tc c tc c tc c c c c c a c a c c  
K R A T Y 
c c a tc c tc a g a a g c c g c c c tg c c g g tc c c ta c c a a a g tc a  
4 , sequence  33813-34972 noc shown-----------------
c o n c ig 2 .1  
human 
HIRA
co n c ig 2 .1  
human 
HIRA
> 35013
> 523
>  102
> 35053
> 528
> 103
gccggctgcagggagcaC C tccatgcagcgcccagagcac 
c c c a c g a g tg c c ttc c tg g c c c c tc tc c c a c a c a g Ig c a c a
Y
c c g g c c cc a g c a c c g tg c c c g g c tc c a g tg g ta a g c ttg c
I G P S T V F G S S G K L A
c o n c ig 2 .1  
human 
HIRA
c o n c ig 2 .1  
human 
HIRA
> 35093
> 568
> 117
> 35133
> 608 
> 130
c o n c ig 2 .1  > 35173
c a a c g tg g ag c a g tg g c g g C g tg tc tc c a c c c tcc g g a a t 
N V E Q W R C V S I L R N  
ca tccag g cg  I g tg a g cg g g ac tg cc tg ttg g g g cg g g tg g  
H S G
g cccc tg ac a c c tg g c c c a g a tca g c a g c a c c g a ca c g tc  
5, sequence  35213-42772 n o t shown-----------------
c o n c ig 2 .1 > 42773 ctggccaagccaacagacaagggcaC caccagg taagaga
c o n c ig 2 .1  
human
>
>
42813
617
tc tc a c c a g a a c c c tc c g tc c tc C c tc a g 1atg cg acg g ac
HIRA > 133 D V M D
co n c ig 2 .1
human
>
>
42853
629
g tag cacg g tc tccccacg acg cccg g c tag cc tcaC g ca
HIRA > 137 V A W S P H D A W L A S C
c o n c ig 2 .1
human
>
>
42893
669
g c g c g g a ta a c a c c g tc g tc a tc tg g a a c g c tg ta a a g tt
HIRA > 150 S V D N T V V I W N A V K F
co n c ig 2 .1
human
>
>
42933
709
c c c a g 1gtcC ggggccC cctctgactgg tcaacagcciagca
HIRA > 164 P
c o n tig 2 .1 > 42973 g ta c c g cccg ccag c tcc tg g ag cag g g g c tg g g c tg cc t
114
---------------- — izicj
c o n t ig 2 .1 > 43933
c o n t ig 2 .1 > 43973
human > 711
HIRA > 164
c o n t ig 2 . I > 44013
human > 745
HIRA > 176
c o n t ig 2 .1 > 44053
human > 785
HIRA > 189
c o n t ig 2 .1 > 44093
human > 825
HIRA > 202
c o n t ig 2 .1 > 44133
human > 865
HIRA > 216
c o n t ig 2 .1 > 44173
cc acg cccccc tcag acaacacccccccacacccccc tcc  
t c t t c a c a g  I a a a c tc ta g c ta c c c c g a g a g g tc a tc c tg g  
P E I L A T L R G H S G  
c t tg g tc a a a g g g t tg a c a tg g g a c c c tg c tg g ta a a ta c  
L V K G L T W D P V G K Y  
a ta g c tc c tc a a g c tg a tg a c c g c a g c c ta a a g g tg tg g a  
l A S Q A D D R S L K V W  
gg acg ccg g ac tg g cag ttg g ag accag ca tcaccaag cc  
R T L D W Q L E T S I T K P  
c tccg acg ag  I g taag tggggacagctcagggagccgagcc  
F O E
c c c g c ag c tg c c c c a g c c C c ttcc tg a c c tc tg c g c a c ag  
in t r o n  7 , sequence 44213-46372 n o t shown-----------------
c o n t ig 2 .1 > 46373
c o n t ig 2 .1 > 46413
human > 873
HIRA > 218
c o n t ig 2 .1 > 46453
human > 908
HIRA > 230
c o n t ig 2 .1 > 46493
human > 948
HIRA > 243
c o n t ig 2 .1 > 46533
human > 988
HIRA > 257
c o n t ig 2 .1 > 46573
human > 1028
HIRA > 270
c o n t ig 2 .1 > 46613
— i n t i
c o n t ig 2 .1 > 48653
c o n t ig 2 .1 > 48693
human > 1042
HIRA > 275
c o n t ig 2 .1 > 48733
human > 1061
HIRA > 281
c a c a a a g g tg g c c t tg a g c tc c t t tc a a g tg c a g a tg c t t  
c t t t c a g  I tg tg g a g g a a c g a c c c a tg tg ttg c g g c tc a g c  
E C G G T T H V L R L S  
tg g tc a c c tg a tg g g c a t ta c c tg g tg tc tg c c c a tg c c a  
W S P D G H Y L V S A H A  
tg aacaac tc a g g c c c c a c tg cc c a g a tc a tc g a ac g g g a  
M N N S G P T A Q I I E R E  
g g g a tg g a a g a cc a a c a tg g a c tttg ttg g g c a cc g g a a a  
G W K T N M D F V G H R K  
g c tg tg a c tg tc g tg  I g tgag tg cccag g g aac taaag g g a  
A V T V V 
g a tg g g c tc c a a g a t t c a g c a a a ta t t a a t t c t tg g t t t a
g g g c a c a g g g g a c a tg c c tg a tg c t tg a t ta a t ta t t t t t  
a a c a tc tg t t a t t tg g c t t t a g I a a a t t c a a c c c a a a a a tc
K F N P K I  
t tc a a a a a g a a g c a g a a g a a tg g g a g ttc tg c g a a g c c ta  
F K K K Q K N G S S A K P
15
c o n t i g 2 .1
hu m an
HIRA
c o n c ig 2 .1 
human 
HIRA
> 48773
>  1101 
> 294
> 48813
> 1141
> 308
c o n c ig 2 .1  > 48853
c o n t ig 2 .1  
c o n t ig 2 .1
c o n tig 2 .1
c o n t ig 2 .1
gctgcccg taccgctgccgcgccgccggcagcaaggaccg  
S C P Y C C C A V G S K D R  
c t c g c t t t c tg tc tg g  I g c g a g c c c g c c a tc c c g a g c ttt t  
S L S V W 
g ttg cag g acg g g ag g tg tag g c tg g taaag cag caag tg
in t r o n  9 . sequence 48893-52332 n o t  shown----------------
> 52333 t t c a g t a a t t t c a t t a a c c t t g a c t g t g t c t t t c c t t c c a  
glC> 52373
> 52413
> 52453
c o n tig 2 .1 > 53053
c o n t ig 2 .1 > 53093
human > 1227
HIRA > 336
c o n t ig 2 .1 > 53133
human > 1250
HIRA > 344
c o n t ig 2 .1 > 53173
human > 1290
HIRA > 357
c o n t ig 2 .1 > 53213
human > 1330
HIRA > 371
c o n t ig 2 .1 > 53253
— i n u
c o n t ig 2 .1 > 55133
c o n t ig 2 .1 > 55173
human > 1332
HIRA > 371
c o n t ig 2 .1 > 55213
human > 1356
HIRA > 379
c o n t ig 2 .1 > 55253
human > 1396
HIRA > 393
c o n t ig 2 .1 > 55293
human > 1436
HIRA > 406
L T C L K R P L V V I H E
CTGTTTCACAAATCCAICATGGATATTTCCTGI g ta a g g tg  
L F D K S I M D  I S W
g a ttc ta c tta c a g g a a ta g g tta a g a a a g g a g a a g c c a c
g g c a c a tg tg tc tg c c tg g g g c tc t tg c ta c c a g g c tg c t  
g a tg g c c a tg tc t t tc a g  I g a c tc tg a a tg g g c tg g g c a tc  
W T L N G L G I  
t tg g ta tg c tc ta tg g a c g g c tc tg tg g c a t tc c tc g a c t  
L V C S M D G S V A F L D  
tc tc c c ag g a tg ag c ttg g cg a tcccc tg ag cg ag g ag g a  
F S Q D E L G D P L S E E E  
gaag I g ta g g c tg a c g g c tc t tg tg c tg c tg g g tg c tc tg t  
K
g g c c a ttg c c a c a a ta g c tc tg a g a g a c c c c tttg a c ta c
11, sequence 53293-55132 n o t shown---------------
c a g c a c tg g c c a c a c tg g c a c tc a tg c tg g c a tg tc a tg c  
c tc tc c t tg c t tc c c c a g  I a g c c g c a ttc a c c a g tc c a c c t 
K S R I H Q S T  
a tg g caag ag c c ta g c c a tc a tg a cc g a g g c c c a g c tc tc  
Y G K S L A I M T E A Q L S  
c a c a g c c g tc a ttg a g a a c c c tg a g a tg c tc a a g ta c c a g  
T A V I E N P E M L K Y Q  
cgaaggcagcagcagcagcagctggaccagaagagtgctg  
R R Q Q Q Q Q L D Q K S A
116
c o n c ig 2 .1  > 55333 
human > 1476 
KIRA > 419
cgaccagggagacgggcccagccaccccagccgcaggcgc
A T R E M G S A T S V A G V
c o n c ig 2 .1  
human 
HIRA
> 55373
> 1516
> 433
cgccaacggggagagcc ttgaaga taccaggaag  I gcgaga 
V N G E S L E D I R K  
c o n c ig 2 .1  > 55413 g c c c c g cc tg g tg g c g c ta a a g a c a tg g ac a ta tg c c c a g  
------------------------- in c ro n  12, seq u en ce  55453-57172 n o t shown---------------
c o n t ig 2 .1  > 57173
ccn C ig 2 .1 
human 
HIRA
c o n t ig 2 .1 
human 
HIRA
> 57213
> 1548
> 443
> 57253
> 1582
> 455
conC ig2 .1 > 57293
human > 1622
HIRA > 468
conC ig2 .1 > 57333
----- ----------— — inC]
c o n c ig 2 .1 > 62813
conC ig2 .1 > 62853
human > 1635
HIRA > 472
conC ig2 .1 > 62893
human > 1670
HIRA > 484
conC ig2 .1 > 62933
human > 1710
HIRA > 497
conC ig2 .1 > 62973
human > 1750
HIRA > 511
conC ig2 .1 > 63013
human > 1790
HIRA > 524
conC ig2 .1 > 63053
human > 1830
HIRA > 537
conC ig2.1 > 63093
c a g tc g g c ca a a a c ttC tg c a c tc ac tta C g ta a c tc C g c  
c c tg c c a g  I aacc tcc tg aag aaacaag ccg ag ac tcg g ac  
K N L L K K Q V E T R T  
a g c a g a tg g ccg g ag aag aa tcacg cc tc tccg ca tag ca  
A D G R R R I T P L C I A  
cag ccg g acac tg g  I g ta c tg g ttc a C C c c c c tttc a tg g c  
Q L D T G 
c c c a c c tg g c g a g a c c tc c c tg tc c c c tttc a g c g g c c a a
c g g c a c c c g a c c ttc a a g g c c g ac c c c c g tc c tta cc c g a  
cgacag  I g g a c ttc tc c a c g g c a tc c tc ta a c a g c a c c c c c  
G D F S T A F F N S I P  
c tc tc g g g c tc c c tg g c g g g c a c c a tg c tc C c tC c tc a ta  
L S G S L A G T M L S S H  
g cag C ccacag c taccg ccaccg g ac tccag tacccc taa  
S S P Q L L P L D S S T P N  
c tc c tc cg g c g c c tc g a a g c c ttg c ac a g a g c c c g tg g tg  
S F G A S K P C T E P V V  
gctgccagC gccagacccgcaggcgattcC g tcaa taaag  
A A S A R P A G D S V N K  
acag  I g tta g c g g g c g c ca a g g c c tg ttc c tg tc c c cg g g g  
D S
a a a g t c c a g g c t tg c a c a c a g t C t  cgaggacagagaat t  c 
in c ro n  14, sequence  63133-65052 n o t shown---------------
c o n c ig 2 .1  > 65053 gccccaaacaacgcaaacaccagacccccagaccccccca
17
conC ig2.1 > 65093
human > 1831
HIRA > 538
conC ig2.1 > 65133
human > 1835
HIRA > 539
conC ig2.1 > 65173
human > 1875
HIRA > 552
c o n c ig 2 .1 > 65213
human > 1915
HIRA > 566
c o n c ig 2 .1 > 65253
human > 1955
HIRA > 579
c o n c ig 2 .1 > 65293
human > 1995
HIRA > 592
c o n c ig 2 .1 > 65333
- in c ro n
c o n c ig 2 .1 > 78933
c o n c ig 2 .1 > 78973
human > 1994
HIRA > 592
c o n c ig 2 .1 > 79013
human > 2018
HIRA > 600
c o n c ig 2 .1 > 79053
human > 2058
HIRA > 613
c o n c ig 2 .1 > 79093
human > 2098
HIRA > 627
c o n c ig 2 .1 > 79133
human > 2138
HIRA > 640
c o n c ig 2 .1 > 79173
huiran > 2178
HIRA > 653
c o n c ig 2 .1 > 79213
— in c i
c o n c ig 2 .1 > 79533
c o n c ig 2 .1 > 79573
mouse > 2195
HIRA p ro ce > 659
g g accg cg cc tg acacg cccccccccccccccaccccag Ic
S
acg aaC gccaccC ccacC cctgctgcatcgccaccctccg  
M N A T S T P A A L S  P S  
C gctaacgaccccgcccaagaccgaacccacgaaagcgcc 
V L T T P S K I E P M K A F  
tg acccccg g tccacag ag cg g cccaaag ccacaccag g t 
D S R F T E R S K A T P G  
g cccc tg ccc tg accag cacg ac tccg acag c tg cg g aaa  
A P A L T S M T P T A V E  
g  I g taggcggcagctgcaggaccccgaaggaccaggcaggg 
R
c g cag g ca tg g g tcaacag cacag cg g cag tg tccccacc
15, sequence 65373-78932 noc shown---------------
cacccccccccgcacgaacggcccccgaagggaagcgcga 
cgcaacgcccccgcgcag I gccaaaagagcagaaccccgcg
R L K E Q N L V  
aaagagccgaggccccgagacccccC ggagagcagcagcg 
K E L R P R D L L E S S S  
acagcgacgagaaagcccccccggccaaggcccccccacc 
D S D E K V P L A K A S S L  
gcccaagcgaaaacccgagcccgaggcagagacagcagag 
S K R K L E L E V E T V E  
aagaagaagaaagggcggccccggaaggacCcCcgCccca 
K K K K G R P R K D S R L  
cgcccgcgcccccgcccgcccag I gCgaggccagCgggccc 
M P V S L S V Q  
accccg ccccccccagcccacccccccgcacccagagccc
16, sequence 79253-79532 noc shewn---------------
accccgcagcgccagagcaaggcccaggaacgcccccggc 
CcCCccag I CccccagccgcccCaaccgcagagaaggaggc
S P A A L S T E K E A
1 8
c o n c ig 2 .1  > 79613
mouse > 2227 
KIRA p ro c e  > 670
c c n c ig 2 .1  > 79653 
mouse > 2267 
HIRA p ro c e  > 683
c o n c ig 2 .1  > 79693
--------------------------inC ron
c o n c ig 2 .1  > 81373
c o n c ig 2 .1  > 81413
human > 2301 
HIRA > 694
cacgcgcccgcccgcaccagcacccgcaccgaagccgcca
M C L S A P A L A L K L P
accccaag cccccag ag ag cac tcaccc tccag  I gcaagcc
 g  a ................ g .................................
I P G P Q R A F T L Q  V
ccag g accccg ccagccccccctcaggcacacccagacac
17, sequence 79733-81372 noc shown--------------
c o n c ig 2 .1 > 81453
human > 2321
HIRA > 701
c o n c ig 2 .1 > 81493
human > 2361
HIRA > 714
conC ig2 .1 > 81533
human > 2401
HIRA > 728
conC ig2 .1 > 81573
human > 2441
HIRA > 741
c o n c ig 2 .1 > 81613
----------------- — inc:
conC ig2 .1 > 83813
c o n c ig 2 .1 > 83853
human > 2454
HIRA > 745
conC ig2 .1 > 83893
human > 2477
HIRA > 753
c o n c ig 2 .1 > 83933
human > 2517
HIRA > 766
conC ig2 .1 > 83973
human > 2557
HIRA > 780
conC ig2 .1 > 84013
human > 2597
HIRA > 793
conC ig2 .1 > 84053
ccCCggagcacgccaccCgggcCgcggcccCCgcccgagc 
agacccgcgcg tccaccccacccag  I g tcag ccccg aC cc t 
L Q V S S D P 
cccacgcacaccgaggcggagaacgaagcgacagcggcgg 
S M Y I E V E N E V T V V  
ggggcgcgaagccgagccgccCgaagcgcaaccgggaagg 
G G V K L S R L K C N R E G  
gaaggagcgggagacggcacccaccagccggacccccacc 
K E W E T V L T S R I L T  
gcCgcgggcagccg I gcaagggcgggcaggcccccagccgg 
A A G S C 
cccaggtgacacaggcacacacgccaC caccccgggcccg 
18, sequence 81653-83812 noc shown---------------
-in c ro n
accgccccggccgcagcacC cagcccccaCgacaccCgcc 
cccaccccgccCCcccag I cgacgcggcgcgcgccgcccgc 
C D V V C V A C  
gaaaaaaggaCgcCgccagCgccccccaccCgcggccgcc 
E K R M L S V F S T C G R  
gcccccccCcCcccaccccccCgccaCccccgaCccccac 
R L L S P I L L P S P I S T  
CCCgcaCCgcacaggcCccCacgCcaCggcgcccaccgcC 
L H C T G S Y V M A L T A  
gcagccacacCcCccgCcCg I gcgagaggcaggcacagggc 
A A T L S V W 
ggggcgggccccagccagggcaggacagggccgCgCaggc 
19, sequence 84093-84572 noC shown---------------
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c o n c ig 2 .1 
c o n c ig 2 .1
c o n t ig 2 .1
c o n t ig 2 .1
> 84573 aggcacactccgacg tgcccacccgggccggcgagcaaac
> 84613 cgttccccgtcccccccccaglGGATCTTCACaGACAGGTG
D V H R Q V
> 84653 GTTGTGGTGAAAGAAGAGTCTCTACACTCCATCCTGGCAGI
V V V K E E S L H S I L A
> 84693 g taa tg cag g caacag g c tg tccc tac tc tC C tg g g g g cc
 in c ro n  20, sequence 84733-85012 noc shown---------------
conC ig2 .1  > 85013
conC ig2.1  
human 
HIRA
conC ig2.1  
human 
HIRA
conC ig2 .1  
human 
HIRA
> 85053
> 2673
> 818
> 85093
> 2712
> 831
> 85133
> 2752
> 845
conC ig2 .1  > 85173
conC ig2.1 > 86733
conC ig2.1 > 86773
human > 2781
HIRA > 854
conC ig2.1 > 86813
human > 2792
HIRA > 858
conC ig2.1 > 86853
human > 2832
HIRA > 871
conC ig2.1 > 86893
human > 2872
HIRA > 885
conC ig2.1 > 86933
gccgaccagagcacacccagaacccacccccaC gcC gccc 
Ccag I gaagcgacacgacggcaccacagaccccgccgacgc 
A G S D M T V S Q I L L T  
agcacggaaC cccagcaacgaacccgcccgacgggaaggc 
Q H G I  P V M N L S D G K A  
gcaccgccccaaCccgccacCCCccacaCg I gcaagceiagc 
Y C F N P S L S T W  
cgacccccagcccCaccccccggaagagCgCcCgcccgcc
in c ro n  21, sequence 85213-86732 noc shown---------------
cccggccggcaaagaggccaaccagaccccccggcccccc 
CgagccccgcccccgccCCCgccCccccag I gaacccggcc
W N L V
ccC gacaagcaggacccaccggcccagcgcgcagacccca
S D K Q D S L A Q C A D F
ggagcagccC gccaccccaggacgccacgccgcgcccagg
R S S L P S Q D A M L C S G
accgccagccacaacccagggccgcacccccaa I gcacgcg
..............................a .......................................
P L A I N Q G R T S N
acccgaacgccacggccaccgcccccagC ccC gccccggg
 incron  22, sequence 86973-87332 noC shown---------------
conC ig2 .1  > 87333
c o n c ig 2 .1  
human 
HIRA
conC ig2.1  
human 
HIRA
> 87373
> 2905
> 896
> 87413
> 2916
> 899
cacgggggcagCCccCgacccCgcgcagCgccCgcCgccc 
caCcacggaaacccCcccggccCccgcag I cCcgggaaggc
S G R
aggcCgcccggcCcCCccccgcgccccaCgCggCgcagca
Q A A R L F S V P H V V Q Q
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c o n c i g 2 .1
h um an
HIRA
contig2 .1 
human 
HIRA
contig2.1
human
HIRA
contig2 .1
contig2 .1
conCig2 .1 
human 
HIRA
contig2 .1 
human 
HIRA
contig2 .1 
human 
HIRA
conCig2 .1
conCig2 .I
conCig2 .1 
human
HIRA
conCig2 .1 
human
HIRA
concig2 .1 
human
HIRA
concig2 .1 
human
HIRA
conCig2 .1 
human
contig2 .1 
hunan
contig2 .1 
human
conC ig2.1
human
> 87453 agagaccaccccggcccacccagagaaccaggtggcagca
> 2956 .......................................................................................
> 9 1 3  E T T L A Y L E N Q V A A
> 87493 gcacC caccctgcagC ccagccacgagcaccgccactggc
> 2996 .......................................................................................
> 926 A L T L Q S S H E Y R H W
> 87533 tc c tc g c c ta c g c a c g g ta c c tc g ta a a c g a a g lg tg a g g c
> 3036 ............................................................................
> 939 L L V Y A R Y L V N E  G
> 87573 tcc tg g cag ccc tg ag cag ccc tc tcc ttcC g ccccC cca
 in t r o n  23, sequence 87613-89412 n o t shown--------------
> 89413 a a t g t g t t c c t a t t t c t g t t t t g t t t t t t g t t g t t g t t g t
> 89453 t t g t t t g t t t t t c t g t a a t t a g I g g t t t g a a t a c c g a c t t c
> 3067 .............................................
> 950 G F E Y R L
> 89493 g a g a a a ta tg c a a g g a c tta c tg g g tc c g g ttc a c ta c tc
> 3087 .......................................................................................
> 956 R E I C K D L L G P V H Y S
> 89533 c a c tg g a a g c c a g tg g g a g tc a a c a g tag tg Ig ta g g tg c t
> 3127 ........................................................................
> 970 T G S Q W E S T V V
> 89573 t c t t t c a t t g t t g c t g c a a g a a t t c t t t c t t g a a a c a t g a
 in t r o n  24, sequence 89613-109292 n o t shown-------------
> 109293 g c c a g g a a a g tc c c c a c a a tc ta g g tc tc ttc a c tg a c a c
> 109333 t tg c a c tc a g c tg tc a c tc tg tg tc c a c a g Ig g tc tg c g g a
> 3157 .........................
> 9 8 0  G L R
> 109373 ag ag g g ag c tg c tg aag g ag c tg c taccag tca tcg g g ca
> 3168 .......................................................................................
> 983 K R E L L K E L L P V I G Q
> 109413 g a a c c tc c g a ttc c a g c g c c tc ttc a c c g a g tg tc a g g a a
> 3208 .......................................................................................
> 997 N L R F Q R L F T E C Q E
> 109453 ca g c tc g ac a tc c tg a g g g a c a a g tag c c tg c c c c a g c c t
> 3248 .......................................................................................
> 1010 Q L D I L R D K ^ ^ *
> 109493 g ccc tg g c tg cag caag g g cag g g ccacac tc tcg ccg c t
> 3288 .......................................................................................
> 109533 g a tg a c a tg ca g g a c c g c c tc tc a cc tg a c c a g g c tg ta g
> 3328 .......................................................................................
> 109573 g g g g ag g ag acac tg g cag g ag a tg tg c tg tcc tg cacca
> 3368 .......................................................................................
> 109613 g c g c c a g c c c a g c tc c c tg g g c a g a tg tg c c c tg tg tc c t
> 3408 .......................................................................................
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co n c ig 2 .1  > 109653 gggnccgacactgccccaggagggggaagcccaccccccc
human > 3448 .......................................................................................
co n c ig 2 .1  > 109693 c tccaagcccccgacgcggagccagggctggagctccgcc
human > 3488 ................................................................................. ng .
co n c ig 2 .1  > 109733 caggtgccctggggccagcaaggcagccccaggcctgccg
human > 3528 ........................................................................................
c o n tig 2 .1  > 109773 C c tccag cacg g ccccaag g tg g acac tag cccc tg c tg c
human > 3568 ........................................................................................
c o n tig 2 .1  > 109813 cg c a g g c g cc a tg c tg c ttc a g c a g tg a cg a ttg a g c c a c
human > 3608 .....
c o n c ig 2 .1  > 109853 ttg tg a g a g a g a ac c c g g a a g c g c ta g g ta ttac a g c a g a
human > 3648  c ........................n ....................... n ..............
\  \
I I
a  a
co n c ig 2 .1  > 109893 c tg a c c c a a g a c c ta tg ta a a a g g a a a g c tg tc c c a a c a c
human > 3690 ........................................................................................
\  \
I I
c  a
c o n tig 2 .1  > 109933 a c g g a c c a tc c c c g ta c ta g a a tc tg c ta a c t tg ta a ta t
human > 3732 .......................................................................................
\
I
a
co n c ig 2 .1  > 109973 tg a a c c tc c c tc g g c c g a c a a tc a g g a c tc c c c ta ta a g t
human > 3773 ......................... .............................................................
c o n tig 2 .1  > 110013 c a c c tg g a c a c tg g tc a c c c g ta g g a a a c c ta a a c c c ta a
human > 3813 ........................................................................................
co n c ig 2 .1  > 110053 tca tg acag ccacaccg aaaaacaaccg cac tg aaaccaa
human > 3853 ........................................................................................
c o n tig 2 .1  > 110093 c c tg tc ta c c c c c a c c tg g tc c ta a c t t t t a a a tg tc c g t
human > 3893 .......................................................................................
conC ig2.1 > 110133 aaaaagagactg ttccgggggaatggggcaaagggg tggg
human > 3933 .......................................................................................
co n c ig 2 .1  > 110173 c g a c t tc c t t tg ta a g tg c a a a a ta a a c g a a c a c g c a c tg
human > 3973 ........................................................................................
c o n tig 2 .1  > 110213 a a c a c c a a a c c c tc c tg a c t t c t c t tg c c t t t t c c t t c c a
human > 4013 ............
c o n tig 2 .1  > 110253 a c c tc ca c c c tc c c c a c a c a g tg c a c c tc tc c c c tg a a g c
Note: Not all sequences are shown. indicates the identity. "I" indicates the splice 
site. Capitalized sequences are exon 10 and 20 which Powerblast program 
failed to find. For exon 17, Powerblast only found mouse cDNA. PoIy(A)
signal is bold.
122
The N-tenninal part of HIRA protein containing exons 1 to 11 is highly similar 
to a corresponding region in the yeast HIRl protein. [^3.258] xhey both contain seven 
WD [259] repeats and have a similar arrangement No relationship is observed between 
the structure of exon/intron and the distribution of the WD repeats. WD repeat I spans 
exons 1,2 and 3. H spans exons 3 and 4. Ill is in exons 5 and 6. IV and V are in 
exons 7 and 8 respectively. VI is in exons 8 ,9  and 10. Finally, VII is in exons 10 and 
11 (Figure 20). The C-terminal part of HIRA protein (exons 13-25) encodes a region 
of significant similarity to the yeast HIR2 protein. [63.258] Exon 12 encodes a 
glutamine-rich region unique to HIRA.
The yeast HIRl and HIR2 gene products have been identified as a negative 
regulator of core histone gene transcription. [258] They are required for the periodic 
repression of three of four histone gene loci during the cell cycle. Not surprisingly, 
HIRA transcription product contains basic dipartite nuclear localization signals (one in 
exons 8 and 9, one in exon 16) which direct it to the nucleus. [260.26 1] with HIRl 
and HIR2, HIRA does not contain any of the known DNA or RNA binding motifs. [631
Part of the 3' end of the HIRA gene lies within the smallest DGS critical region. 
In situ hybridization experiments performed on mouse and chick embryo sections 
showed that the murine and avian homologs of HIRA were expressed in the neural 
crest region. [262.263] This observation is compatible with the implication of the gene 
product in the early development of the tissues afiected in DGS. If like HIRl and 
HIR2 in yeast, HIRA protein is expected to interact with several other proteins to 
preserve the function of the multicomponent regulatory complex, it will be necessary in 
future studies to find the human counterparts of those proteins to study the function of 
HIRA and the involvement of this gene in DGS.
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Figure 20: Exon/intron organization and features of human HIRA gene in contig2.1
B a s ic  b i p a r t i t e  
n u c le a r  l o c a l i z a t i o n  
s ig n a l
Exons 1 2 345 67 8 9 10111213 14 15 16-18  19-24 25
WD r e p e a t I II III IVV VI VII
Note: Exon (green) sizes are not shown in scale. Introns are shown in scale approximately.
3.4 .1 .2  Nucleotide composition of the 5' region o f the HIRA gene
The overall G/C content of contigl. 1 is 46%. The G/C content of the 
noncoding region of exon I is as high as 86%. The G/C content of the 5' region of the 
HIRA gene from -1020 to 220 (see Figure 21), which is from 8212 to 9452 in 
contigl. I, is 74%. As predicted by Xgrail program, there is a CpG island from 
position 7705 to 9721 which includes about 1.6 kb of 5’ region, exon 1 and about 0.23 
kb of intron I. This large CpG island categorizes HIRA gene to the family of widely 
transcribed house keeping genes containing a CpG island in their promoter region.
Detailed analysis of the 5' region of the HIRA gene is visualized in Figure 21. 
The studied region is from -1200 to 393 (defining the start position of exon 1 as 
position 1) which is from 8123 to 9716 in contigl. 1. This region consists of 1.2 kb of 
proximal HIRA promoter, followed by exon 1 and 228 bp of the 5' end of intron I. 
This region has an unusual cluster of 19 rare G/C-containing restriction sites including 
five BssHn (gcgcgc), three Nael (gccggc), one Narl (ggcgcc), one SacII (ccgcgg), five 
Smal (cccggg) and four Xmain (cggccg).
A TATA box is not evident in the sequence of this region. However, it is 
normal for a G/C rich promoter not to have a TATA box. 265] Furthermore, 
several GC boxes (GGGCGG), which bind the Spl transcription factor and have been 
shown to be required for interaction of transcription factor HD ( I hllD) with a TATA- 
less promoter, P 64.266] ajg present. There also is a putative TFHD binding site. Other 
putative regulatory elements in the region were identified using online SIGNALSCAN 
against the TRANSFAC database to identify transcription factor binding sites. These 
identified potential sites are: AP-2 (retinoic acid-inducible activator protein 2), CCAAT 
box, CREB (cyclic AMP regulatory element binding protein), GR (glucocorticoid
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receptor), H4TF-2 (human histone H4 gene-specific transcription factor), LF-Al (liver 
specific trans-acting factor), NF-l (nuclear factor I), NF-I/L (nuclear factor 1-like), 
NF-E (erythroid specific nuclear factor), NF-kappaE2 (nuclear factor kappa enhancer 
2), SRF (serum response factor). The positions of these potential elements are shown 
in Figmre 21.
Figure 2 1 : G/C-rich region of 5' of HIRA gene
-1200
Smal LF-Al
-1140 tg g a a g g tttC e c M « a tc ttC c g tt:c a g a c c a c a g « g g a c e ta a g c a g g a c c g c C g c tc  
TFIID GR
-1080 g c c « g g g tg c tc a g a ttc tc a tg c a c a a g a a tc a c g a c c a g a tg g c tc a c c c c tg a g a ta  
N F-l
-1020 C ccgtggaccgggaggcgagcagggagcacaggcgagtcctggcggacagtcgcgaagac
-960 cccg cacg cg ccc t0 g g cacC ccg C C aeccg Q eeS g cg tccg cac tcacccg ccag tcg g  
LF-Al NF-E N F-l
-900 gcgcagggctagcgagatacttcgcagcacggaggccgtcacggccacccCcgccgctCc 
-840 CQaocotacaceccteeacaatccoacccQcoQrtaccccctactaaggteeaacaaacca 
Spl SacII H4TF-2
-780 ggcgcccagcgcccaggcgccccggccgcgC gggccgggacgcgcctB t cecCflCCCccg
GR Spl
-720 acgcagccccgcctaggg tg tcagctB C ffC acacacgagggccC C gcg tttcacgcggct
s p l
-660 cggT O tC C C cccttccg tccC C ffC C C C gtgctgggagcgggcctctgcagcflggcacagt 
H4TF-2 Spl B s s m i LF-Al
-600 c taecc«g tcaggccc tagccggC C gg tcgg tcC ffC 9C cctcgcgcgggcc tcggc tccg  
N F-l S p l
-540 caa tg caaccg q aaca a cc a a u g B q a c g C c c c tc tg c tc c tc c q a a te c a a a ta t tc a ta  
XmallX Spl NF-l
-480 cccaggcaaacggccccgaC eeC ceaacaaacgcgC C C gC cecagcctcccccaccaggg
GR S p l
-420 C cg g c tcg ccccccg ca tccg tccg ag tccg aag cccg g a tcg ca ttccg g cg sssg cg c
N ael
-3 60 g g ag cc c g g cg c tc g c a a g a C g c C C M ta g c g c g tg ttg a cg a a tg g e g g a a g c ta g tta
SRF/CCAAT box CREB
-300 acaag ccg g acccag ac tg g cg ag g C * g # @ ct:g g C g acg g g cg g teC acg cc# ec tg g g c
GR CREB S p l H4TF-2 NF-kappaE2
-240 cccqcccoccccC qcg a a c a a cccqqoct:qcaaccqcaoaccccoct:cqC taC C caccaC
Spl Smal NF-E
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-180 C gaaocoaaC C C rceettC ccacrcacacccac occcaoQcccaacccaaaacccccg eeaQ  
NF-l Spl N arl Smal NF-l
-120 cggaggagccgOTgencccagCccgcgCsgnagcggctccccveeggggcgacCegffC  
S p l AP-2 S p l N F-l/L
-60 a a a to c o c a c c a tQ a c ttc c o a c o ttocccaooaQccacctaaqaaaCTaacgqcocaaaa
B ssH II Smal
1 GAIGCGGCTGTGGTGGCGGCGGCGGCGGCCGAGœCGGgIXXXXXÎCTGTGGCGGCGGAGG
3QnaIII
61 GGGGCGCGGGCCGGCCaTGGCGCGGCGGCCCTGAGGGCGCGGGGCGGGCGGCGGCCGGflG
Nael &naIII
121 GGCGGGCGGCGCGGGAQCaAQ^æaxaJSGTCGCTCCATGGCCCGGGCGCGCTGAGQGAC
Smal BssHII
181 CCGGCGCrcGCCKaGCCCGGOXX33GCGCÏÏ2222ift*CAATGAAGCTCCTGAAGCCGAC
XmalII M K L L K P T
241 CTGGGTCAACCACAATGgtgagtacacacaggggtcgcgggaggccgagcccggagccgg
W V N H N BssHII
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BssHII
361 cggtacccggcgcccaagccaagaagc£sacgg
Nael
Note: Position l corresponds to the start site of exon I of the complete cDNA
sequence. The sequence of exon 1 is capitalized, with the deduced amino acid 
sequence below the coding region. The G/C containing restriction sites are 
underlined and the putative regulatory elements are outlined.
It also is interesting to note that there are three H4TF-2 (human histone H4 
gene-specific transcription factor) binding sites present in the promoter region of the 
HIRA gene since the putative function of the human HIRA gene is to negatively 
regulate core histone gene transcription and H4TF-2 is required for maximal 
transcription of histone H4 gene. Thus it is possible that there is a mechanism 
controlling the competitive binding of H4TF-2 to the histone H4 gene and the HIRA 
gene to maintain the appropriate amount of H4 in the cell, or H4TF-2 binds to the 
HIRA gene as an inhibitor of HIRA gene transcription to achieve the high transcription 
rate of the H4 gene in the S phase of the cell cycle. 1258]
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3 .4 .1 . 3  Repetitive elements in the HIRA gene region
Alu, LI, Mer, Mir and Mit are interspersed repetitive elements found in 
contig2-I. Total repeat sequence content of contig2.1 is 32.0% (37737/118000). The 
individual Alu elements found in this region tend not to be full length and are small in 
size and the Alu percentage (total Alu bases divided by total contig length) is only 
15.7%. A summary of all repetitive elements is listed in Table 6. Comparing the 
repetitive elements in the HIRA region and those in other regions, one can tell that there 
are big differences. For Alu elements, the percentage in other regions is almost two­
fold higher than in the HIRA region (31.2% and 15.7% respectively). The percentage 
of non-Alu elements in other regions also is significantly higher (18.9% Vs 13.3%). It 
is worth noting that none of the interspersed repetitive elements appears to be in 
translated regions within the contig.
Table 6: Interspersed repetitive elements in contig 2.1
HIRA gene region other regions total
Family number bases % region number bases % region % region
A lu 62 15824 1 5 . 7 19 5 3 1 2 3 1 . 2 17.9
LI 15 9818 9.7 4 2421 14.2 10.4
Mer/Mir/Mlt 9 3562 3.5 2 800 4.7 3.7
Total non-Alu 24 133 8 0 1 3 . 3 6 3221 18 .9 14.1
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The human HIRA gene is a relative large gene which covers approximately
101.1 kb. The percentage of intronic sequence of this gene is 95.9%, which is higher 
than the average percentage of intronic sequence of most large genes (89.8%), while 
the percentage of repeat elements of this gene is 29.0% which is almost the same as the 
average (30.4%). 1267]
3 .4 .2  Contig 2.2
Contig2.2 is 93,386 bp in length. It contains one known gene, the gene for 
human ubiquitin fusion-degradation protein (UFDIL). The entire UFDIL gene lies in 
the first one third of contig2.2 and the transcription direction is from telomere to 
centromere. The results of Xgrail and Powerblast are provided in Figure 22. The 
Xgrail result showed there is a exon cluster region right after the human UFDIL gene 
and Powerblast found that the first three exons belong to an EST which is the 5' end of 
a cDNA similar to heparan sulfate proteoglycan. This adjacent exon cluster region, 
therefore may represent a second putative gene in this region.
3 .4 .2 .1  Human ubiquitin fusion-degradation protein gene
Human ubiquitin fusion-degradation protein gene is found in contig 2.2 from 
position 38227 to 9699 with coding on the negative strand. Previous study revealed 
that this gene encodes a product containing 343 amino acids, 1268] ttiis does not 
agree with the genomic DNA sequence. However, mouse UFDIL cDNA agrees with 
human genomic DNA very well. Carefully examining these three DNA sequences 
revealed that the previously reported human UFDIL cDNA has an extra exon which is 
almost identical to an adjacent exon. This extra exon, termed exon 5', encodes for 
thirty-six amino acids. The first twenty-seven amino acids can be found at the
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c o lo r  b a r s  above o r  be low  th e  p e a k s  i n d i c a t e  th e  q u a l i t y  o f  ex o n s , G reen  f o r  e x c e l l e n t ,  b lu e  f o r  
good an d  r e d  f o r  m a r g in a l . Peak above th e  g ra y  l i n e  m eans th e  exon i s  on fo rw a rd  s t r a n d  w h ile  peak  
u n d e r th e  l i n e ,  r e v e r s e .  The i n t e n s i t y  o f  th e  g ra y  l i n e  m eans th e  GC c o n te n t s .  The l i g h t e r  th e  
r e g io n  i s ,  th e  h ig h e r  th e  GC c o n te n t s .  The p in k  bo x es on th e  g ra y  l i n e  a r e  CpG i s l a n d s .
P o w e rb la s t  r e s u l t  i s  on th e  b o tto m . The b la c k - g r a y  l i n e  i s  DNA se q u e n c e . The g ra y  r e g io n s  a r e  r e p e a t  
s e q u e n c e . The sm a ll  c o lo r e d  b a r s  a r e  m a tch es  found  in  QenBank. The num bers u n d e r g re e n  b a r s  a r e  exon 
num bers o f  human UFDLl gene and p u t a t i v e  g en e .
beginning of exon 5 which is right after exon 5’ according to previous report. The last 
six amino acids can be found at the end of exon 4 which proceeds exon 5’. 1268] \  
dotplot showing the comparison of the previous reported cDNA and human genomic 
DNA is in Figure 23. The DNA sequence of human genomic DNA (contig 2.2) has 
been carefully examined, and no suspect region was found. Based on the accuracy of 
genomic DNA sequence data and the exon structure of mouse UFDIL cDNA, it might 
be concluded that the previous report of human UFDIL cDNA contained an error. In 
addition, another discrepancy observed is that the previous reported cDNA has an 
additional ten bases at the beginning, and this also may represent a sequencing artifact 
in the cDNA sequence. Alignment of genomic sequence, human UFDIL cDNA and 
mouse UFDIL cDNA is provided in Figure 24.
Despite the extra exon and the extra ten bases at the beginning of exon one, the 
similarity of human cDNA and genomic DNA is very high, 99%. The deduced human 
UFDIL gene coding region sequence and the amino acid sequence from genomic DNA 
are listed in Figure 25.
The size of each of the exons and the size of the introns as well as the splice site 
of the exon/intron boundaries are listed in Table 7.
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Figure 23: Dotplot comparison of human UFDIL cDNA (U64444) and human genomic DNA. 
Genomic DNA is horizontal and part of UFDIL cDNA is vertical.
Figure 24: Alignment of genomic sequence, human UFD IL cDNA and mouse
UFDIL cDNA
c o n c ig 2 .2  > 9405 ttta g tc a c c c tc a c a g g tc c tg a c a g a a c ta g g g a tg c a
c o n c ig 2 .2  > 9445
U64445 < 1294
g aaC cg cccc tg c tg ag g cag tg g g ag ctccccccaag c t 
-  ----- . . . . C . . . a . g . .  . . . g ..........
c o n c ig 2 .2  > 9485 
U64445 < 1262
gaaagcg tgaagaggcgaggaggcagctacctacaggccc  
• g • . » C » g  «g a ********** c a a c * a  » * » g  * *.a* * 
\
I
g
c o n tig 2 .2  > 9525 
U64445 < 1224
ccag g g acag c tccccg tccc tccccaaaccaag cacaca  
c . . . c . ---------- . - .   ---- -. . . . . . . g ................ . c . . .
c o n tig 2 .2  > 9565 
U64445 < 1193
accacaaag tcccg ccg cC ccacc tccaag tcaaac tC aa
. .  c t z  . C . . . . C . . . . . . . .  C C g c a . . . .  g . a . . .  g . . .  g .
c o n c ig 2 .2 > 9605
U64445 < 1153
c a a c c c c ta g g ta a c c c c a a a ta a a tc tc a a g c a a c a g a g  
. . g  c ................ t ____ c — c . a ___a ...............
c o n tig 2 .2  > 9645 
U64445 < 1113
c o n t ig 2 .2  > 9685 
U64445 < 1084
U64444 < 1156
c a c tc tc tg a tg a g g c tc g c c c c tg tc a g c g c c a g c a a c c  
—  - ............ a ---------------- . c ..............a ....................
poly(A) signal
a a a a g c c a a g a tg c tg c a a a c g a c c c t t t ta t ta tc c c c c  
g t - . . . . . g . ------ . . . . . c c . g a . . . . . . . . . ---- . . . .
...................a a ................................
c o n tig 2 .2  > 9725 
U64445 < 1051
u b iq u i t in  < 3 0 2
U64444 < 1130
u b iq u i t in  < 338
a a tc a g c c a a c a g tc c tc a c t t a g g g c t t t c t t c c c t t t t
. g ......................... t t . a ............................................ c .
p K R G K K
\
I
9
p K R G K K
c o n t ig 2 .2  > 9765
U64445 < 1010
u b iq u i t in  < 289 
U64444 < 1090
u b iq u i t in  < 3 2 5
ta c g c a a tg a c tg tc c t tc tc c a g a g a a a g c g a c g a a tc t
. c  g c .................................................. a ................
R L S Q G E G S F A V F R
R L S Q G E G S F A V F R
c o n tig 2 .2  > 9805 
U64445 < 970
u b iq u i t in  < 283 
U64444 < 1050
u b iq u i t in  < 319
g c c tc c a g c t tc a tc I c ta g g t t tg a a g a g a a g a ta c ta t t  
G G A E D E
G G A E D E
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c o n c i g 2 . 2  > 9 8 4 5  c c c a g a a a c c c c c c g g a g g t t c a c a a c a a a c g c c t c a c c c
------------in c ro n  11, sequence 9885-13764 noc shown—
c o n c ig 2 .2  > 13765 aCcaccagcaaaCciaaCccccccac caccctaccaaggaaa
c o n t ig 2 .2  > 13805 
064445 < 956
u b iq u i t i n  < 277
cacaag g aaa tacacccac  I c c c c tc a a c c c ttc tg a c a a g  
E E V K K V L
c o n t ig 2 .2  > 13845 gggacgcgaacccccgacgaaagccaccccaccaagccca
064445 < 934
u b i q u i t i n  < 264
..................................................................g ...............................C - -
F R S N R I F T I K G L K
c o n t ig 2 .2  > 13885 a a t t c a ta a t tg g g a a t t c c t  I c tg taag aag ag acag ag a
064445 < 894
u b iq u i t i n  < 256
 g  a ...............................
F E Y N P I G  R
c o n t ig 2 .2  > 13925
- in t ro n  10, sequence 13965-14684 n o t shown----------
c o n t ig 2 .2  > 14685 ag g c tg cccg accccag cg g g c tg g cacag a tcc tcc tcc
c o n t ig 2 .2  > 14725
064444 < 953
u b iq u i t i n  < 289
064445 < 864
u b iq u i t i n  < 253
tg tcc tggaggagagccaggacagacc tac  I c t t t t a a t a t
R K I D 
D
c o n t ig 2 .2  > 14765
064444 < 943 
u b iq u i t i n  < 2 7 6
064445 < 863 
u b iq u i t i n  < 240
c tc c a g g c ttg a ttg g g g a g g g g c tg g g c tc ta c c c c ttt
G P K I P S P S P E V G K
...............................................a ..........t .  . a .................
G P K I P S P S P E V G K
conC ig2 .2  > 14805
064444 < 903
u b iq u i t i n  < 263
064445 < 823
u b iq u i t i n  < 228
c t tc t t tc c a tc c a g tc ta tc g c c a g a tc c a g a g a a a g c  I c
K K G D L R N G S G S F A
t  c ............................. c ..........a .................
K K G D L R N G S G S F
c o n tig 2 .2  > 14845 ta g a c a g g aa g ta g g tg a g tc a ta ta a ta a g c c c a a g tg t
----------- in t r o n  9, sequence 14885-15604 n o t shown—
c o n t ig 2 .2  > 15605 c tc ta a tttc a a g g a g c a g a g g g c a c a g c a a ta ta a g tc a
c o n t ig 2 .2  > 15645 agtggtctggtactcaclGCGGAAGCCCAGCTCTCCAGCAT
R F G L E G A Y
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c o n c ig 2 .2  > 15685 AGCCACTGTGGTCGGCTTOiCCTTC I ccgacagggaaaaag
G S H D A E G E
c o n tig 2 .2  > 15725 aa a aacag g tg ag cccc t cagcggggacacccagcc cccc
----------- inC ron 8, sequence  15765-15884 n o t shown-----
c o n tig 2 .2  > 15885 agca tg cag cag g acag caaag g acac tg ag g a taacac t
c o n tig 2 .2  > 15925 
U64444 < 817
u b iq u i t in  < 2 3 5
ta c  I tg tc g a c tc c t c a tg c tg g a c t tg tc t t t c g g g t t c t  
T S E E H Q V Q R E P E
c o n tig 2 .2  > 15965 t tg ta g c c c a g g g g a g c a tc a a a g tc c a c lc tg tg tt tc c a
064444 < 779 ...............................................................
u b iq u i t in  < 225 K Y G L P A D F D V
c o n tig 2 .2  > 16005 g g a t t t ta a a a g ta a a a ta t tg a g a c a tg a c c a c c c t tg g
----------- in t r o n  7 , sequence  16045-17084 n o t shown—
c o n tig 2 .2  > 17085 g g tc a c c a a c tg c c c a tc c tc cc a g g g c c c a g g c tc ac tg
c o n tig 2 .2  > 17125
064444 < 753
u b iq u i t in  < 219
ta a c tg g a c a g a g c c a c tc a c  I g t tc a tg tc a c a c tc a a tg
........................................... tg a
V N M D C E H
c o n t ig 2 .2  > 17165 a tg g a c a c tg c c t tg tc g g g tt tg g tc tc c a tc a c a c g c a
064444 < 731 .......................................................................................
u b iq u i t in  < 205 I S V A K D P K T E M V R L
c o n tig 2 .2  > 17205 g t tc g ta g a t  I c tg tg g g g caa iacacag aaa tcag ttg g a t
064444 < 6 9 1  ...........................
u b iq u i t in  < 201 E Y I  K
c o n tig 2 .2  > 17245 g g t t tc c tg g c a g c a c tg g a g c tg tc g c tg tc c a tg t ta c
----------- in t r o n  6, sequence 17285-24204 n o t-shown----
c o n tig 2 .2  > 24205 c c c c a ttc a a a c a tta g a a tg g a c a c tg c a g g tg g c tc t t
c o n tig 2 .2  > 24245 
064444 < 717
u b iq u i t in  < 207
g tc a g g a a tg a c c tg c a tg a a c tg g g c tc a c I c t t t tc a t t
K E N
c o n t ig 2 .2 > 24285
064444 < 672
u b iq u i t in  < 186
a ta g ttg a tg g c a a tc a c a tc c c c g g tg g tc a g a c a g g c a
g  a ............................................................................................
Y N I A I V D G T T L C A
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c o n n ig 2 .2  > 24325 aagc tcccaag cg cg ccccccaac Iccg cag acacaccccg
U64444 < 632 .....................................................
u b iq u ic in  < 178 F N R L A N E L
c o n c ig 2 .2  > 24365 ccaag g ce iacacg g caag acg g acacc ttaa tc tg aaaca  
----------- in c ro n  5, sequence 24405-26884 n o t shown—
c o n tig 2 .2  > 26885
c o n c ig 2 .2  > 25925 
U64444 < 608
u b iq u i t i n  < 172 
U64445 < 519
u b iq u i t in  < 136
c o n t ig 2 .2  > 26965
U64444 < 590
u b iq u i t i n  < 158
U64445 < 510
u b iq u ic in  < 122
c o n t ig 2 .2  > 27005 
U64444 < 550
u b iq u i t in  < 145 
U64445 < 470
u b iq u i t in  < 109
c o n tig 2 .2  > 27045 
U64444 < 510
u b iq u ic in  < 134 
U64445 < 430
u b iq u ic in  < 98
c o n tig 2 .2  > 27085
t t ta a c a a c c g c c a g c a c a c tc tc c t t tg tc ta g a a g a a c
tc c g c c c a tc c g a a a a a g a ta c  1 acggctccggggccggcg
V A K P N T
.................a
P N T
a C g tccag g aag tcag g g ccc tg ag g c tg g aa tttg g ag c
.................................. c ..................................................
I D L F D A S Q P Q F K S Y
. - a ....................... t ........................c ..........c.  . a ------
I D L F D P S Q P Q F K S Y
a g g tg g c c a c ttg a a g g c tg a c g c tc tc c a c c tg g a c c a g
T A V Q L N V S E V Q V L
 c ................ g ................. a. .- t .................a ..........
T A V Q L N V S E V Q V L
g c c g c c t tc t tc c a a g a g ta a g t tc tg c a tc a C  I c tg a a a g
G G E E L L L N Q M M
— c  c  c .  . c.  . a .........................
G G E E L L L N Q M M
g a a g aag ag g c taca tg ag ac tcc tag ag a tg aag cag cc  
- in t r o n  4 , sequence 27225-30685 n o t shown------
c o n tig 2 .2  > 30685 g g g c c a g g a c tc tc g a g tg c a g g a g a tg tc tc tg c c ta a g
c o n tig 2 .2  > 30725
U64444 < 369
u b iq u ic in  < 97
tg g c tg c tc tc ta g a g a c c c tg g c a g c c c c a c tc a c  I ccag
w
c o n c ig 2 .2  > 30765 
U64444 < 365
u b iq u ic in  < 83 
U64445 < 390
u b iq u ic in  < 83
tg tg g g a g g ta g c a g a tg c c c tc a tc a g c c a c a a a c tc c a
............................................t .............................. t ------
H P L Y C I G E D A V F E L
................ a ................. t .................a .....................
P L Y C I G E D A V F E L
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co n C ig 2 .2  > 30805 g cacg ccacaa tg cg cca tg cg g tccg aacccccac tg g c
U64444 < 325................ .........................................................................................
u b iq u ic in  < 7 0  V G C K T M R D S N K N T
U64445 < 353 .c .  . a .  .g .  .g .  . c  c . . a . . c ..............................
u b iq u ic in  < 7 0  V G C K T M R D S N K N T
co n C ig 2 .2  > 30845 cagcccgaacagcacgggacaggcaacgccaagccggcIcc
U64444 < 285................ ....................................................................................
u b iq u ic in  < 5 7  L K F L M P Y T I N L R S
U64445 < 313 . . a . . . a ................ a ...............................
u b iq u ic in  < 5 0  L K F L M P Y T I N
c o n c ig 2 .2  > 30885 gaaaacaagagagagaccacgaggcacagcccccacgaag
------------in c ro n  3, sequence 30925-34084 noc-shown-----
co n C ig 2 .2  > 34085 acccccggcgcccacacgcacaccacccaagcccccaagc
co n C ig 2 .2  > 34125 cacccagaagaCacCCaclTGAGTTGGTCCAGGGCCGAGGG
L Q D L A S P
c o n c ig 2 .2  > 34165 TGGCATAATTAIccgcggeiaageiacacccctagaaacaccéta
P M I  I
c o n c ig 2 .2  > 34205 aaaacaaaaaC aaaaaggacagaccaaaggcaagacgcag
------------in c ro n  2 , sequence 34245-34484 noc-shown-----
c o n c ig 2 .2  > 34485 ccacagcaccgcagacccagggcaggaaaagccaccaccc
c o n c ig 2 .2  > 34525 aaaCaaaaacaagcacaCacIccCCccccccCCCccccaca
U64444 < 214 ............................................
u b iq u ic in  < 4 0  K G G K E V
064445 < 242 .............................................
u b iq u ic in  < 4 0  K G G K E V
c o n c ig 2 .2  > 34565 cccgacccgccaccaggcccC gccagcacggacacagaga
064444 < 194................ ......................................... a ............................................
u b iq u ic in  < 2 6  D S R D N P W A L M S V S F
064445 < 222  g ------
u b iq u ic in  < 2 6  D S R D N P G A L M S V S F
c o n c ig 2 .2  > 34605 agcagcggCaccgCgCggagaagcggCCCCggaagacccC
064444 < 154 ...........................................
u b iq u ic in  < 1 3  C R Y Q T S F R N Q F V R
064445 < 182  c ................ c ...................... g
u b iq u ic in  < 1 3  C R Y Q T S F R N Q F V R
c o n c ig 2 .2  > 34645 gggaacagggcggccgaacacgccgaaagagaaIccagaag
064444 < 114............................................................................................
u b iq u ic in  < 2  P I P H D F M N F S F
064445 < 142  c .................a ...............................
u b iq u ic in  < 3  P I P H D F M N F S
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3ncig 2 .2  > 34685 g ag g aaag ag aaacaag ca ttaaaacaaag g tacaccccc  
------------in t r o n  1, sequence 34725-38084 n o t shown—
c o n tig 2 .2  > 38085 cc tg ccccg tcg g g tcc tacc tcag g ccccg g g ccaag g c
c o n tig 2 .2  > 38125 
064444 < 81
u b iq u ic in  < 1
c c a g c c c c c g tc c g c tg tc c g tc a g c g c tta c  I c a tg a tg g
M
co n c ig 2 .2  > 38165 acacca c c c g g c a g a c tc cg c tc c tc tc a g g c a a tg c a a c  
064444 < 73 ........................................................................................
c o n c ig 2 .2  > 38205 gaagaaaccccgccgaccgccctcccagccgccgctgccg
064444 < 3 3  .................................................
c o n tig 2 .2  > 38245 c tg ccg ccgcgccaagccgg tacgccccagaggctcaccg
Note: Not all sequences are shown. The transcription direction of UFDIL is from 
telomere to centromere while contig2.2 is opposite. indicates the identity.
"I" indicates the splice site. Poly(A) signal is bold. indicates stop codon. 
Capitalized sequences are exon 3 and 9 which Powerblast program failed to 
find. Exon 5' is not shown. U64444 is human cDNA and U64445 is mouse 
cDNA.
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Figure 25: The human UFD IL gene coding region deduced from genomic DNA
1 a c g tc c tc ttc c a a c a c g ttc g a c c a c c c c a c tc c c a g g g tc tc c c a a a a
M F S F N M F D H P I P R V F Q N  
51 c c g c ttc cc c a c a c a g C a c cg c tg c ttc tc C g tg tc c a tg c ta g c ag g g c
R F S T Q Y R C F S V S M L A G  
101 c ta a tg a c a g g tc a g a tg tg g a g a a a g g a g g g aa g a ta a tta tg c c a c cc
P N D R S D V E K G G K I I M P P  
151 c c g g c c c c g g a c c a a c c c a g c c g a c tta a c a c ta c c ta tc c c a tg c tg tc
S A L D Q L S R L N I T Y P M L F  
201 caaactgaccaacaagaaC C cggaccgcaC gacgcattg tggcg tgctgg
K L T N K N S D R M T H C G V L  
251 a g tc tg tg g c c g a c g a g g g c a tc tg c ta c c tc c c a c a c tg g a c g a tg c a g
E F V A D E G I C Y L P H W M M Q  
301 aacccac tcc tggaagaaggcggccC gg tccagg tggagagcg tcaacc t
N L L L E E G G L V Q V E S V N L  
351 ccaag cg g ccacc taccccaaaccccé iacc tcag ag ccc tg ac ttcc tg g
Q V A T Y S K F Q P Q S P D F L  
401 a c a c ca c c a a c c ccaaag ccg tac tag aaaacg cac tcag g aac tc tg cc
D I T N P K A V L E N A L R N F A  
451 c g tc tg a c ca c c g g g g a tg c g a c c g c ca c c a a c ta ta a tg a a a a g a tc c a
C L T T G D V I A I N Y N E K I Y  
501 c g a a c tg c g c g tg a tg g a g a c c a a a cc c g a c a a g g c a g tg tcc a tc a tc g
E L R V M E T K P D K A V S I I  
551 a g c g tg a c ac g a a c g tg g ac tccg a tg c tcccc tg g g c tacaaag aaccc
E C D M N V D F D A P L G Y K E P  
601 g aaag acaag tccagcatgaggag tcgacagaagg tgaagccgaccacag
E R Q V Q H E E S T E G E A D H S  
651 tg g c ta c g c c g g a g a g c tg g g c ttc c g c g c tc tc tc tg g a tc tg g c a a c a
G Y A G E L G F R A F S G S G N  
701 g ac tg g a tg g aaag aag aaag g g g tag ag cccag cccc tccccaa tcaag
R L D G K K K G V E P S P S P I K
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751 cccg g ag ataccaac iag ag g aacccccaaccacg aa ttcaaactcg g caa
P G D I K R G I P N Y E F K L G K  
801 g a ta a c c tc c a tc a g a a a c tca c g tc c c c c c g tca a a a a g g c tg a a g a g g
I T F I R N S R P L V K K V E E  
851 acg aag c tggaggcagac tcgccgc tC C ctc tggagaaggacagccattg
D E A G G R F V A F S G E G Q S L  
901 cgtaaaaagggctagaêiagcccCaa
R K K G R K P
Note: Disagreements with human cDNA are shown in bold. indicates stop 
codon.
Table 7: Size and boundary of exons and introns of the human UFDIL gene
s i z e
e x o n
#
91bp 1 . .
1331?) 2 . .
33lp 3 . .
122fap 4 . .
1311^ 5 . .
73bp 6 . .
691^ 7 . .
66bp 8 . .
48bp 9 . .
89bp 10
82bp 11 . .
121bp 12 .
i n t r o n  
# s i z e
.GTCCATCATGIgcaagcgctg—  1, 3480bp 
.GGAGGGAAGAIgtaCgtgctt—  2 , 369bp
.GACCAACTCAIgtaagtaccc—  3, 3299bp 
.CCCACACTGGI g tg a g tg g g g —  4 , 3683bp 
.CCAAAGCCGTIgtaCcccctt.. .  5, 2598bp 
.TAATGAAAAGIgtgagcccag.. .  6, 7062bp 
.TGACATGftACIgtgagtggct—  7 , l lS lb p  
. GGAGTCGACAI g ta a g c g c ta —  8, 217bp
.GGGCTTCCGCIgtgagtacca—  9, 857bp
. ATAITAAAAGI g ta g g tc tg c  10, 850bp
.GGTTGAAGAGIgtgagtgtat — 11, 4004bp 
.................. ATCATTTGCA
e x o n
W
—  ctccttctaglTTCTCTTTCA. . . 2
. . . cttcccacagITAATTATGCC —  3
. . . CtatCCtcagIGCCGACTTAA.. .  4
. . . cccctttcagIATGATGCAGA  5
. . .  g tg tc tg c a g  IATTAGAAAAC —  6
. . . tgccccacagIATCTACGAAC. . .  7
. .ggaêiacacaglGTGGACTTTG.. .  8
. . .cccctgtcaglGAAGGTGAAG.. .  9
. . . CCCtgtCtagIGCTTTCTCTG  10
. . ctCcttacagIAGGAATTCCC. . .  11 
. . tcaaacctagIGATGAAGCTG —  12
c o n se n su s : (C/A) AGI g t  (a /g )  a g e ............................. ( c /c )n n (c /t)a g lG
Note: Upper case letters are exons while lower case letters, introns. The bold 
letters are those do not match with the consensus.
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Although this protein lacks significant sequence similariQf to any human 
proteins of known function, Blastp program reveals that it has a high similarity to the 
known yeast protein ubiquitin fusion-degradation protein 1 (UFDIP), therefore this 
gene most likely represents the human equivalent of ubiquitin fusion-degradation 
protein. UFDIP protein is believed to be involved in ubiquitin fusion degradation 
proteolytic pathway (UFD pathway). The common feature of UFD pathway is the 
covalent conjugation of ubiquitin to short-lived proteins prior to their degradation by the 
proteasome, a multisubunit, multicatalytic protease. The actual function of this protein 
still remains unknown although it is known that UFDIP does function at a post- 
ubiquitination step of UFD pathway. [269.270]
A multiple sequence alignment of the human, mouse and yeast ubiquitin fusion- 
degradation proteins using the ClustalW multiple sequence alignment program is 
provided in Figure 26. The identity between the human and mouse UFDIP is 98.7% 
while the identity between human and yeast is only 36.6%. The major areas of 
sequence conservation occur at the middle of this protein, most notably between 
residues 43 to 200 and the C-termini diverge greatly because of large insertions in yeast 
UFDIP.
141
Figure 26: CLUSTAL W( 1.60) multiple sequence alignment among yeast, human
and mouse ubiquitin fusion degradation protein 1.
CLUSTAL W(1.60) nulciple sequence alignmenc
h. vs. m. «**_***»***»*•»***•_*»******»*»**• *************************
humanufdll MFS-FNMFDHPIPRVP0aR-FSTQYRCFSVSMLAWPNDRSDVEKGGKIIMPPSALDQLSR
mouseufdll MFS-FNMFDHPIPRVF®JR-FSTQYRCFSVSMLAGPNDRSDVEKGGKIIMPPSALr)QLSR
yeastufdlp 
h/m/y
h. vs. m.
humanufdll
mouseufdll
yeastufdlp
h/m/y
LNITyPMLFKLTNKNSDRMrHCGVLEFVADBGICYLPHWMM®ILLLEEGGLVQVESVNLQ 
LNITYPMLFKLTNKNSDRMrHCGVLEFVADEGICYLPHWMM®)LLLEEGGLVQVESVNLQ 
LNIRYPMLFKLTANETGRVTHGGVLEFTAEBGRVyLPQWMMETLGIQPGSLLQISSTDVP 
* * *  * * * * * * * *  *  * *  * * * * *  *  * *  * * *  * * *  *  *  *  *  *
h. vs. m.
humanufdll
mouseufdll
yeastufdlp
h/m/y
VarySKFQPQSADFLDITNPKAVLENALRNFACLTTGDVIAINYNEKlYELRVMETKPD-
VATYSKFQPQSPDFLDITNPKAVLENALHNFACMrTGDVIAINyNEiaYELRVMETKPD-
LGQFVKLEPQSVDFLDISDPKAVLENVLRNFSTLTVDDVIEISYNGKTFKIKILEVKPES
***** ******* ****
h. vs. m.
humanufdll
mouseufdll
yeastufdlp
h/m/y
— KAVSIHECIMNVDFDAPLGYKEPE--------- RQVQHEES---------------------------TEGEADHSG
— KAVSIIECCMNVDFDAPLGÏKEPK--------- RPVQHEES--------------------------- lEGEADHSG
SSKSICVIETDLVTDFAPPVGYVEPDyKALKaBQDKEKKNSFGKGQVLDPSVLGQGSMST
h. vs. m.
humanufdll
mouseufdll
yeastufdlp
h/m/y
 * * * *  * .
 YAGELG-----------FRAFSGSOIRLDGKKKGVEPSPSPIKPGDIKRGIPNyEFKLGKITF
 YAGEVG-----------FRAFSGSCaJRLDGKKKGVEPSPSPIKPGDIKRGIPNYEFKLGKITF
RIDYAGIANSSRNKLSKFVGQG(»IISGKAPKAEPK-QDIKE»1KITFDGEPAKLDLPBGQL
h. vs. m.
humanufdll
mouseufdll
yeastufdlp
h/m/y
IRNSRPLVKKVEEDEAGG RFVAFSGEGQSLRKKG-RKP-----------------------------------------
IRNSRPLVKKVEEDEAGG RFVAFSGEGQSLRKKG-RKP-----------------------------------------
FFGFEMVLPKEDEESAAGSKSSE®JFQGQGISLRKSNKRKTKSDHDSSKSKAPKSPEVIE
h. vs. m.
humanufdll
mouseufdll
yeastufdlp
h/m/y
ID
Note: indicates identity, indicates similarity, " " (space) indicates dissimilarity,
and indicates deletion/insertion. Similarity parameters above amino acid 
sequences indicate the comparison between human and mouse and those below 
indicate similarity among all three.
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The 140 bp in 5' region, the first exon and 276 bp of the first intron of UFD IL 
gene are located in a CpG island. The CpG island is 488 bp in size and has a G/C 
content of 67.8 while the overall G/C content of contig2.2 is 48.9%. The 300 bp of 5’ 
region (firom 38527 to 38228) was analyzed by the SIGNALSCAN program against 
the TRANSFAC database and the results are shown in Figure 27. A potential TATA 
box is present in position -200 and two potential SPl binding sites are within the -100 
region. The position of the TATA box seems too far away from transcription start 
point indicating that this TATA box might be false. Other putative regulatory elements 
that were identified include the GR (glucocorticoid receptor), F2F (a transcriptional 
repressor in nonpituitary cells), LF-AI (liver specific trans-acting factor), NF-E 
(erythroid specific nuclear factor), and Pit-1 (pituitary transcription factor-1).
Figure 27: 5' region of UFD 1L gene
g tg g g c a g c g ta g tcg taa g g a c a a tg g g c c c tac e M * tC c g tc tg g a g  -251
P it-1
g g g a a c a C t g t C a a c a c g c a a t t f  a * t a a c g c t t a a a a a t a c c f t —  -201
NF-E F2F TBP
•a g g g g a a a t  « « « t  c a c g a a a O T g c » t t t ta a tg c t tc ta c tg a g g g tg t  -151
P i t - 1  LF-Al
t t ta g a g c c ta g c g tc t tc g c c tg g c c t t t t c tc t t t tg c a g c c g a c g c t  -101
ttaeccC gggcacccC C C C fcC C ggg tc tcggg tccggcacttccgg tgag  -51
GR SPl
cctctgO T B C B taccggcttggcgcggcggcagcggcagcggcggctggg -1
S pl
Note: The start point of transcription is defined as position 1. Outlined regions are 
putative regulatory element or transcription factor binding sites. See text for 
detail.
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3 .4 .2 .2  A Putative gene in the distal region of contig 2.2
Powerblast program found three regions of homology to the EST database in 
contig2.2 at the region firom about 38700 to 41900 which were homologous to 
EST64671 (T34235). Actual alignment of this EST and genomic sequence showed that 
Powerblast failed to find a match between positions 76 to 132 of this EST. T34235 is 
the 5’ end of a human cDNA whose origin is not clear. There is another EST, 
EST35508 (T31599), which is identical to T34235 but is 62 bases shorter at the 3' end. 
This EST is a human cDNA’s 5’ end which is similar to heparan sulfate proteoglycan 
from a human embryo cDNA library. There are eight other regions with EST 
homology found, and the Xgrail program predicted a cluster of exons at the region 
from about 38700 to 79800. Since the direction of EST hits and the cluster of exons 
are the same, when the results of Powerblast and Xgrail are taken together, a putative 
gene is expected in this region.
In the first EST hit, there is an ATG start codon at position 39039 followed by 
an open reading fimne. Assuming this is the first exon of the putative gene, the first 
exon/intron boundary could be located by comparing the genomic DNA sequence and 
the conservative exon/intron splice site. The second exon is found by comparing the 
EST sequence (from positions 76 to 135 of the EST) and the genomic sequence. The 
third and fourth exons also were found by comparing the genomic sequence with the 
second and third EST hits and the consensus exon/intron splice site. Among the 
remaining exons, exons 16, 18, 19 and 20 also have homology to ESTs in the data 
base. The remainder of the exons were deduced by studying the Xgrail results and 
exon/intron boundary consensus sequence using Xgrail version 1.3 and both exon 
predicting models, 2 and la. Exons 5,7-15, and 17 were predicted by exon model 2 
and exon 6 was predicted by exon model la. The other exons were predicted by EST
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homology. Exon 20 does not contain any coding region but has homology to the 3' 
end of an EST whose 5’ end is contained within exon 19. Thus, the coding region of 
this putative gene ends at exon 19, and exon 20 contains the poIy(A) signal sequence.
Throughout this dissertation research, the main criterion for determining exons 
is that the qualiQf of Xgrail predicted exons was high and that the exon/intron boundary 
agreed well with consensus. If the boundary matched well but this boundary 
introduced a stop codon into the open reading firame by causing a shift in the translation 
frame, this boundary would not be used. The open reading frames predicted by this 
method were translated into amino acid sequence and then used as a query to search the 
protein database. Any high score (> 100) hit was aligned with the open reading frame 
using Clustal program and compared. By this comparison, any missed and extra exons 
predicted would be revealed and the context region of the genomic sequence would be 
examined to resolve the problem.
The predicted coding region is hypothetical and even arbitrary and may not 
reflect the true coding region of the gene because of following reasons: 1) the 
exon/intron boundaries were not always conserved, 2) In some instance, Xgrail did 
not predict all the exons, and in other, it predicted extra exon(s), 3) there also were 
more than one "good" exon/intron boundary near each other, 4) this gene predicting 
method cannot predict the S' and 3' untranscribed regions without additional direct 
evidences for promoters and poly(A) signal regions, respectively. Further study is 
needed to define the true coding region of the gene. Similarity analysis (Powerblast) is 
the most successful method for accurately predicting coding regions, especially exons 
with UTRs. However full-length cDNA data sometimes are not available or 
incomplete. Xgrail predicts exons very well but fails to identify 5' and 3' UTRs. It is
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possibly because UTRs lack splice acceptor (5’ UTR) or splice donor (3’ UTR) and do 
not start or end with the coding regions.
The alignment of the genomic sequence with the putative gene exons is 
provided in Figure 28. One can see that the similarity between T34235 and genomic 
sequence is perfect with only two "n"s in T34235 sequence. The identity between 
these two sequences is 99.4% (320/322) and the exon/intron boundaries of this putative 
gene match consensus as shown in Table 8.
Table 8: Comparison of the exon/intron boundary of putative gene and the
consensus sequence
1 . . . CCflGflGCCAGIgtgacgccca. .
2 . .  .GATCCTTCAGI g t g a g t t c t g . .
3 . .  .TAAAGAACAGIgtactgaaga..
4 . . .  TGTCGTCAATIgcacacaacg. .
 5  GTTAGAAGAGI g t g a g t t t g g . .
6 . .  .GAIGTTCTTGI g tg g tg tC g g ..
7 . . . AGGCCCGGAGIgtgagtctgt. .
8 . . .  TGGGACATCGIgtaagtaCga. .
 9  TGTTGCCITGI g tc a g tg c c a . .
1 0 . .  .AGATCACTCAIgtaaggacac. .
1 1 . .  .TCTCCTTTGAIgtacgagtat..
1 2 . .  .CAGACATGGGI g tg a g tg a c t . .
1 3  ATAAATTTGGI g ta a a c a c a c . .
14 — GCCTCTCCflG I g ta g c a g g a g . .
15 — TCTCATGGAGIgtcaggctCc. .
16 — TGTGTGTTCGIgtgaggggcc..
1 7  ACAGGAAGAAI g tg a g c a g c t . .
1 8 . .  .GACCTCTCflGlgtgagagtct. .
1 9 . .  .CTGTCCTAGGIgtgagtcaca.. 
consensus (C /A )A G Ig t{a/g )agC ..
in tro n  
. 1 
. 2 
. 3
exon
2
3
4
5
6
7
8
9
10
. . .  cccccgacag  IAGGGTCCTTC. . .
. . .  c t c t c tc c a g  I GCCrTGTTCC. . .
. . .C ttttctcaglTTTCRTTATT.. .
. 4 — CtgaacttaglATCAAATTAC.. .
. 5 . .  .cttgctacaglCTTCGCAAGG.. .
. 6 . .  .cctgtatcaglGAGflTAGTGG.. .
. 7 . . .  t c a a g t t t a g  ICATTTTTCCA.. .
. 8  ttcctcacaglTCAGCCATGG.. .
. 9 . . .cttCttCcaglGTGGGCCATC.. .
. 1 0 . . . c t t t t t c c a g  IAATGRAATAC. . .  11 
. 1 1 . . . ctgactgcagIGCCCAGCCTC. . .  12 
. 1 2 . . . c t c t c tc c a g  ITCTTCCCCTG. . .  13 
. 13 . . .  c c c a tg ac a g  I GATGflAGGAC. . .  14 
. 1 4 . . . cctgttacagIGAGTAACCTG. . .  15 
. 1 5 . . . gcctccgcagIGGCACTCCAG. . .  16 
. 16— g a c tc c a ta g  IACAAAGAACC 17
. 1 8 . . . a t t a c t t c a g  ITAAITGAGCT.
. 1 9 . . . t g t t t t c t a g  IAATTTGATTC.
. . . ( t / c ) n n ( c / t ) a g lG
18
19
20
Note: Upper case letters are exons while lower case letters, introns.
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Figure 28: Alignment of genomic sequence and exons of putative gene in contig 2.2
c o n t ig 2 .2  > 38725 ccaaag taaag a tg C C C g C C g ag cg tcg c tc ttc tg g g ta
S p l
c o n t ig 2 .2  > 38765 aaagcgagtC «B *® ttgaaggflB B C «acag tg ttcgcgct
GR LF-Al
c o n c ig 2 .2  > 38805 c g g c c to g g g g C g g C g c t tc t t tg g g g g c g g g c tg g a g t
GR CREB S p l
c o n t ig 2 .2  > 38845 c tcc tggccg tg aacg g C g g sg cg ccaaC g g ccg cc tcca
GR
c o n c ig 2 .2  > 38885 atgtggcC C M tcagaaagaaaggaaggcC gggaacC aag
SRF/CCAAT box
c o n t ig 2 .2  > 38925 a a g c taC tg g tC g g tg a tccc tg g aC C M tcg g ag g ag cc
CCAAT box SRF/CCAAT box
c o n c ig 2 .2  > 38965 g tg a ttc g g c g g g a g tc t tg a c c g c c g c c g g g c tc c tg g t
s p l
c o n t ig 2 .2  > 39005 accccagcgcgagcgccaggcgtccggccgccgtggccac
T34235 > 1  ........................................................
M
c o n c ig 2 .2  > 39045 g ttc g tg tc c g a c ttc c g c a a a g a g ttc ta c g a g g tg g tc
T34235 > 27  n .................................................................
F V S D F R K E F Y E V V
c o n c ig 2 .2  > 39085 cagagccagIg tgacgcccag tccgggacccccgccgaggc
T34235 > 6 7  ...................
Q S Q
c o n t ig 2 .2  > 39125 cttgccggtggggaagggacgagggggagcgaccgtgggt
--------------------------in t r o n  1, sequence 39145-39164 n o t shown  -----------------
c o n t ig 2 .2  > 39165 gaccgggaggcaggggagggccggggttcgggtcgccgtg
c o n t ig 2 .2  > 39205 t tc a g c c g g tc tg c tc t tc c c c g a ta g la g g g tc c t tc tc t
R V L L
c c n t ig 2 .2  > 39245 tc g tg g c c tc g g a c g tg g a tg c tc tg tg tg c g ta c a a g a t
F V A S D V D A L C A Y K I
c o n t ig 2 .2  > 39285 cc ttcag Ig tg ag ttc tg cg g accc tag g ag g g cg g g g ccg
L Q
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c o n c ig 2 .2  > 39325 gcgcgcgaggcgagggcgccgcgcgggggcgcagggcgga 
--------------------------in t r o n  2, sequence 39365-39964 noc shown--------------
c o n t ig 2 .2  > 39965 c tcc tc aa g g ta a a c c g c c a ac g tc c ta a a c a ag a c a g g c
c o n tig 2 .2  > 40005 
T34235 > 133
c o n t ig 2 .2  > 40045
T34235 > 154
C tc g a a a a c a c tc tc tc tc c a g Ig c c tc g c tc c a g tg tg a c
A L F Q C D 
cacg cg caa ta tacg c tg g tC ccag ttC c tg g g tg g caag  
H V Q Y T L V P V S G W Q
conC ig2 .2  > 40085 
T34235 > 194
a a c ttg a a a c tg c a c c tc c tg a g c a ta a a g a a c a g Ig ta c c
....................................n .....................................
E L E T A F L E H K E Q
c o n tig 2 .2  > 40125 g a a g a c g c g ttc c a g a a c a a c g tg g cc c c tta c tc a a cc g  
--------------------------i n t r o n  3, sequence 40165-41684 noc shown--------------
c o n t ig 2 .2  > 41685 g aacaac tcag ag g c ttag tg a tg aag g aaaag g g g cccc
c o n t ig 2 .2 
T34235
c o n t ig 2 .2  
T34235
c o n t ig 2 .2  
T34235
c o n t ig 2 .2  
T34235
> 41725
> 226
> 41765
> 230
> 41805
> 270
> 41845
> 310
c o n t ig 2 .2  > 41885
c tc g a c a ta g c ta c c t t a c a a ta tc t t c c t t c tC t t c a g I t
t tc a c c a t t t ta t tc tc a C a a a c tg tg g a g c ta a c g ta g a  
F H Y F I L X N C G A N V D  
c c ta t tg g a ta t tc C tc a a c c tg a tg a a g a c a c ta ta t tc  
L L D I L Q P D E D T I F  
t t tg c g tg tg a c a c c c a c a g g c c a g tc a a tg tc g tc a a tIg 
F V C D T H R P V N V V N  
ta ta c a a c g a ta c c c a g g ta c t t tc tg tg c ta tg c c c c c a
- in t r o n  4, sequence 41925-42884 n o t shown-
c o n t ig 2 .2  > 42885 a g t tc tc c g ta g a a a g a g g a g a g g c t ta a t tc c t t t tc g t
c o n t ig 2 .2 > 42925
c o n tig 2 .2  > 42965
c o n tig 2 .2  > 43005
c o n t i g 2 . 2  > 4 3 0 4 5
t t tg a a c t ta g Ia tc a a a t ta c tc a tC a a a c a a g a tg a tg a  
I K L L I K Q D D D
c c ttg a ia g ttc c c g c c ta tg a a g a c a tc ttc a g g g a tg a a
L E V P A Y E D I F R D E
gag g ag g a tg aag ag ca ttcag g aaa tg acag tg a tg g g c
E E D E E H S G N D S D G
cag ag cc ttc tg ag aag cg cacacg g c tag aag ag Ig tg ag  
S E P S E K R T R L E E
148
c o n c i g 2 . 2  > 4 3 0 8 5  t c t g g g t c c c c c a c a g c c a c c c c a g a g g a a c c t g c a c c c c
------------------------- in c ro n  5, sequence 43125-52084 noc shown---------------
c o n c ig 2 .2  > 52085 cccCCggccCcccCgaCaccaccagacagagggcccgggg
conC ig2.2  > 52125
conC ig2.2  > 52165 
co n c ig 2 .2  > 52205
CgccCCgccacagIctCcgcaaggacgggagccCaggcccc 
L R K D G S L G S
cacCgggcctCCgccggggCggaCacggaCgCCctCgIgcg 
H W A F A G V D M D V L
gCgccggccagagCagaCgggcCaccgccCaaaagcCCCc
-inC ron 6, sequence 52245-53324 noc shown-
conC ig2.2  > 53325 aacccccccgggccgcggggacaaatccccggcgcacccg
c o n c ig 2 .2  > 53365 
co n c ig 2 .2  > 53405 
c o n c ig 2 .2  > 53445 
conC ig2.2  > 53485
ccccaccccccg ccccccccg tccccg caccag Ig ag acag
G D S
cggagcaaaccaC gcggaggaggcagcggcgagagtggga
G A N H A E E A A A R V G
ggcccggagIgcgagCccgCgcCCccagccgcCcccagcac 
G P E
cagaagcccacC C gcccgggggcccgcggcgccacccaca
'in c ro n  7 , sequence 53525-54024 noC shown-
c o n c ig 2 .2  > 54925 gaaaacaaacagcaccacgacccaacccgcaccccaccga
c o n c ig 2 .2  > 54965 
c o n c ig 2 .2  > 55005 
c o n c ig 2 .2  > 55045 
co n c ig 2 .2  > 55085 
co n c ig 2 .2  > 55125
aCaccgCcaagCCCagIcaCCCCCccaaaaCaCCCggcccc 
H F S K I F G F
ccg caccg ccac tccccg tcg aag acccg caccccacg cc
L Y C Y F L L K T C I L C
accacagaagagacaccccccccgaccacgagcagcacga
H Y R R D I L F D Y E Q Y E
acaccacgggacaccgIgCaagCaCgaaCaggcggaacCca 
Y H G T S
ccacaaagccccgaccccaggggccagcgcccccaaacgc
-in c ro n  8, sequence 55145-56404 noc shown-
c o n c ig 2 .2 > 56405
c o n c ig 2 .2  > 56445
c o n c i g 2 .2  > 5 6 4 8 5
gccccagcacaCgccccCcccacgagccCCagacCCcccC
g cccccccacag Iccagccacggcgacg tccgagccggccc  
S A M V M F E L A
ggacgccgcccaaggacccgaacgacacgccgcggcacgc
W M L S K D L N D M L W Y V
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c o n c i g 2 . 2  >  5 6 5 2 5 agcccctgcggcagccgcg tgggagcacccgc tgccccg  I g 
A P A A A V W E ï L L P W
co n c ig 2 .2  > 56565 tcag cg ccacaC aag cag c tc tg tcc tcccacag g g ag g g  
- in c ro n  9 , sequence 56605-58124 noc shown---------------
co n c ig 2 .2  > 58125 agcccaggcgggcCaCaggccggccccacCgccCCcCccc
c o n c ig 2 .2  > 58165 
conC ig2.2  > 58205
cccccag  I gCgggccaCcgccggacCaacagaccagCgggc 
W A I V G L T D Q W V
gcaagacaagaccacC ca 1 gcaaggacacacCcccCCgccC 
Q D K I  L Q
co n c ig 2 .2  > 58245 CgcagggccagccccgcgccgCggccaggCgcacagcccg 
--------------------------in c ro n  10, sequence  58285-64364 noc shown-------------
co n c ig 2 .2  > 64365 cccaggcccaggccgcccggcaagagccggagggaaccag
co n c ig 2 .2  > 64405 
co n c ig 2 .2  > 64445 
c o n c ig 2 .2  > 64485 
c o n c ig 2 .2  > 64525
c o n c ig 2 .2  > 64565
ccgaggcCCgCgcCacCCCCCCCCccag I a acg aaacacg c
M K Y V
gaccgacgccggcgccccgcagcgccacgccccccgccac
T D V G V L Q R H V S R H
aaccaccggaacgaggacgaggagaacacacC ccccgcgg
N H R N E D E E N T L S V
accgcacacggaC cC ccctcga I gcacgagcacccccgcgg  
D C T R I S F E
cccagcccgaggggcacaggcagcacccccgcccagcagg
- in c ro n  11, sequence  64605-66404 noc shown-
co n c ig 2 .2  > 66405 agcgcccagggcggccagcgggcgcccgcacgccccccga
co n c ig 2 .2  > 66445
c o n c ig 2 .2  > 66485 
co n c ig 2 .2  > 66525 
conC ig2.2  > 66565 
co n c ig 2 .2  > 66605
ccgcag I gcccagccC ccgccC ggcgccccaccagcaccgg 
P S L R L V L Y Q H W
ccccC ccaC gacagcccgC gcaacaccagccacaccgcag
S L H D S L C N T S Y T A
ccaggCCcaagccgcggccCgCgcacggacagaagcggcc
A R F K L W S V H G Q K R L
ccaggagccccccgcagacacggg I gcgagcgaccgcccgg  
Q E F L A D M G
gcccccgcagcgccagcccC ggccacccccaagggaaaag
- in c ro n  12, sequence 66645-66764 noc shown------------------------
c o n c i g 2 .2  > 6 6 7 6 5 c g g c c c g g g c c c c c c c c c a c c c c g c c g g c g c g c g g c g a c c
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concig2  
concig2  
c o n c ig 2 , 
c o n c ig 2 , 
c o n c ig 2 .
2 > 66805 ccac cc a c g c g g c c tg g g c c tg c tc tc c c c a g itc tC c c c c
L P
2 > 66845 cgaagcaggcgaagcagaagctccaggccacggacacccc
L K Q V K Q K F Q A M D I S
2 > 66885 c tc g a a g g ag a a c ttg c g g g a a a tg a c tg aa g a g tc tg c a
L K E N L R E M I E E S A
2 > 66925 a a t a a a t t t g g I g t a a a c a c a c a c t t t t c tg g a t t c a t c t t
N K F G
2 > 66965 c a tta c a tc c a g g c tc a c tê ia a g tg a a g g g tC c ta c ttta
------------ in tro n  13, sequence 67005-67524 noc shown---------------
c o n c ig 2 .2  > 67525 cacacccg ccg g cc tg cc tg g cag tg ag ag cc tg cccaca
c o n c ig 2 .2  > 67565 
c o n c ig 2 .2  > 67605 
c o n c ig 2 .2  > 67645 
c o n c ig 2 .2  > 67685 
c o n c ig 2 .2  > 67725 
concig2
a tccg ag g g cg acag ccg cg ttcg c tcccacg acag Ig a tg
M
a ag g aca tg cg cg cg cag ac tcccag ca tccaccc tg g g t
K D M R V Q T F S I H F G
ccaa g ca c a a g tc tc tg g c c a g cg a c g tg g tc c c tg c c a c
F K H K F L A S D V V F A T
catgC ccttgaC ggagagccccgagaaggatggctcaggg
M S L M E S P E K D G S G
a cag a cc a c c tc a c c c ag g c tc tg g a c a g c c c c tc c a g Ig t 
T D H F I Q A L D S L S R
2 > 67765 ag cag g ag g gctgcggg ttcgcc tcacggggccaccac tg
------------ in tro n  14, sequence 67805-73764 n o t shown-
c o n tig 2 .2  > 73765 ttta c c a a g a g ttc c tg a c a a g c a c c a c c a a a g c c a tg tg
c o n tig 2 .2  > 73805 
c o n tig 2 .2  > 73845 
c o n tig 2 .2  > 73885 
c o n tig 2 .2  > 73925 
c o n tig 2 .2  > 73965
tc tg c c c tg tta c a g Ig a g ta a c c tg g a c a a g c tg ta c c a t  
S N L D K L Y H
g g cctg g aactcgccaagaagcagctgcgagccacccagc
G L E L A K K Q L R A T Q
a g a c c a t tg c c a g c tg c c t t tg c a c c a a c c tc g tc a tc tc
Q T I A S C L C T N L V r s
c c a g g g g c c tt tc c tg ta c tg c tc tc tc a tg g a g Ig tc a g g  
Q G P F L Y C S L M E
cttcccacag ag cacag g cg cc tg g tcacag caccag tg g
—— — — ——in tro n  15,
c o n t i g 2 . 2  > 7 4 0 0 5 c ttc g tc tg a c c a tc tg tc tc g c c tc c g c a g Ig g c a c tc c a
G T P
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co n c ig 2 .2  > 74045 
co n c ig 2 .2  > 74085
gacgccacgccg tcccccaggccggcacccccaagcctgc
D V M L F S R P A S L S L
C cag caaacacc tg c tcaag ccccC tg tg tg tccg Ig tg ag  
L S K H L L K S F V C S
coricig2 .2  > 74125 gggccaggcggg tgctg tggg tacaggagggcagg tgctc  
------------------------- in t r o n  16, sequence 74165-75524 n o t shown-------------
c o n tig 2 .2  > 75525 g ttg g g c tc tg g g c tc tg a g tg ttg a g c tg g g g c c c a c c a
c o n tig 2 .2  > 75565 
c o n tig 2 .2  > 75605 
c o n tig 2 .2  > 75645 
c o n tig 2 .2  > 75685 
c o n tig 2 .2  > 75725
ta c c c tg a c g g a g g g tg c tc tc c g a c tc c a ta g  I acaaaga
T K
accg g cg c tg c a a a c tg c tg c c c c tg g tg a tg g c tg c c c c
N R R C K L L P L V M A A P
cc tg ag ca tg g ag ca tg g cacag tg accg tg g tg g g ca tc
L S M E H G T V T V V G I
cccccagagaccgacagctcggacaggaagaa I g tgagcag  
P P E T D S S D R K N
c ttc c a c tc g tc c tg g g a c tg g a g g g tc g g g g g tg ttg g g
—in tr o n  17, sequence 75765-75844 n o t shown—
c o n tig 2 .2  > 75845 a t tg c a g g c c g c c tg g c c c c c g a c a tg tc ttg tg tg tc a g
c o n tig 2 .2  > 75885 
c o n tig 2 .2  > 75925
c a g Ic ttttttg g g a g g g cg tttg a g a a g g c a g c g g a a a g c  
F F G R A F E K A A E S
a c c a g c tc c c g g a tg c tg c a c a a c c a ttt tg a c c tc tc a g l
T S S R M L H N H F D L S
c o n tig 2 .2 > 75965 g tg a g a g tc tc c tg c c a c tc tg c c a c a c tt tc c c a c c tg a
------------------------- in t r o n  18, sequence 76005-77844 n o t shown-------------
c o n tig 2 .2  > 77845 g g g a g t t c tg tg c c c tg tc t tg tg t tc c c a c tc c tc c c t t
c o n tig 2 .2  > 77885 
c o n tig 2 .2  > 77925
c o n tig 2 .2  > 77965 
c o n tig 2 .2  > 78005
c t c a c g g c t g t t t t t c t t t c a t t a c t t c a g I t a a t t g a g c t
V I  E L
g a a a g c tg a g g a tc g g a g c a a g tttc tg g a c g c a c tta tt
K A E D R S K F L D A L I
tc c c tc c tg t c c ta g g 1g tg a g tta c a g g g g ttc tg ca g g g  
S L L
g tg g c tg cag cag ccccc tcag ag cccg accc tg a tg ccc
------------------------ in t r o n  19, sequence 78045-79484 n o t shown-
c o n t i g 2 . 2  > 7 9 4 8 5 c a g t t t c t t c a a t t c g g t g g c a c a t c a a c a t c g t t t g a a a
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c o n c i g 2 . 2  > 7 9 5 2 5  c c c g c c c c c c c c c g c c t t g c c c c c c a g l a a c t t g a c c c c c c
c o n c ig 2 .2  > 79565 c a g a a c g a c c c c c tc a tc ta c g ta a c tg g c c ttc a tc c a g
c o n c ig 2 .2  > 79605 a c tg c a ag tta tg g a c a c g a c tc g a g ac g ta g a a g c c a c c
c o n c ig 2 .2  > 79645 c c c c a c ta a a ta a a a c g c t ta tc t ta g g c c c c g tc c c c a c
Poly(A) s ig n a l
conC ig2.2  > 79685 c g tg g c tc tg g tc tc g a g g c c a g c g c tc g a g tg tg c tc tg
co n c ig 2 .2  > 79725 agcctC ccg tg g g tcc tg g g ccccag g ag ccc tcag cg cc
co n c ig 2 .2  > 79765 C ggcaggaaaccagcaC ggggatcggcccaaaggacaaga
c o n tig 2 .2  > 79805 c c c c c tta c tc tg tc c c c c a g g c c c tc c g g g tg g c a g tg g
c o n tig 2 .2  > 79845 acag aggccaggaccccccggcacccccgcc tcccca tag
co n c ig 2 .2  > 79885 cacctg caccg g ccac tg cc tg g cg g cg ccag ccag cacc
c o n tig 2 .2  > 79925 c g g c tc tg tc c a c c ta c c a c ttc c C c tg g tc c a c c tg g c c
co n c ig 2 .2  > 79965 ccag ccaca tag caag tccaccccc tcag ccaC cccccca
co n c ig 2 .2  > 80005 c c c g tg g g tc tc a c c a c c c a g c a c c c c t t tc c a g g tc t t t
Note: Not all sequences are shown. indicates the identity between genomic 
sequence and T34235. "I" indicates the splice site. indicates stop codon. 
Poly( A) signal is bold. The potential regulatory sites of the 5’ promoter region 
are outlined.
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The 5’ region of this putative gene, the first exon that contains the 5' UTR, the 
second exon, the first intron and part of second intron all are within a CpG island 
(position 38939-39379 according to Xgrail prediction). The G/C content of this CpG 
island is 67.6% and the overall G/C content of contig2.2 is 48.9%. The potential 
promoter region fi'om 38725 to 39018 was analyzed by SIGNALSCAN and the 
TRANSFAC data base. The putative regulatory elements and transcription factor 
binding sites identified are three CCAAT boxes, one CREB (cyclic AMP regulatory 
element), three GR (glucocorticoid receptor), one LF-Al (liver specific trans-acting 
factor) and three Sp 1 (see Figure 28). There was no TATA box present but three Sp 1 
transcription factor binding sites were present in different locations as required for 
interaction of transcription factor HD ( I FUU) with TATA-less promoters.
The deduced amino acid sequence of this putative gene was used to search for 
similarities in the non-redundant GenBank protein database with the Blastp program 
and four high score hits were found. These were to the yeast protein similar to C. 
elegans hypothetical protein F34D10.2 (U53876), yeast ORF YLR103c (Z73275), C. 
elegans hypothetical protein F34D10.2 (Z34799), and Ustilago maydis protein Tsd2 
(U50276). U53876 and Z73275 are actually the same protein. The alignment of 
putative gene amino acid sequence and yeast protein similar to C. elegens hypothetical 
protein F34D 10.2 was done with the ClustalW program and the result is provided in 
Figure 29.
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Figure 29: Alignment of yeast F34D 10.2-like protein and amino acid sequence of
putative gene in contig 2.2 by CLUSTAL W
CLUSTAL W (1.60) rau lc ip le  sequence a lig n m en t
putgene_62 —MFVSDFRKEFYEWQS-------------QRVLLFVASDVDALCAYKILQALFQCDHVQYrLVP
y e a s c f3 4 d l MYYGISQFSEftXNKILRNSSSHSSCQLVIFVSCXNIDALCflTKMLSLLFKKQLVQSQrVP
*  ♦  *  ♦  * * * * *  *  *  * *  * *  * *
pucgene_62 VSGWQELETAFLEHKBQFHVFILirJCGfllJVDLLDILQPDEDTIFEVCDTHRPVNWNIKL
y e a s c f3 4 d l IFGYSELRBHYSQLDENINSIiLLVGEGGVIDLEftFLEIDP—QEYVIDTDEKSGEQSFRR
pucgene_62 LIKQDDDLEVPAYEDIFRDEEEDEEHSCaroSDGS-EPSEKRTRLEELRKDGSLGSHWAFA
y e a s t f 3 4 d l  DIYVLDAHRPWNLmEFGSQIIQCFDDGTVDDTLGEQKEAyYKLLELDEES—GDDELSG
putgene_62 GVDMDVLC33SGANHAEEAAARVGGPEHFSKIPGFLYCYFLLKTCILCHYRRDILFDYEQY
y e a sc f3 4 d l DENDNNGGDDEATDADEVTDED—EEDEDETISNKRGNSSIGPNDLSKRKQ—RKK-QIH
* « * * . * .  * _ *
putgene_62 EYHGTSSMVMFELAWMLSKDLNEMLWYVAPAAAVWEYLLPWWAIVGLTDQWVQDKILCM
y e a s c f3 4 d l EYEG—VLEEYYSQGTTWNSISAQrYSLLSAIGETNLSNLWLNILGTTS LDIAYAQ
* *  *  *  * * * * *
puCgene_62 KYVTDVGVLQRHVSRHNHRNEDEENTLSVDCTRISFEPSLRLVLYQHWSLHDSLCNTSYT
y e a sc f3 4 d l VYNRLYPLLQDEVKRLTPSSPN—SVRrPDTLTLNIQPDYYLFLLRHSSLYDSFïYSNYV
*  * * * *  *  * * * * * * * *  *
putgene_62 AARFKLWSVHGQKRLQEFUU3M3I^ IiCQVKQKFQAMDISLKENLREMIEESANKFGMKm
y e a s tf3 4 d l  NAKLSLWNENCaOCRLHKMFAFMSIPLSTAQEIWLyMDHSIKRELGIIFDKNLDRYGLQDI
*  * *  *  * * ♦  *  *  *  * *  * *  *  *  *  *  *
pucgene_62 RVQTFSIHFGFKHKFLASDWFAIMSIilES PEKD------------------ GSG--------------
y e a s tf3 4 d l  IRDGFVRTLGYRGSISASEFVEALTALLEVC»ISTDKDSVKINNIMŒ)DTDGEEEEI»ISAQ
» * » » _  *  *  . * . *  , * *  »
puCgene_62  TDHFTQALDSLSRSNLDKLYHGI.ELAKKQLRATQgriASCLCTNLVISQGP
y e a sc f3 4 d l KLTrOUy(RWVSNEV»LSWDALDDRKVELLNRGIQLAQDLQRAIFNTGVAILEKKLIKHLRI
* * * * * ** * * *
pucgene_62 FLYCSLMBGTPDVMLFSRPASLSLLSKHLIiCSFVCSTKNRRCKLLPLVMaAPLSMEHGTV
y e a sc f3 4 d l YRLCVLQDG-PDLDLYRNPLTLLRLC3*JLIECCAESEDKQ LLPMVLASIDENKD-TY
putgene_62 TWGIPPETDS--------SDRK---- NFFGK.AFEKAAESTSSPMLHNHFDLSVIELKAEDRSK
y e a sc f3 4 d l LVAGLTPRYPRGLDTIHTKKPILNNFSMAFQQITAETDAKVRiraJFESSIIEIRREDLSP
*  *  *  * * * * *  *  * * * * * * *
pucgene_62
y e a s tf3 4 d l
FLDALISLLS-
FLEKLTLSGLL
Note: indicates identity, indicates similarity, " " (space) indicates dissimilarity,
and indicates deletion/insertion.
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The similarity between human putative protein and yeast protein is only 40.2%. 
There is a large gap (29 amino acids) in the middle of the human putative protein 
compared with yeast F34D 10.2-like protein. This gap is within exon 14 of the putative 
gene, and thus within a predicted open reading frame. Because of the low similarity of 
these two proteins, it is possible that these two proteins may carry out slightly different 
functions but belong to the same gene family.
The deduced amino acid sequence of this putative gene then was analyzed by 
the Online Protein Secondary Structure Prediction Program which is available at the 
web site of the Hiunan Genome Center, Baylor College of Medicine. Because the 5' 
end of this putative gene (protein) is identical to EST35508 (T31599), which is similar 
to heparan sulfate proteoglycan, a putative transmembrane protein, searching for 
possible transmembrane helices on this putative protein was reasonable and the result of 
this search was as expected. Four inside to outside helices and three outside to inside 
helices were found by this program. As shown in Table 9 and the graphic output of 
this prediction (Figure 30), four significant helices easily can be seen.
Table 9: Possible transmembrane helices in putative gene
The sequence p o s i t io n s  i n  b ra c k e ts  denom inate th e  c o re  re g io n .
Only s c o re s  above 500 a r e  c o n s id e re d  s ig n i f i c a n t .
I n s id e  t o  <o u ts id e  h e l ic e s  : 5 found
from to sc o re c e n te r
19 { 19) 45 ( 37) 520 29
201 ( 201) 217 ( 217) 723 209
252 ( 257) 278 ( 274) 964 265
479 ( 487) 505 ( 503) 1096 495
540 ( 545) 561 ( 561) 147 553
O u ts id e  to in s id e  h e l ic e s  : 4 found
from to sc o re c e n te r
201 ( 201) 217 ( 217) 1142 209
255 ( 258) 276 ( 274) 1085 266
479 { 484) 501 ( 501) 698 493
491 ( 494) 515 ( 512) 77 504
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Figure 30: Graphie output of transmembrane domain prediction of putative
gene. X-axis; amino acid number, Y-axis: score. represents 
the peaks of helices.
It also can be seen from Table 9 that several regions were predicted as both 
inside-to-outside and outside-to-inside helices. The scores for each helix were analyzed 
and the preference of each helix orientation was calculated and is given in Table 10:
Table 10: Preferences of the orientation of helices in putative gene
H e lic e s  shown in  b rack ecs  a r e  c o n s id e re d  in s ig n i f ic a n c .
A •+■-sym bol in d ic a te s  a  p r e f e re n c e  o f  t h i s  o r i e n ta t io n .
A -sym bol in d ic a te s  a  s t r o n g  p re fe re n c e  o f t h i s  o r i e n t a t i o n .
in s id e - s o u ts id e  I o u ts id e -> in s id e  
19- 45 (27) 520 ++ I
201- 217 (17) 723 I 201- 217 (17) 1142 ++
I ( 234- 250 (17) 169 ++ )
252- 278 (27) 964 I 255- 276 (22) 1085 +
479- 505 (27) 1096 ++ I 479- 501 (23) 698
I ( 491- 515 (25) 77 ++ )
(540- 561 (22) 147 ++ ) I
According to the above table and considering only significant transmembrane 
segments (with scores higher than 5(X)), a possible model for transmembrane topology 
is suggested as in Table 11. This suggestion is purely speculative, because it is based 
on the assumption that all transmembrane helices have been found.
Table 11 : Suggested model for transmembrane topology of putative gene
STRONGLY p r e f e r r e d  m odel: N -ten tiin u s in s id e  
4 s t ro n g  transm em brane h e l i c e s ,  t o t a l  sc o re  : 3324
# from  to  le n g th  s c o re  o r i e n ta t io n
1 19 45 (27) 520 i - o
2 201 217 (17) 1142 o - i
3 252 278 (27) 964 i - o
4 479 501 (23) 698 o - i
The S' end of this putative gene is similar to that of heparan sulfate 
proteoglycan. It also probably is expressed in the embryogenesis stage, The 
function of several membrane-inserted heparan sulfate proteoglycans is to mediate the 
adhesion of cells in the embryogenesis stage, [272-276] and recalling that DGS is an 
early developmental field disorder involving improper neural crest migration and
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attachment to the third and fourth pouch in embryogenesis, it suggests that this putative 
heparan sulfate proteoglycan-like gene play a role in the etiology of DGS.
3 .4 .2 .3  Repetitive elements in contig 2.2
Contig2.2 contains the interspersed repetitive elements Alu, LI, Mer, Mir, Mit, 
Mst and The lb as found by the Powerblast program. This contig contains 60 Alu 
elements which include full, half and quarter-length Alu fragments with a similarity 
higher than 70% and 12 LI elements, all of which were less than 550 bp. Powerblast 
also identified 3 Mers, 2 Mirs, 2 Mlts, 2 Msts and 2 The lbs. The total repetitive 
element content was 22.6% (21057/93386) and compared with contig 1 and contig2.1, 
contig2.2 contains less total repetitive element sequence since contig 1 had 31.4% total 
repeat in which 19.5% were Alu and 11.9% were non-Alu and contig2.1 had totally 
32.0% in which 17.9% were Alu and 14.1 were non-Alu. The content of Alu elements 
in all three contigs is comparative while the non-Alu contents differ significantly 
(11.9%, 14.1% and 6.2% respectively). A summary of all repetitive elements in 
contig2.2 is listed in Table 12.
Table 12: Interspersed repetitive elements in contig 2.2
Family number bases % region
Alu 60 15276 16 .4
LI 12 3288 3.5
Mer/Mir/Mlt/Mst 9 1982 2.1
The lb 2 511 0.6
Total non-Alu 23 5781 6 .2
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3 .5  Analysis of contig 3
ContigS contains 157,885 bp and the Xgrail and Powerblast results for this 
contig are given in Figure 31. No known genes were revealed in this region by a 
Powerblast search vs. the non-redundant GenBank database, but three regions with 
EST homology were found. These three ESTs correspond to no open reading frame 
predicted by Xgrail but they correspond to a region similar to human Tiggerl 
transposon element (U49973) at positions 53280- 57520 and at positions 134577- 
135352 to the human breakpoint cluster region(BCR) gene.
3 .5 .1  Major similarities found in database by Powerblast in
contig3
EST H55130 begins at position 121251. The entire EST (127 bp) matches 
perfectly with contig3. This EST was prepared by an expression-independent method 
and should correspond to an open reading frame, ^^ 8] However, Xgrail predicted 
an excellent exon in this position but in the opposite orientation and thus this EST most 
likely would be expressed in the opposite orientation as well, but this was the only 
Xgrail predicted exon within 35 kb of either side of this region.
A second region of EST homology was observed to begin at position 141140. 
The similarity between this EST, EST H55395, and contig3 is 100% (with a one base 
deletion in EST). The origin of this EST is the same as EST H55130 but Xgrail did not 
predict any exon in this region.
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Figure 31 : Result of Powerblast and Xgrail analysis of contig 3
SÛK fiOK 7ÛK 8ÛK 9ÛK 1Û0K 11ÛK 12ÛK 130K 14ÛK 1SÛK
CpG DNA 
Z56979
o\
I I!
cm r e p e a t ^  ^
STS 608766
X 4L
> i \
■rl EsT
I
EST N69625
Human Tiggerl 
Transposabie eim ent 
U49973
HI/
EST H7278 
STS 116320 
H3805I
| e A ESTH04149 Î
EST 88206581 ESTH55I30
EST H55407 
EST H55395
Similar to BC8
N ote  I X g ra i l  r e s u l t  i s  on th e  to p .  I h e  g ra y  l i n e  i s  DNA se q u e n c e . The p e a k s  a r e  p r e d i c t e d  e x o n s . The sm a ll  
c o lo r  b a r s  above o r  below  th e  p e a k s  i n d i c a t e  th e  q u a l i t y  o f  e x o n s , G reen  f o r  e x c e l l e n t ,  b lu e  f o r  good 
and r e d  f o r  m a rg in a l .  Peak above th e  g ra y  l i n e  m eans th e  exon i s  on fo rw a rd  s t r a n d  w h ile  p eak  u n d e r 
th e  l i n e ,  r e v e r s e . The i n t e n s i t y  o f  th e  g ra y  l i n e  m eans th e  GC c o n te n t s .  The l i g h t e r  th e  r e g io n  i s ,
th e  h ig h e r  th e  GC c o n te n t s .  The p in k  b o x es  on th e  g ra y  l i n e  a r e  CpG i s l a n d s ,
P o w e rb la s t r e s u l t  i s  on th e  b o tto m . The b la c k - g r a y  l i n e  i s  DNA se q u e n c e . The g ra y  r e g io n s  a r e  r e p e a t
se q u e n c e . The sm a ll  c o lo r e d  b a r s  a r e  m a tch es  found  i n  GenBank. The b lu e  b a r s  a r e  m a tch es  w ith  v e ry
h ig h  i d e n t i t y .  The p in k  b a r s  a r e  m a tch es  w ith  r e l a t i v e  low  s i m i l a r i t y .
Another region of EST homology to EST H55407 begins at position 147588 
that matches perfectly with contigS. The direction of this EST is opposite to two 
previously discussed ESTs and the origin of this EST is the same as those just 
mentioned. Even though this EST corresponds to no Xgrail predicted exon, there is a 
cluster of Xgrail predicted exons nearby. However, about half of those exons contain 
internal stop codons. Furthermore, several of the exons without stop codons are 
located in repetitive regions. It still is possible that there is a putative gene around this 
region but analysis of the genomic sequence alone fails to provide sufficient evidence to 
predict it.
Xgrail also predicts many open reading frames throughout this contig in 
addition to those discussed above but most of them are located either in repetitive 
regions or contain internal stop codons and no significant EST homologies were 
observed.
However, beginning at position 33476, there is a region with a perfect match to 
GenBank accession number Z56979. 2^56979 was purified from genomic DNA by 
using a methylated DNA binding column. 1279] Although this method does not screen 
the DNA fragments directly by the density of CpG dinucleotides,the restriction enzyme 
Msel (recognition site TTAA) was used to cleave out the assumed non-CpG region. 
Thus, this DNA fragment represents a putative CpG island containing a short stretch of 
DNA with a high density of non-methylated CpG dinucleotides, predominantly 
associated with the 5' region of a human gene. However, Xgrail failed to consider this 
region a CpG island. Because of the shortcoming of the method of purification of 
2^56979 as a CpG island, this CpG island could be false.
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Starting at position 53280, there is a region similar to human Tiggerl 
transposon element (U49973) which also closely resembles Drosophila melanogaster 
DNA transposon pogo. \  DNA transposon element is a fragment of DNA which 
may represent a mobile genomic element that can be excised out of and reintegrated into 
the genome. It is different from other interspersed repetitive elements because its 
reiteration does not involve retrotransposition, which is a transposition mediated by 
RNA. A DNA transposon usually has terminal inverted repeats whose sizes vary and 
may contain internal inverted repeats. The DNA fragment carried by a transposon 
usually has coding capacity and may code for proteins for a transposase. However, the 
inverted repeats and the coding region may be altered during evolution and no longer be 
conserved and expressed.
The human Tiggerl-like transposon element found in this region is 4240 bp 
long and the terminal inverted repeats of this transposon are imperfect and short. A 
dotplot comparison result between human Tiggerl and this region is provided in Figure 
32. The comparison showed that the Tiggerl-like transposon contains all the sequence 
elements the human Tiggerl has, but instead of being contiguous, the sequence similar 
to human Tiggerl transposon in this region is broken into five fragments. The 
sequences between fragments are unique to Tiggerl-like transposon, and this 
transposon has multiple internal inverted repeats. Almost all of these internal inverted 
repeats are within regions unique to this transposon, i.e. regions not found in human 
Tiggerl. The positions of major internal inverted repeats are shown in Figure 34. 
Human Tiggerl transposon has two open reading frames and there is no gap between 
them. The first one is a putative transposase similar to the pogo element and the 
function of the second one is unknown, 282] However, in this Tiggerl-like 
transposon, the coding regions have been altered and contain multiple stop codons in all 
reading frames. The translation of the coding region is provided in Figure 33.
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Figure 32; Dot plot of human Tiggerl vs. the genomic region sequences. Tigger I-like 
sequence in chromosome 22 is horizontal and Tigger I sequence is vertical.
F igure 33; T ranslation  o f  hum an T ig g er  I-lik e  transposon  cod in g  region
(L inear) MAP o f :  T ig g e rIrev .G cg  check : 2950 from : 1 co : 4240
1 c a g g c a c a c c c g ta c tc c a c c g ta g tc c g c c tc a tc g c a c t tc a ta g a ta t tg tg t t tc c
61 c a c a a a c c g a a g g c ttg tg g c a a g c c c g tg tc C a g c a a g tc tc ttg g tg c c a ttt t tc c a
121 a c a g ta tg c g a c c C c tg g c tc tc c g tg tc a c a C tg g ta a ttc c c a ta a ta tg tc a ta c c t
181 c c tc c ttac ta g g c a tc c a tc a cg g c g a c c g g c g a c tg tc g c cg g c a g a g g g tc g tg a c t
241 g caag tC g tc c ag g ttc ttg g tg tttc g a a c a a a g a ac tg g a c a a a a c ac c c a g c a a a g c
301 aaagaaag aacg aag caacaaaag aacg aaag cag g tg tc ta ttg aaaa tg aaag aacac
361 gccacagC gtgggagcgggcccaagcag tggcccagggcccagatacagaatcc tc ttgg
421 g tc c a a a c a c c c c c a a g a a g tttc c c a tc g g c c a c tc c a C g c tc a tc tc a tg ta a a tg a a
481 g tgacagcccacaatcatC ctgactgg tcgcagaaagcagccaaccagaggctgaagC eia
541 tg tC acaeiaggtcacacC cctgtgcaaacaccC gaC tggttgcciaaaagcaaccagaggc
601 tag g a tg aag tC acag ag tta tac tcc tacg caaacaaag accc tg cccacaa tcag C cC
661 gattgaccgtggacagcaaccartccêiaggccagcigcgzÆ gttaccêiagttgcaaacêiaa
721 g a c tc c ac c g g c a a tcag tcag acc tg ttg aag acag ccaaccccccacc tg ccag tg ca
781 g a a a a g g c g a g g a c tta g g tc c c c tg c ttc c a g a c c c ta ttc c c c tg c c tc a tg a g ta a c
841 gatCCCtTTTTTTTmTTGAGftCAGGGTCTCACTCTGTCACCC:AGGCTGGAGTGCAGTA
901 CIGCAGTCATGGTTCACTGCAGCCrrCAATCTCCCAGGCTCACGCGATCCTCCCACCTCAG
9 6 1  CCrcCCCÏAGTAGCrrGGGACCACAGGCACACGTGTGCCACCATGCCrrGGATAACTTTTGTA
1021 TTTTTTGTAGAAACTGGGTTTCACCATGTTTCCCAGGCTGGTCTCrAAACTCCTGGGCrcA
1081 AGCAATCTACGTGCTTCAGCCTCCCAAAGTGTTGAGATTACAGGTGTGAGCXACTGCACC
1141 c a g c c tg tg a tc tt tg a tg tta c c a c tg tc a c tg c c ttg g g c c c g g a a c c a c g c c c g c a t
1201 a a g a c a g tg a a c tc c tg a ta a ta tg tg tg ttc tg a c tg c tc c a c tg a c c g tc c a tg c c c c
1261 a c c tc tc tc C c tc tc c c ta g g c c tc c c ta t tc c c tg a g a c a c a a c a a c a ttg a a a tta g g
1321 ccaa tC aacaac c c ta c aa c g g c c tc ta a g tg ttc a ag tg a c ia g g a a g g g ttg c a c a ttc
a  M A S K C S S E R K G C T F -
b W P L S V Q V K G R V A H F -
c G L * V F K » K E G L H I S -
1381 c tcacctcaag tcaaciagccagaaacgactaagcccag tgaggaaggccg tcaaaagccg
a L T L S Q K L E M I K L S E E G C Q K L
b S L * V K S * K * L S L V R K A V K S » -
C H F K S K V R N D * A * - * G R L S K V E -
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1441 agacaggctgaaagcnagacctcccgcaccciaacaaccaciactgcgaatgcaaaggcaaa
a  R Q A E S * T S C T K * S N C E C K G K
b D R L K A R P L A P N N Q I V N A K V K
c T G * K L D L L H Q I I K L * M Q R * S
1501 g tC cc tg aag g ag atcaaaag tg c tcc tccag tg aag acacaaa tg aC aag aaag tg aaa
a  V P E G D ' K C S S S E D T N D K K V K
b F L K E I K S A P P V K T Q M I R K ' N
C S * R R L K V L L Q * R H K * * E S E T
1561 c a g c c tta ttg c tg a c a tg g a g a a tg c g g ta g tg g tc tg g a C a g a a g a tc a a a c c a g c c a
a  Q P y C * Y G E C G S G L D R R S N Q P
b S L I A D M E N V V V V W I E D Q T S H
c A L L L I W R M W * W S G » K I K P A M
1621 tg c a tt tc c c ta a g tc a a a g c c ta a tC c a g a g c a a g a tc c ta c tc c tc tC c a a tc c ta tg
a  C I S L S Q S L I Q S K I L L L F N S M
b A F P * V K A * F R A R S Y F S S I L *
c H F L K S K P N S E Q D P T S L Q F Y E
1581 aag g ccg ag ag ag g tg ag g aag c tg cag aag aaaac ttag aag c tag tag ag a tc tg cg c
a  K A E R G E E A A E E N L E A S R D L C
b R L R E V R K L Q K K T * K L V E I C A
c G * E R * G S C R R K L R S * * R F V H
1741 acgaggg tciaggaaggaagccatctacaC aacataaciag tgcaagg tgaaggagcaag tg
a  M R V R K E A I Y I T * K C K V K E Q V
b * G * G R K P S T * H K S A R * R S K C
C E G K E G S H L H N I K V Q G E G A S A
1801 ccg acg tag aag c tg ccg caag ttaC ccag aag acc tg g c taag a tcac tg acg aag g tg
a  L M * K L P Q V I Q K I W L R S L M K V
b * C R S C R K L S R R S G * D H * » R W
c D V E A A A S Y P E D L A K X T D E G G
1861 g c c a c ac ta a a c a a c a g a tc g tc a a tg ta g g c g a a ac a g c c ttc c a tc a g aa g a g g a tg c
a  A T L N N R S S M » V K Q P S I R R G C
b P H * T T D R Q C R * N S L L S E E D A
c H T K Q Q I V N V G E T A F Y Q K R M P
1921 c a tc ta g g ac tC tc c ta g c ta g a g a g g a g a ag tc a a c g a c C g g c ttc a aa g tttc a a a g g
a H L G L S * L E R R S Q » L A S K F Q R
b I * D F P S * R G E V N D W L Q S F K G
c S R T F L A R E E K S M T G F K V S K E
1981 a a a g g c tg g c tc tg tta g g g g c ta a c g c a g c tg g tg a c ttta tg C tg a a g c c a a tg C tta
a  K G W L C * G L M Q L V T L C » S Q C L
b K A G S V R G * C S W » L Y V E A N V Y
C R L A L L G A N A A G D F M L K P M F I
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2041 cccg cca tcccag aaa tcccag g g ccc taag aa tca tg ccaaaC cccccccg cccg cg cc
a  F A r P E I L G P * E S C Q I F S A C A
b S P F Q K S * G L K N H A K F S L P A L
C R H S R N P R A L R I M P N F L C L R S
2101 ccag aaacg g a a c a a g a aa a c c ta g a tg a c a g ca c a tc c g C tta c a g c ag g g c tta c tg a
a  L E M E Q E N L D D S T F V Y S R A Y »
b * K W N K K T * M T A H L F T A G L T E
c R N G T R K P R * Q H r C L Q Q G L L N
2161
a  I F * A H C * E M L L R K K K R I L S K
b Y F K P T V E K C C S E K K K E S F Q N
c I L S P L L R M A A Q K K K K N P F K I
2221 ta tta c tg c a c c ta g tc a c c c a g g a g c c g tg a tg g a g a tg g a c a a g g a g a c g a a a g c tg t
a  Y Y C T * S S R S C D G D G Q G D E S C
b I T A P S H P G A V M E M D K E M K A V
C L L H L V I Q E L * W R W T R R * K L C
2281 g cg cacg cc tg c taacacaaca tccaccccg cag cccacg g ac tg aag ag caa tC tcaaC
a  V H A C * H N I H S A A H G L K S N F N
b C M P A N T T S I P Q P M D » R V I S I
c A C L L T Q H P F R S P W T E E * F Q F
2341 t tc a a g tc t ta c ta c tc a a g a a a c a c a t t tc a ta a g g c ta ta g tc g c c a c a g a tg g tg a c
a  F K S Y Y S R N T F H K A I V A I D G D
b S S L I I Q E I H F I R L » L P * M V X
c Q V L L F K K Y I S * G Y S C H R W » F
2401 c c c tc tg a tg g a tc cg g g cg aag cacaccg aaaa tcc tccg g aaaag acccaccag ccca
a  S S D G F G R S T L K I F W K R F T S L
b P L M D S G E V H * K S F G K D S P V »
c L * W I R A K Y I E N L L E K I H Q S R
2461 ga tg ccacg aae iag cag cc iag ccg cg g tg acccacacccg c taa ttccaacaa tc tg g g a
a  D A M K S S K L W *
b M P * K A A S C G D
c C H E K Q Q V V V T
2521
2581
2641
2701
2761
g g ccg ag g cag aag aa tcacC tg ag tccag g ag tttg ag accag ccag g g caaca ta tg g
tg g tg c a c g c c ta ta g ttc c a g c ta a tC g g g a g g c tg ag g c a g g g c tc a c c tg a g cc c a g
aa g g c c g ttg a tg tcc tc g c g a tc a c a cc a c c g c a c tc ca g a c tg g g c a a c g a g tg a g ac
a
b
c
H F C F M G R G Q N I N I
I F A S W E E V K I S T L
F L L H G K R S K Y Q H *
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2821 aacaggagcccggaagaagcagaccccaaccctcacggacgaccctgagggcccaggacc
a  N R S L E E V D S N P H G » L * G F R T
b I G V W K K * r P T L M D D F E G S G L
c ‘ E F G R S R F Q P S W M T L R V Q D F
2881 ccagcggagaaag tcaccgcagacg tgggggaaacagcaggagaaccagatccagaag tg
a  S V E K V T A D V G E T A G E P D L E V
b Q W R K S L Q M W G K Q Q E N Q I * K W
c S G E S H C R C G G N S R R T R F R S G
2941 gagcctagaccaGGTGCAGTGGCTCACACTGGTAATCCCAGCACTTTGGGAGTCCGflGGT
3001 GGGTGGATCACGAGGTCAGGAGTTaSftGACCATCCTGGCTAACACGGTGftAACCCCATCT
3061 CTACTAAAAATAC.4AAAAATTASCTGGGCGTGATGGCGGGCGCCTGTAGTCCCAGCTACT
3121  CAGGaGGCTGSGGGAGGAGGATGGCGTGAACCCGGGflGGCGGAGCTTGCAGTGflGCCftAG
3181 ATTGCACCAGIGCACTCCAGCCTGGGCGACASAGCGAGACTCœTCTCAAAAAAAAAAAA
3241 g aag cg g ag cccg aag aag g g g ctg aaC cg ccg caa tc tcag g a tccaacc tg aacaca t
a  E V E P E E G A E L L Q S Q D P T * T H
b K W S P K K G L N C C N L R I Q L E H M
c S G A R R R G *  l A A l S G S N L N T *
3301 g ag g ag c tg c tccc tag g g acg aacaê iag aaag tg g c tccc tg ag acg g aacg tcc tcc t
a  E E L L L R D E Q R K W F L E T E R P P
b R S C F L G M N K E S G S L R R N V L L
c G V A S * G * T K K V V P * D G T S S W
3361 ggggcagacgctgcgaacacgg tcgcaatgacaacaaagcg tC cagaaC actccaC aacc
a  G A D A V N M V A M T T K R S E Y F I T
b G Q M L * T W L Q * Q Q S V Q N I S * P
c  G R C C E H G C N D N K A F R I F H N R
3421 g a a a a a a c a c a g c a g g c cc g a g a g g a c c c c c aa c tttg a a a g a c c ttc tac c g tg g g ta a
a  E K T Q Q A * E D F * F * K T F Y C G *
b K K H S R L E R I S N F E R P S T V G K
c K N T A G L R G F L I L K D L L L W V K
3481 aacg g taccaag cag cc tccag cg ccg g g g g cca tc tcccg tg aaag g cag ag tcaa tca
a  N G I K Q P P V P G A I S C E R Q S Q S
b M V S S S L Q C R G P S P V K G R V N Q
C W Y Q A A S S A G G H L L * K A E S I N
3541 a C g c g g ta a a c tc c a c tg tC g tc c g a tc c g a a C a c a c tg tc a c a g c c c c tc ta c c c ttc a
a  M W * T S L L S D L N T L S Q P L Y P S
b C G K L H C C L 1 * I H C H S P S T L Q
c V V N F T V V * F E Y I V T A P L P F S
3601 g caaccaccaccccg a tcag tcag cag cca tcag caccg ag g caag g ccc tccaccag ca
a A T T T L I S Q Q P S A P R Q G P P P A
b Q P P P * S V S S H Q H R G K A L H Q Q
c N H H P D Q S A A I S T E A R P S T S K
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3661 aaaagaccccgacccaccgaagactcggacgaccaccagcacccccagcagcaaagcccc
a K R F * L T E D L D D H *
b K D S D S L K T W M I I S
c K I L T H * R L G * S L V
3721 c tc c c c t t t c t c c c tc t t t c c c tc t t t t t c t c a g a c g g a g c c tc g c tc c g tc a tc c a g tc
3781 c g g a g tg c a a tg g c g tg a tc tcg g cccacC accacc tccg tc tcccg g g c tcaag ag ac t
3841 c tcccgccccagcctccC gagcagctgggaccacaggcgcgcgacaccaC gcccagctaa
3901 c t tc tc t tc t t tg ta tc c c ta g c a g a g a c g g g g c c c c a c c a c a c tg a c c a g g c tg g tc t t
3961 gaaC C cctgagg tcacgacccC cccgcctcaaccC cccaaaatgctgggatC acaggcat
4021 g a g c c a c c a c g c c c g g c c a a g ta c c ttta a a tg a a g g c a c a c a a a a a ttg c c ttt tc ta g
4081 a tg tg a C g c ta tc c ta C a tc ta a C a g a c C a c ag tC C ag tg taa a c a ta a c tc tC a ta tg t
4141 g c c g g g a a a c c a a a a a a tc c a ta C g a c c c a c ttc a t ta tg a ta t tc a c tt ta c tg c a g tg
4201 tg g c c c g g a ac c g a a c tc a c a c ta c c tc c a a a g ta tg c c c
Note: Three translation firames are used. Stop codons are shown as Uppercase 
regions are the largest internal inverted repeats.
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Figure 34: Position of major internal inverted repeats in Tigger 1 -like transposon
At positions 134577-135352, there was an observed Powerblast homology to 
the human breakpoint cluster region (BCR) gene (U07000). The similarity is 
approximately 63% with 189 single base mutation and ICX) indels. The similar region 
in the BCR gene is within the large intron between alternative exon b and exon 2.
There is no breakpoint in this region and the region contains no known repetitive 
elements and thus may represent a previously undescribed low copy number repeat 
element.
3 .5 .2  Repetitive elements in contig 3
The interspersed repetitive elements found in contig3 include Alu, LI, Mer, 
Mir, Mit, Mst and The lb. A summary of these repetitive elements is listed in Table 13.
Table 13: Interspersed repetitive elements in contig 3
Family number bases % region
Alu 126 35601 2 2 .6
LI 50 17239 10.9
Mer/Mir/Mlt/Mst 25 7875 5.0
The lb 2 443 0.3
Total non*Alu 77 25557 16 .2
This region has a high density of non-Alu repeats than contig I and contig2. 
Contig 1 has 11.9% total non-Alu repeats and contig2 has 10.6%. The Alu repeats in 
this contig are slightly higher than those in contig 1 and contig2 as contig 1 has 19.5%
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and contig2 has 17.2% total Alu, respectively. The total interspersed repetitive 
elements in contigS is 38.8%.
3 .6  Analysis of contig 4
Contig4 is 67,378 bp and is located near the distal end of the DGCR. It 
contains two overlapping cosmid, 68f and 24b. The consensus of this contig is shown 
in the direction from centromere to telomere. The results of Xgrail and Powerblast are 
shown in Figure 35. This contig contains the genomic organization information of a 
gene highly similar to the mouse TIO gene. The transcription direction of this putative 
human TIO gene is from centromere to telomere.
3 .6 .1  TIO gene
Positions 26936 to 54800 in contig4 contain eight coding regions with high 
similarity to the coding regions of the mouse TIO gene. Positions 54801 to 56053 
contain the region similar to the 3' UTR of the mouse TIO gene but the similarity is 
very low and there is a poly(A) signal sequence at the end of this region. A region 
homologous to the 5' UTR of the mouse TIO gene was not found in contig4.
A frurther study of the Powerblast results revealed that the first coding region of 
the mouse TIO gene also is highly similar to the 3' end half of EST T53435 in the 
database. The 5' end half of this particular EST is highly similar to contig4 in positions 
11280-11390. This EST contains the 5’ end of a human cDNA from a placental cDNA 
library. In the largest part of this region and the region right proximal of this region, 
from 10993 to 11361, there is a CpG island which contains a CAAT box and several 
Sp I binding sites, which are the major features of a promoter. In contrast, the close
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Figure 35: R esu lt o f  P ow erb last and X gra il a n a ly sis  o f  co n tig  4
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Similar to  mouse TIB gene
N ote ! X g ra il  r e s u l t  i s  on th e  to p .  The g ra y  l i n e  i s  DNA se q u e n c e . The p e a k s  a r e  p r e d i c t e d  ex o n s . The s m a ll  c o lo r  
b a r s  above o r  below  th e  p e a k s  i n d i c a t e  th e  q u a l i t y  o f  ex o n s , O reen  f o r  e x c e l l e n t ,  b lu e  f o r  good an d  r e d  f o r  
m a rg in a l .  Peak above th e  g ra y  l i n e  m eans th e  exon i s  on fo rw a rd  s t r a n d  w h ile  p eak  u n d e r  th e  l i n e ,  r e v e r s e .  
The i n t e n s i t y  o f  th e  g ra y  l i n e  m eans th e  GC c o n te n t s .  The l i g h t e r  th e  r e g io n  i s ,  t h e  h ig h e r  th e  GC 
c o n te n t s .  The p in k  b o x es  on th e  g ra y  l i n e  a r e  CpG i s l a n d s .
P o w e rb la s t r e s u l t  i s  on th e  b o tto m . Ih e  b la c k - g r a y  l i n e  i s  DNA se q u e n c e . The g ra y  r e g io n s  a r e  r e p e a t  
s e q u e n c e . The sm a ll  c o lo r e d  b a r s  a r e  m a tch es  found  in  GenBank. The b lu e  b a r s  a r e  m a tch es  w ith  v e ry  h ig h  
i d e n t i t y .  The p in k  b a r s  a r e  m a tch es  w ith  r e l a t i v e  low s i m i l a r i t y .  The g re e n  b a r s  a r e  ex o n s o f  TIO gene and 
th e  number u n d e r them  a r e  exon n u m b ers .
upstream region of the first coding region of the TIO gene does not show any specific 
feature of a promoter. Other expression studies showed that the transcript of the T 10 
gene is larger than the cDNA sequence reported and suggested that TIO has a longer S' 
untranslated region than reported. 1^  ^ The region from positions 11280 to 11390 
therefore may be a potential first exon for the human TIO gene. The alignment of 
contig4, EST T53435 and mouse TIO cDNA is provided in Figure 36.
Figure 36: Alignment of contig 4, EST T53435, and mouse TIO gene (X74504)
concig4 > 11240 gggcgcggcacccggaagtcggcggcggcggcggaggcgg
concig4 > 11280 C gagtgcgcggctccggggccggccgactccgctag tggc
T53435 > 17  t i ................
concig4 > 11320 ccggccggcctgggcccgggggctccgggctc tgggctcc
T53435 > 57 .........................c ...........................................................
co n tig 4  > 11360 ggg tgcgcggaccgggccaggctgcttgaag  I gtgggcggg
T53435 > 9 7  ...................................................................
co n tig 4  > 11400 c tg g c c g c a c ttc c c c a c c c c g c c c c a g tttc c c c ttc c C
------------------------- in c r o n l ,  sequence 11441-26839 n o t shown---------------------------
co n tig 4  > 26840 g ag g g cag ccc tg a g tg tc tg c c a tc c g c tca a c c c a g tg
co n tig 4  > 26880 tc t tc c t t t tc c c g c a g Ia c c tc g c g a c c tg tg tc a g c a g a
s t a r t  codon
co n tig 4  > 26920 g c c g c c c tg c a c c a c c a tg tg c a tc a tc t tc t t ta a g t t t
X74504 > 4 8  ........................................................
co n tig 4  > 26960 g a tc c tc g c c c tg tttc c a a a a a c g c g ta c a g I  g ta a c c cc
X74504 > 7 4   t ..............................
co n tig 4  > 27000 c tc g c tc tg c a tc tg c tg c g c c c tg c a g g g tc c tg g g tg c
 in tro n 2 , sequence 27041-33439 n o t shown-
contig4 > 33440 a c ttg g c tc g c tc g t t tc c a tc tg a a g c c a tc a g tg a tg c
concig4 > 33480 t t tc c tc t tg c a g Ig c tc a tc t tg g c a g c c a a c a g g g a tg a
X74504 > 1 0 3   a ..........
174
concig4  > 33520 ac tc tacagccgaccccccaagccagccgacccccggggg  
X74504 > 133  C .a .a .g .  . g .................g . . a ..........................
concig4  > 33560 aacaacaacgagacccccagcg  I g tg a g tc c tc cc g c g c g c  
X74504 > 173  g t ..............................
concig4  > 33600 c c a g c g g tg g c tg c g c c ttg c tg c ttc c c ta g c c c c c g c g  
------------------------- in c ro n  3, sequence 33641-42519 n o t shown---------------
concig4  > 42520 C gcg tc tcccagggctgggaaccaggtgggggactggaac
concig4  > 42560 g g g cg g caC caa tg g tg g taacac tg tcacc tg ccacag Ig
concig4  > 42600 gctggacatggaggaaggcaaggaaggaggcacatggctg  
X74504 > 200  c ............ a ...................
concig4  > 42640 ggcaccagcacacgtggcaagccggcagcacccaccaacC  
X74504 > 236  g ...............g g ............................
concig4
X74504
> 42680
> 276
acctgcagccgcagctggactggcaggcccgagggcgag  1 g
conCig4 > 42720 caaggcgagcggggtggggccaaggtgagacagggtgggg
------------------------- in c ro n  4 , sequence 42761-43519 n o t shown---------------
conCig4 > 43520 agaagagcacaCgccCgcagccgcggacacagcacccgcc
concig4  > 43560 c c c c g c c ta c a g lg tg a a c c tg c c a c c c a c ttc c tg a c c a c  
X74504 > 313  gC.C.............................g
concig4  > 43600 cgacgcggacagcCCgccccacccgaagaaggccCccacg 
X74504 > 343  . a .................c ..................................................... ca
conCig4 > 43640 gagggccaCccgtacaaCggcCccaaccccacagcagccg 
X74504 > 383  c .......... t . . c .......... C___a ...................... c .
concig4  > 43680 acccgagIgcgggCcCgccagagggggacggcggcccCgcc
X74504 > 4 2 3  ..............
conCig4 > 43720 cagcacCgccccgggggcaggccCcaggcccaccaggaag 
------------------------- in c ro n  5, sequence 73761-45999 n o t shown--------------
concig4  > 46000 gggccgcgagaccaccgggcagcgccggggaggacgcccc
concig4  > 46040 a tg g c tg cag cccg acaccc tccccccccg g cc tg cag Ica
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c o n c i g 4
concig4
co n tig 4
> 46080 cagcaaagggagacg tca tccgccaccatgggaaccgagg
T A K G D V I C Y Y G N R G
> 46120 g g a g c c tg a cc c ta tc g tc c tg a c g c ca g lg tg a g c c c g c c
E P D P I V L T P
> 46160 c tg g c ag cc tg a tg g g g tg g g g g ac tg tC tc ta tg cag ag
 in tro n . 6 , sequence 46201-51599 n o t shown----------------
co n tig 4  > 51600 c a g g tg g c a a tttg c c c tg a c a tg g c a c a g c a g g g c c tc t
co n tig 4
co n tig 4
co n tig 4
co n tig 4
co n tig 4
co n tig 4
> 51640 g c a tg g c c c g c tg a ttg c tc c tc a c a g lg c a c c ta c g g g c t
G T Y G L
> 51680 g ag caacg cg c tg c tg g ag ac tccc tg g ag g aag c tg tg c
S N A L L E T P W R K L C
> 51720 tt tg g g a a g c a g c tc ttc c tg g a g g c tg tg g a a c g g a g c c
F G K Q L F L E A V E R S
> 51760 a g g c g c tg c c c a a g g a tg tg c tc a tc g c ca g c c tc c tg g a
Q A L P K D V L I A S L L D
> 51800 tg tg c tc a a ca a tg a a g a g g c lg tg a g tg g g c g g g tc c tg c
V L N N E E A
> 51840 tgggg tgagccccag tg tcccgccaccagggcagagggaa
 in t r o n  7 , sequence 51881-53399 n o t shown-----------------
c o n tig 4  > 53400 ggtgggctggggctagacccggctgcgggcgggccacaga
co n tig 4  > 53440 g g g a c ta a tg g c c a c c a c ttc tc tc c a tc c tg c a g lg c a g c
Q
co n tig 4  > 53480 tgccagacccggcca tcgaggaccaggg tggggag tacg t
L P D P A I E D Q G G E Y V
c o n tig 4  > 53520 g c a g c c ca tg c tg ag caag tacg cg g c tg tg tg cg tg cg c
Q P M L S K Y A A V C V R
co n tig 4  > 53560 tg c c c tg g c ta c g g c a c c a g Ig ta ttg c a g c a c c g tg g g tg
C P G Y G T R
co n tig 4  > 53600 c g c c a c c tc c ta tc c c a tg tc c c a c c tc c c a c g c ta g a g g
------------------------- i n t r o n  8 , sequence 53641-54599 n o t shown----------------
co n tig 4  > 54600 tc t tg c c c ta t t tg tg g c tg tg a c a g g c a g g g c a g g g c tg
co n tig 4  > 54640 a g g g a c a cc a g g tg a a c g a g g g c c c c tg c tc tc tttc a g I a
c o n tig 4  > 54680
X74504 > 761
a c c a ac a c ta tc a tc c tg g ta g a tg c g g a c g g c c a c g tg a  
................ c ................. t .  .g ..........a a . t .....................
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c o n tig 4
X74504
> 54720
> 801
ccc tcac tg ag cg tag cacg a tg g acaag g acc tccccca  
-g ................a .  . g .............c ...............a — a c . . .c .g
c o n tig 4
X74504
> 54760
> 841
s to p  codon
c tg g g a g a c ca g a a c c ta tg a g c tc ac a c tg c a g a g c ta a
concig4 > 54800 ccccacc tc tgggcccggccag tgggctcc tggggggccc
concig4 > 54840 tg c c ttg a g g g g c ac c g tg g a c a g g a a a c cc tc c tttg c c
conCig4 > 54880 a ta c tg c a ttg c a c tg c c c g tg g c ttg g c c a g c a tc c c c c
conCig4 > 54920 g g a tc a g g g c c c tg tg g tc tg c g tg tta c c c a tc tg tg tc
c o n tig 4 > 54960 c c c a tg cc c a g ttc a g g g c c tg c c c tta c g c c a g tg a g g a
c o n tig 4 > 55000 g cag cag ag tccg a tac tag g tc tag g accg g ccg ag g ta
concig4 > 55040 ta c c a cg a a c a c g tg g a c a c ac c tg a g c c c a c tc ttg c a c
c o n tig 4 > 55080 a tg ta c a c a g g c a c c c a c a tg g c a c a c a c a ta c a c tc c tg
conCig4 > 55120 c g tg tg c a c aa g c a c a c a c a tg ca a g g c a ta ta c a tg g ac
conCig4 > 55160 a ccg aca c a g g c a c a tg ta c a tg c a c a g g tg tg c ta c a ca
conCig4 > 55200 tg tg cacaca tg cacag ttg cacag acacacacacacag g
c o n tig 4 > 55240 cgcacacacacgatgccgaacaaggcagaagggcgaccct
conCig4 > 55280 c a c c c c tc a tg tg c c tc tg g c c a g c a g g tc t t tg t tc c g g
concig4 > 55320 tc c a a c g a c a g g a g ta g g c ttg ta tt ta a a a g c g g c c c c t
co n tig 4 > 55360 c c tc tc c tg tg g cc a c a g a a c a ca g g c g tg c ttg g a c ttC
c o n tig 4 > 55400 tgacaiagcagacc tgcccc tgcagaggagacagccaca tt
c o n tig 4 > 55440 tg g aa ttg g g caccg ag aag acc tg ag aaaaacccac tcc
c o n tig 4 > 55480 c t c t t t t C t t t t t t t t t g a g a c g g a g t c t t g c t c t g t c a c
concig4 > 55520 c c a g g c tg g ag tg cag tg g cacg a tc tcg g c tcac tg caa
concig4 > 55560 c c tc c g c c tc c c a a g ttc a a g ca a ttc c c c tg c c cc c ig c c
concig4 > 55600 tc c tg a tc ag c tg g g a c ta c a g g c g tg tg c c ac c a tg c c c
c o n tig 4 > 55640 a g c ta a tc t t tg tg t t t t ta g ta g a g a c g g g g tc tc a c c a
concig4 > 55680 tg t tg g tc a g g c tg g tc t tg a a c tc c tg a c g tg g tg a tc c
concig4 > 55720 acc tg ccccg g c c tc c c a a ag tg c tg g g a tta c a g g c g tg
c o n tig 4 > 55760 agccaccacg cc tg g ccg aaaaacccac tc tcacaacag a
concig4 > 55800 a g tg c a g a c tc a ttg c ta g a c tc a g tg c c c ttg a g tg tg c
concig4 > 55840 c a g a g g c c c tc tg c g tc tg a g a c a a tc c tg tg tg tg c c a g
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concig4 > 55880 gaggccccgcgcgcaccaggggcccccagaaccccgccca
concig4 > 55920 cccagctggagaccacgcccccggcagccccaccccagcc
concig4 > 55960 agccccg ccc tc tccc tcccccc tccag g tg ag g caaacC
concig4 > 56000 ccataggaaccCgtacctgaatgtgagcccctgacA A TA A
p o ly  (A)
co n tig 4  > 56040 A a c tc tg a g g cc c tg g tg a g c g c a tttc g a g g c c ttc c c c
Note: Not all sequences are shown. indicates the identity. "I" indicates the splice 
site. Powerblast program failed to find exons 5,6 and 7. Start codon and stop 
codon are bold. Poly(A) signal is capitalized.
In summary, contig4 contains the human TIO gene. The transcription direction 
of this 9 exon containing gene is from centromere to telomere, which disagreed with 
that previously reported by hybridization. 1®^ The first putative exon is similar to a 
human EST and the coding region starts in exon 2. Comparative analysis of the human 
genomic sequence and the mouse cDNA sequence revealed the position and the size of 
all 9 exons (Table 14) except for the first and last exons because the boundaries of the 
5' and 3' UTR can not be determined by the information provided only by the genomic 
sequence. The boundaries of the exon/intron were determined with the available 
genomic data and the nearly invariant consensus S' GT and 3' AG dinucleotides of 
intron boundaries. The comparison of all splice sites and the consensus is provided in 
Table 15.
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Table 14: Position and size of exons and size of introns of human T 10 gene in
contig 4
Exons Entrons
Exon Start End Size Intron Size
I unknown 11390 - 1 15496
2 26897 26991 95 2 6501
3 33493 33581 89 3 9017
4 42599 42718 120 4 853
5 43572 43686 115 5 2391
6 46078 46148 71 6 5518
7 51667 51820 154 7 1654
8 53475 53579 105 8 2127
9 54689 unknown •
Note: The size of exon 1 and exon 9 are unknown because the genomic sequence data 
can not define the boundaries of the 5' and 3' untranslated regions. Start codon 
ATG begins at position 40 of the second exon. Stop codon TAA begins at 
position 89 of the last exon.
Table 15: Exon/intron boundary of human TIO gene
exon
. -CTGCTTGAAGIgtgggtgggc. 
. -ACGCCSTACAGIgtaaccccct. 
. .ATCCTCAGTGIgtgagtcttc. 
. . CGAGGGCGAGIgtaaggcgag. 
. .CCGACCTGAGIgtgggtctgc. 
. .TTGACGCCAGIgtgagcccgc. 
. . ATGAAGAGGCIgtgagtgggc. 
8 . . . ACGGCACCAGIgtactgcagc. 
co n sen su s  (C /A )A G lg t(a /g )ag t.
in t r o n  exon
. .  1 — CttcccgcaglACCTCGCGAC. 
. .  2 . . . cctcttgcagIGCTCATCTTG. 
. .  3 . . . tctgccacagIGGCTGGACAT. 
. .  4 — ctgcctacaglGTGAACTTGT. 
. .  5 . . . cggcctgcagICACAGCAAAG. 
. .  6 — ctcctcacaglGCACCTACGG. 
. .  7 — catcctgcaglGCAGCTGCCA. 
. .  8 — tctctttcagIAACCAACACT. 
 ( t / c ) n n ( c / t ) a g |G
. 2 
. 3 
. 4 
. 5 
. 6 
. 7 
. 8 
. 9
Note: Upper case letters are exons and lower case letters, introns.
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The similarity of the coding region between mouse TIO gene and human TIO 
gene is 83.8% identical at the DNA level and at the amino acid level, they are 87% 
identical and 93.5% similar. Using the deduced amino  acid sequence of the human T 10 
gene to search the non-redundant GenBank protein database with Blastp revealed no 
similarities for this protein to any protein except for the mouse TIG gene and a weakly 
similar C. elegens hypothetical gene (1483279) products. Alignment of amino acid 
sequences of these three proteins with ClustalW program is provided in Figure 37. The 
similarity between human TIO gene and C. elegens putative gene is only 29.7% 
identical and 47.8% similar.
Figure 37: CLUSTAL W(1.60) multiple sequence alignment among human, mouse
and yeast T 10 gene products.
CLUSTAL W (1.50) m l c i p l e  sequence alignm en t
h  v s  m.
h c l0 p e p _ 2
mmtlOpep
y t l0 1 ik e _
h /m /y
MCIIFFKFDPRPVSKNAYRLILAANRDEFYSRPSKLADFWCTiNNEILSGT.nMEEGKBGGT 
MCIIFFKroPRPVSKNAÏRLILA.ANRDEFYNRPSKLADFWa®ISEILSGLIMEBGKAGGT 
MCITFIKTAKS—SLDKYKLILLNNRDEQLLRPTKEMH-WHDG— ILSGVDKQEN-ARGT
* • *  •  *  *  *  * * *  * * * *  * *  * ► ** * *• »*
h . v s  m.
h t l0 p e p _ 2
mmtlOpep
y t l0 1 ik e _
h/m /y
WLGISTRGKLAALTNYLQPQLDW—QARGRGELVTHFLTTDVDSLSYLKKVSMEX3HLYNG 
WLGISTRGKLGALTNYLQPRQEP—DARGRGELVSHFLTSIMDSLSYLKKVSTEGHLYNG 
WLGLNENGRIC3dMLSITC3TQESKNLHAPSRGGIVNEFLNAN-DrSKMIESLKKCASKYNG
h . v s  m.
h tlO pep  2
mmtlOpep
y t l0 1 ik e _
h/m /y
FNLIAADLSTAKGDVICYYOIR—GEPDPIVLTPGTYGLSNALLETPWRKLCFGKQLFLE 
FNIIAADLSTSKGDWCYY<2JR—GEPEPIVLTPGTYGLSNALLETPWKKLCFGKQLFME 
FQLVAVEKNSTGLYEVRTLANQQVDEIEVCQLKDEÏHWSNSPPTKPYQKAVQGKKLLRE 
* *  * *  * ** * ♦ * * * »
h . v s  m.
h t l0 p e p _ 2
mmtlOpep
y t l0 1 ik e _
h/m /y
* *******  * * * * *  *  * * * ,
AVERSQALPKDVLIASLLDVLNNEEAQLPDPAIEDQGG EYVQEMLSKYAAVCVRCPG
AVEQSEALPKDVLVTQLLDVLNNEEAQLPDPAIEDQGQ EYVQPILNKYAAVWCRCAS
HLENSDQFSVDQIFEKLLSIAKNTTQWyPDAQLQYQTWVEEYNRPLSAIFIKYPEGTRM
180
h . vs m. »**»*****«♦•* •*•***•***_*<• *_**» ********
hClOpep 2 YGnOTmiLVDADGHVTFTERSMMDKDLSHWETRTYEFTLQS-
mmclOpep YGTHTNTIILVnfiNCSIVTFTERSMLDKDTSRWBINrYEFrLQS-
y c l0 1 ik e _  YGTRCHTLITVDQKDKINILERHLLP-BQSTWHDflRFEFVLNGS
h/m /y  • * * * ..* .*  ** . . .  •*  . .  . » * .** ».
Note: indicates identity, indicates similarity, " " (space) indicates dissimilarity,
and indicates deletion/insertion. Similarity parameters above amino acid 
sequences indicate the comparison between human and mouse and those below 
indicate similarity among all three.
The potential 5' promoter region of the human TIO gene was analyzed by using 
the SIGNALSCAN against the TRANSFAC database. A potential promoter region 
was found within a Xgrail predicted CpG island, and the size of this promoter region is 
about 3(X) bp. The position of the CpG island is from 10993 to II361 in contig4 and 
from -288 to 81 if the begiiming of the match of EST 53435 is defined as +1. The C/G 
content of this CpG island is 78.6% and the total C/G content of contig4 is 54.2%.
No TATA box or the potential binding sites for transcription factor HD (TEED) 
were found in this region, but at least five putative binding sites of transcription factor 
Spl are present in this region. Other putative regulatory elements and transcription 
factor binding sites found by SIGNALSCAN are: NF-l (nuclear factor I), cac-binding 
protein, and SRF (serum response factor). The position of these putative features are 
provided in Figure 38.
1 8 1
F igure 38: G e n o m ic  seq u en ce  o f  5 ’ reg ion  o f  the hum an T IO  g en e
ccca tggcg tccc tgcaggcagggagccgcggag tccccgaaggccgc tgga tcaggaag  -240
-180
S p l Spl N F-l
G TG G caacctccaaacaacaocacacccAGCCAAccraaacQccaacatacQagQcoCCGC -120 
c a c -b in d in g  p ro  N F-l
CCCGCCCCtcacTGCGCQacCCAATaataaacacaccaccttcaaactGGGCGGta c c a a  -60 
Spl S p l SRF Spl
gctggctgcggtggcgcgcgggcgcggcacccggaagC cggcggcggcggcggaggcgg p c c e n t ia l  -1
Note: The starting point of match of EST 53435 is defined as +1.
The function of TIG gene is unknown and no putative function has been 
proposed. However, its expression analysis has been studied and reported. [^ 5] xhg 
expression level of TIO gene is highest in fetal liver, but is also detected in lung, heart 
and kidney. In situ hybridization on mouse embryos from 8.5 days to 15.5 days 
showed that TIO gene is expressed during early embryogenesis at a time slightly later 
than when the structures commonly affected in DOS are forming. Therefore it is not 
likely that the TIO gene product plays a role in the DOS phenotype.
3 .6 .2  Repetitive eiements in contig 4
Contig4 has an overall G/C content of 54.2%. Compared with the other three 
contigs discussed previously, this G/C content is slightly higher, since none of these 
three earlier contigs has a G/C content higher than 50% (G/C% of contig 1=45.2, G/C% 
of contig2=47.2 and G/C% of contig3=48.2). As shown in Table 16, the Alu repeat
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element density found in contig4 is slightly more than the other three contigs but the 
non-Alu repeat density is much less.
Table 16; Interspersed repetitive elements in contig 4
Family number bases % region
Ala 53 1 6 5 2 4 2 4 .5
LI 3 878 1.3
Mer/MIt/Mst 9 2066 3.1
Thelb 3 743 1.1
Total aon>AIu 15 3 6 8 7 5 . 5
3 .7  Analysis of a mouse BAC containing the mouse HIRA gene
The 89508 bp mouse BAC b264nl was sequenced and analyzed. This BAC 
was shown to contain exons I through 16 of the mouse HIRA gene. The results of 
Xgrail and Powerblast are given in Rgure 39. Comparing the results of Xgrail and 
Powerblast, only one of the known exons of the mouse HIRA gene, namely exon 10 
could not be found by Powerblast. This exon is relatively small (71 bp in length) and 
very close to exon 11 (intron 10 is 466 bp in size). In contrast, Xgrail failed to predict 
exons 1,4,9 and 15 but instead predicted several additional exons which are not 
present in the mouse HIRA cDNA sequence. The majority of these additional predicted 
exons lie in the opposite orientation and within three large introns on the mouse HIRA 
gene, namely exon 1, 17 kb, intron 5, 11 kb, and intron 15, 11 kb.
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Figure 39: Result of Powerblast and Xgrail analysis of mouse BAC b264n 1
m m
20K 25K 30K 35K 4CK 45K S5K eoK m  T»
004^ I I I I I I I I I  i r  I
2 3 4  5 6 7 8 9 10/111213 14 15 16
mouse HIRA gene
N ote ! X g ra il  r e s u l t  i s  on th e  to p .  The g ra y  l i n e  i s  DNA se q u e n c e . The p e a k s  a r e  p r e d i c t e d  ex o n s . I h e  sm a ll 
c o lo r  b a r s  above o r  be low  th e  p e a k s  i n d i c a t e  th e  q u a l i t y  o f  ex o n s , G reen  f o r  e x c e l l e n t ,  b lu e  f o r  good 
and  r e d  f o r  m a r g in a l . Peak above th e  g ra y  l i n e  m eans th e  exon i s  on fo rw a rd  s t r a n d  w h ile  p eak  u n d e r th e  
l i n e ,  r e v e r s e .  The i n t e n s i t y  o f  th e  g ra y  l i n e  m eans th e  GC c o n te n t s .  I h e  l i g h t e r  th e  r e g io n  i s ,  th e  
h ig h e r  th e  GC c o n te n t s .  The p in k  box  on th e  g ra y  l i n e  i s  CpG i s l a n d s .
P o w e rb la s t r e s u l t  i s  on th e  b o tto m . The b la c k - g r a y  l i n e  i s  DNA s e q u e n c e . The g ra y  r e g io n s  a r e  r e p e a t  
s e q u e n c e . The sm a ll c o lo r e d  b a r s  a r e  m a tch es  found  i n  GenBank. The num bers u n d e r g re e n  b a r s  a r e  exon 
num bers o f  mouse HIRA g e n e .
3 .7 .1  Mouse HIRA gene
If it is assumed that the region of mouse chromosome 16 in BAC b264nl and 
the corresponding region of human chromosome 22 are in the same orientation, then 
the transcription direction of this gene is from centromere to telomere. Comparative 
analysis of the genomic sequence and the cDNA sequence also reveals the positions and 
the sizes of exons I to 16 and introns 1 to 15, as listed in Table 17. The boundaries of 
exon/intron were determined assuming that the nearly invariant consensus 5' GT and 3' 
AG dinucleotides of intron boundaries must present at the cleavage point A list of the 
deduced splice sites and the consensus splice sequences is provided in Table 18.
The alignment of the mouse genomic DNA sequence determined here and the 
mouse HIRA cDNA sequence (Genbank accession number X92590) is shown in 
Figure 40. These two sequences match perfectly except for one mismatch at position 
89111, where a "c" occurs in the genomic sequence instead of the "t" found in cDNA 
sequence. This discrepancy was checked carefully and there was six-fold redundancy 
in genomic DNA sequence with gel readings in both orientations. Thus, at least in the 
sequence determined here, a "c" occurs at position 89111 and would result in a Leucine 
rather than a Phenylalanine in X92590 cDNA sequence. Immediately after exon 3, at 
positions 39174 to 39350, there is an alternatively spliced exon, exon 3a 1263] and at 
positions 65451 to 65556, which is in intron 11, there is another alternatively spliced 
exon, 11a 1263] Both of these alternatively spliced exons introduce stop codons as 
indicated in Figure 40.
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Table 17; Positions and sizes of exons and size of introns of the mouse HIRA 
gene
Exons Introns
Exon Start End Size Intron Size
1 20093 20349 257 1 17033
2 37383 37445 63 2 1617
3 39063 39173 111 3 1133
(3a 39174 39350 177 3a 0)
4 40307 40397 91 4 1574
5 41972 42066 95 5 11198
6 53265 53360 96 6 1302
7 54663 54823 161 7 4213
8 59037 59204 168 8 2368
9 61573 61686 114 9 3227
10 64914 64984 71 10 466
11 65451 65556 106 11 2688
(11a 66933 67039 107 11a 1376)
12 68245 68460 216 12 1574
13 70035 70120 86 13 5344
14 75465 75659 195 14 1956
15 77615 77776 162 15 11159
16 88936 89137 202 16 unknown
Note: Exon I contains the 5' untranslated region. The start codon ATG begins at 
position 231 of the first exon. The size of intron 16 is unknown and the 
alternatively spliced exons 3a and 1 la are in parentheses. Intron 3 includes 
exon 3a and intron 3a. Intron 11 includes exon 1 la and intron 1 la.
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T able 18; E xon /in tron  boundaries o f  the m o u se  H IR A  g en e
exon in c ro n
 1  AACCACAATGIgtgagtgcac—  1 .
2 . .  .GGflGGACAAGIgtatgtttgc.. .  2 .
 3  AATCACTrAGIgtattacaga.. .  3 .
 4  AGCGGGCTACIgtaagcaCca.. .  4 .
 5  CACTCAGGCGIgtaagcaggc—  5 .
 6  AAGTTCCCftGlgtctggggct—  6 .
7 — TTTTGATGAGI g ta a c g g a a a —  7 .
8 ...G A CTG TTG TG Igtgagtgtcc... 8 .
9 ...CTCTGTCTGGIgtaagcctga.. .  9 .
1 0  ATAITTCCTGIgtaagatgga— 10 .
11— GGSGGAAAAGIgCaggcttgc— 11 .
1 2  TATCAGGAAGIgtgagggcat — 12 .
1 3  TGGACACTQGIgtactcacCc— 13 .
1 4  CTAftGGACAGIgctagtaaac — 14 .
1 5  CTGTTGAAAGIgtaggtggta— 15 .
1 6 . . . GTCCGTCCAGIgcgaggccca— 16
exon
..CCgtttccaglGGflAGCCAAT... 2 
. .ttcatCccaglGGCAGGATTC... 3 
. .  c t c t t c c c a g  1 CftTGTGTGftA—  4 
. .  C ttc a c a c ag  IGTACATTGGG —  5 
..CtCcttccaglATGTGOTGGA.. .  6 
. .tccctcacaglAAATTCTTGC.. .  7 
. .CttatttcaglTGTGGflGGAA.. .  8 
. .  C tgacC tcag IAAAITCAACC —  9 
. .  c c c c t  tg ta g  I CTCACflTGTT —  10 
. .CCtctCtcaglGACTCTGAAT.. .  11 
. .  c tC c c ta c a g  IAGCCGAAITC —  12 
. .actttgccaglAATCTTTTGA—  13 
- .  t t a a tg a c a g  IGGACTTCTCC —  14 
. .  C ttc c c c c ag  ITATGAATGCT —  15 
. . CCgaCCtcagIGTTGAAAGAG. . .  16
co n sen su s: (C/A) AG I gc (a /g )  a g e ............. (c /c>nn(c/C )ag |G
Note: Upper case letters represent the exons portion and lower case letters, introns. 
The bold letters are those nucleotides which do not match with the consensus.
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Figure 40: Alignment of mouse genomic DNA and mouse HIRA cDNA
mbconsphas > 20085 aggaggagcggcgcaggggatgcggctgtggcggcggcgg 
X92590 > 1  ......................................................................
mbconsphas > 20125 cggcggccgagcgcaggaggcggctgtggcggcggctggg 
X92590 > 33.................. ........................................................................................
mbconsphas > 20165 ggcacgggccggcgacggcgcggcggcgctgagggcaagg 
X92590 > 73 ........................................................................................
mbconsphas > 20205 gtgggcggcggccggagggcgggcggcgcgggaggaagct 
X92590 > 113 ........................................................................................
mbconsphas > 20245 
X92590 > 153
mbconsphas > 20285 
X92590 > 193
HIRA p ro c e  > 1
gcggcagccccacggcccaggcg tgctgagggacacggct
sc a re  codon 
c tg g c c c ca g c c c g g cag cg g ccg aacaa tg aag c tc ttg
M K L L
mbconsphas > 20325 aagccaacctggg tcaaccacaaC g I g tgagcgcacgcagg
X92590 > 2 3 3  ..........................................................
HIRA p ro c e  > 5  K P T W V N H N G
mbconsphas > 20365 agccgtgggcggccgaacccgcaccggggcggggcccggg 
 inC ron 1, sequence 20405-37324 n o t shown---------
mbconsphas > 37325 a g c c ta ttg ttc c c ta g c g a a c a a a a g c c a a g c c c g a c a t
mbconsphas > 37365 gcccccccccgcccccagIggaagccaacccccccagccga
X92590 > 2 5 7  ....................................................
HIRA p ro c e  > 1 3  G K P I F S V D
mbconsphas > 37405 CacccaccccgaCgggaccaagCCcgcaaccggaggacaa
X92590 > 280 ........................................................................................
HIRA p ro c e  > 2 1  I H P D G T K F A T G G Q
mbconsphas > 37445 g igcacgcccgcagagcgaacaccacccccccgccgccgca
X92590 > 3 2 0
HIRA p ro c e  > 3 4  G
mbconsphas > 37485 ccccgccccccccggacccacggccagccgcaacgagaca 
 in c ro n  2 , sequence 37525-39004 noC shown---------
mbconsphas > 39005 gccaccaccgccgcccccaccccccgcacaccgagccccc
1 8 8
mbconsphas > 39045 c c tg c c c c c c c a c c c c a g Iggcaggaccccgggaaggccgc
X92590 > 3 1 9  ......................................................
HIRA p ro ce  > 3 4  G Q D S G K V V
mbconsphas > 39085 g a tccggaatacgC ctccag tcc tccaggaggaC gacgag
X92590 > 343 ........................................................................................
HIRA p ro ce  > 4 2  I W N M S P V L Q E D D E
mbconsphas > 39125 aaggaCgaaaacaCCcccaagacgcCCCgccagaCggaca
X92590 > 383 ........................................................................................
HIRA p ro ce  > 5 5  K D E N I P K M L C Q M D
mbconsphas > 39165 
X92590 > 423
HIRA proCe > 68 
X99713 > 1
aCcacCCag I gcaccacagagcggccccccgcaggccccgc 
N H L
mbconsphas > 39205 
X99713 > 32
mbconsphas > 39245 
X99713 > 72
mbconsphas > 39285 
X99713 > 112
gcgc cg g cag ag cg cccaag g c tag cacacg cg t t  Cgtaa
scop  scop
ccagaaagateaggccccgcgcggcgccaaccccccC cgg 
scop
cccgcCgCccgaaggcacagaCgccggcCgcacacccggg
exon 3a
mbconsphas > 39325 
X99713 > 152
mbconsphas > 39365
tgagccaCCcggcagaagacCcggcc I cgcccacagaacca 
scop
cccccggacagcccgcaggcacccccggcgaccccccgcc
—inC ron 3, sequence  39405-40244 noC shown-
mbconsphas > 40245 ccacacciacgcaaacgggcacgcccaccggacccccacca
mbconsphas > 40285 ccccacccccccccccccccag Icacgcgcgaaccgcgcgc
X92590 > 4 3 0  .............................................
HIRA p ro ce  > 7 1  A C V N C V
mbconsphas > 40325 ggcggccaaacagcgggacgcaccCagcCCcCgggggaga
X92590 > 450 ........................................................................................
HIRA p ro ce  > 7 7  R W S N S G M Y L A S G G D
mbconsphas > 40365 cgacaaaccgaccacggcgcggaagcgggccacIgcaagca
X92590 > 4 9 0  .................................................................................
HIRA p ro ce  > 9 1  D K L I M V W K R A T  Y
mbconsphas > 40405 ccaccccccccccccacacccaacccccagaagccccccc
------------------------------ inC ron 4, sequence 40445-41924 noC shown---------
mbconsphas > 41925 cacccagaacaccccccgagcgcacaccccacgccccccc
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mbconsphas > 41965 cacacag  I g tacaccg g g cccag caccg tg c trg g ccccag
X92590 > 5 2 3  ........................................................................
HIRA p ro c e  > 102 Y I G P S T V F G S S
mbconsphas > 42005 cggcaagctC gccaa tg tggagcaacggcgg tgcg tcccc
X92590 > 556 ........................................................................................
HIRA p ro b e  > 113 G K L A N V E Q W R C V S
mbconsphas > 42045 a tc c tc c g g a g tc a c tc a g g c g  I g ts ia g ta g g c c c c tttg c
X92590 > 5 9 6  ...............................................
HIRA p ro c e  > 126 I  L R S H S G
mbconsphas > 42085 ccgggcgagcggaccccccccccccccccccccccccgag  
  in c ro n  5, sequence 42125-53204 noC shown---------
mbconsphas > 53205 accaccacccaagcgcaC accaggC aaaaggC cccacccc
mbconsphas > 53245 
X92590 > 617
HIRA p ro c e  > 1 3 3
cacacccC gcccccccccag I acgcgacggacgcagcacgg  
D V M D V A W
mbconsphas > 53285 
X92590 > 638
HIRA p ro c e  > 140
CcCccccacgacgccCggccggccccaCgcagcgcggaca 
S P H D A W L A S C S V D
mbconsphas > 53325 acaccgccgccacccggaacgccgcgaagcccccagIgccc
X92590 > 678 ...............................................................................
HIRA p ro c e  > 1 5 3  N T V V I W N A V K F P
mbconsphas > 53365 ggggCCccccccacCgcgcagcaaccgaagaggcccgccg
------------------------------ inC ron  6, sequence 53405-54604 noc shown-----------
mbconsphas > 54605 ccccccccccacag acaacacccg cccacaccccacccca
mbconsphas > 54645 ccccacccccccccacagIaaaCCcCCgcaacccCgagagg
X92590 > 700 .........................................................
HIRA p robe  > 161 P E I L A T L R G
mbconsphas > 54685 ccaccccggcccagcaaaaggccCgacCcgggabcccgbc
X92590 > 736 ........................................................................................
HIRA p ro ce  > 1 7 3  H S G L V K G L T W D P V
mbconsphas > 54725 ggcaaacacaccgccccccaagccgacgaccgaagcccga
X92590 > 776 ........................................................................................
HIRA p ro ce  > 186 G K Y I A S Q A D D R S L
mbconsphas > 54765 aggcacggaggacgccggaccggcagccagagaccagcac
X92590 > 816 ........................................................................................
HIPA p ro ce  > 1 9 9  K V W R T L D W Q L E T S I
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mbconsphas > 54805 caccciagcctc tcgacgag ig taacggaaacagcccagagc
X92590 > 8 5 6  ........................................
HIRA p ro c e  > 213 T K P F D E
mbconsphas > 54845 c tg g cccc tacccc tg ccacacc tc tC g aacag tg ag g g a
------------------------------ in c ro n  7, sequence 54885-58964 noc shown-----------
mbconsphas > 58965 aaaccacagcccgacccacccccgaggcgagaaccccccc
mbconsphas > 59005 gaaccccccccaagcccacaccccacccacagiC gC ggagg
X92590 > 8 7 3  .......................
HIRA p ro ce  > 218 E C G G
mbconsphas > 59045 aacgacgcacgCCcCccggcCCagCCggCcacccgaCggc
X92590 > 883 .......................................................................................
HIRA p ro c e  > 222 T T H V L R L S W S P D G
mbconsphas > 59085 caCCacccggcaCcCgcccaCgccacgaaCaaccccggcc
X92590 > 923 .......................................................................................
HIRA p ro ce  > 235 H Y L V S A H A M N N S G
mbconsphas > 59125 ccacC gcC cagaccaccgaaagagagggccggaagaccaa
X92590 > 963 .......................................................................................
HIRA p ro ce  > 248 P T A Q I I E R E G W K T N
mbconsphas > 59165 cacggaccccgcgggccaccggaaagccgcgaccgccgcgi
X92590 > 1003 .......................................................................................
HIRA p ro c e  > 262 M D F V G H R K A V T V V
mbconsphas > 59205 gcgagcgccccccaccccagaaaC cccagccaccagcacc
------------------------   in c ro n  8, sequence 59245-61524 noc shown------------
mbconsphas > 61525 Caccccggcacccgaccacccaccccaaccgcggccaccc
mbconsphas > 61565  gaccccag I aaaC C caacccaaaaacccccaagaagaagca
X92590 > 1042 ..........................................................................
HIRA p ro ce  > 275 K F N P K I F K K K Q
mbconsphas > 61605 gaagaaCgggagcCccacaaagcccagccgcccacacCgc
X92590 > 1075 .......................................................................................
HIRA p ro ce  > 286 K N G S S T K P S C P Y C
mbconsphas > 61645 cgccgCgcCgCCggcagcaaggaccgcCcacccCccgccC
X92590 > 1115 .......................................................................................
HIRA p ro ce  > 299 C C A V G S K D R S L 3 V
mbconsphas > 61685 gg I gcaagcgcccgagccccggccgcacggcaggccaagaa
X92590 > 1155
HIPA p ro ce  > 3 1 2  W
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mbconsphas > 61725 ccgggaagacagagactccggaagactbcaaggaaagaga
------------------------------ in c ro n  9, sequence 61765-64844 noc shown-----------
mbconsphas > 64845 gacggccaaacccagcgcacagaccggcccccagcgaccc
m bconsphas > 64885 caccaaccccaacccccccccccccgcag  ICTCACATGTTT
AA437523 > 4 7 9  ............................
L T C L
mbconsphas > 64925 GAAACGGCCTCTGCnnXSTCATCCATGAACTGTTTGACAAG
AA437523 > 491 ........................................................................................
K R P L V V I H E L F D K
mbconsphas > 64965 TCCATCATCGATaTTTCCTG I gcaagacggacccccaccac
S r  M D I  S W
mbconsphas > 65005 acCgcaCCggccaccccaaccCgagaccCcCCggccacCC
------------------------------ in c ro n  10, sequence 65045-65404 noC shown-
mfaconsphas > 65405 cccaggCacaccgcccaccC aggcccccgacagccgcccc
mbconsphas > 65445 ccccagIgaccccgaacgggccgggcaccccggcgcgcccc
X92590 > 1227 ...............................................................................
HIRA p ro c e  > 336 W T L N G L G I L V C S
mbconsphas > 65485 acggacggccccgcggcgccccccgaccccccccaggacg
X92590 > 1262 ........................................................................................
HIRA p ro c e  > 348 M D G S V A F L D F S Q D
mbconsphas > 65525 aacccggagacccccCgagCgaggaggaaaagI gcaggccc
X92590 > 1302 .......................................................................
HIRA p ro c e  > 3 6 1  E L G D P L S E E E K
mbconsphas > 65565 gcggcccacgcgccacgacaccggccccgagaacccaccc
 inCron l i a ,  sequence 65605-66884 n o t shown----------
mbconsphas > 66885 g ccccg ccccacccgccgcagacacagaaaccg tcccccc
m bconsphas > 66925 ta c c g a c a g la c c ttc g c c a a c c g tta a tg g g g c a tc a c a c
X99722 > 1  ........................................................................
scop
mbconsphais > 66965 ccacccgCccgaaCggagcCcCgCggaagcccagagcagg
X99722 > 33 .........................................................................................
mbconsphas > 67005 ccag cag ccacccacC tag tg a tg ccg c tg ccg g g g  I gcaa
X99722 > 7 3  ..............................................................................
scop scop
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exon l i a
mbconsphas > 67045 gccacccc tcaacccaccg cg cg acaccaccacccccaac
-------------------------------i n t r o n  11, sequence 67085-68164 n o t shown--------
mbconsphas > 68165 tacaccg cacc tg c tg g ccag caaccccag ccacg acg ac
mbconsphas > 68205 a c c c a a a c c c a tg ta tc a a a c c tc tc c c tg c t tc c ta c a g
X92590 > 1332
HIRA p ro c e  > 371 K
mbconsphas > 68245 
X92590 > 1334
HIRA p ro c e  > 372
lagccgaacccaccagcccacccacggcaagagcccggcaa
S R I H Q S T Y G K S L A
mbconsphas > 68285 caacgaccgaggcccagccccccacagccgccaccgagaa
X92590 > 1374 ........................................................................................
HIRA p ro c e  > 385 I M T E A Q L S T A V I E N
mbconsphas > 68325 ccccgagacgcccaagcaccagcggagacagcaacagcag
X92590 > 1414 ........................................................................................
HIRA p ro c e  > 399 P E M L K Y Q R R Q Q Q Q
mbconsphas > 68365 cagccggaccagaagaacgccaccaccagggagacaagcc
X92590 > 1454 ........................................................................................
HIRA p ro c e  > 412 Q L D Q K N A T T R E T S
mbconsphas > 68405 cagcacccccagccacgggC gcggC caacggggaaagtcC
X92590 > 1494 ........................................................................................
HIRA p ro c e  > 425 S A S S V T G V V N G E S L
mbconsphas > 68445 agaagacaccagaaagI gcgagggcaC ggtccagcggcacc
X92590 > 1534 ..................................
HIRA p ro ce  > 439 E D I  R K
mbconsphas > 68485 aaaagacCcgagcacaCgcccagagacagggcaaaggggg
—  --------------------------in c ro n  12, sequence 68525-69964 n o t shown--------
mbconsphas > 69965 ccg ag ccc tcg a tacccg g acg tg g ccag ccg aaacccc t
mbconsphas > 70005 g cacccacc tacccg accccaccccg ccag Iaaccccccg a
X92590 > 1548 ...........................
HIRA p ro c e  > 443 K N L L
mbconsphas > 70045 agaaacaagC ggaaacCcggacagcagacggccggaggag
X92590 > 1560.............. .................................................................................. c . .
HIRA p ro c e  > 447 K K Q V E T R T A D G R S R
mbconsphas > 70085 aaCcacgccCccccgcacagcacagcCggacacCggIgcac
X92590 > 1600.............. ....................................................................................
HIRA p ro c e  > 461 I T P L C I A Q L D T G
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mbconsphas > 70125 cc a c tcc c tc a c c a a g c c tc c c g tg g c c tc g c c cg g g g a g  
------------------------------ in t r o n  13, sequence  70165-75404 n o t shown--------
mbconsphas > 75405 g c c a c a a a a c a a c c a c a c g tg a c a ttc c tg c g c tg a c c ta
mbconsphas > 75445 c tc c c c c tc g t ta a tg a c a g  I g g a c t tc tc c a c g g c a t tc t
X92590 > 1635 ................................................
HIRA p ro c e  > 472 G D F S T A F
mbconsphas > 75485 C caacagca tcccacC c tccag ccccc tag cag g cacca t
X92590 > 1656 ........................................................................................
HIRA p ro c e  > 479 F N S I P L S S S L A G T M
mbconsphas > 75525 gcccCccCcccccagCggccagcagcCacCaccaccggac
X92590 > 1696 ........................................................................................
HIRA p ro ce  > 493 L S S P S G Q Q L L P L D
mbconsphas > 75565 cccagcacccccccccccggcgccC caaagccccgcacag
X92590 > 1736 ........................................................................................
HIRA p ro ce  > 506 S S T P S F G A S K P C T
mbconsphas > 75605 aaccagcggcagccaccagcgccaggcccacaggcgaacc
X92590 > 1776 ........................................................................................
HIRA p ro ce  > 519 E P V A A T S A R P T G E S
mbconsphas > 75645 C gccagcaaggacagIgccagC aaacaccaaggaccagcca
X92590 > 1816 ................................
HIRA p ro ce  > 5 3 3  V S K D S
mbconsphas > 75685 cgcccccggggaaagcccaggccccagggacaagagcccc
   in c ro n  14, sequence  75725-77554 noc shown--------
mbconsphas > 77565 accag gcgcctcgccgcccgcgcccgacgaaccccccacc
mbconsphas > 77605 
X92590 > 1828
HIRA p ro ce  > 537
ccccccccag  I cacg aacg c tacccccacccccg ccg cacc  
S M M A T S T P A A S
mbconsphas > 77645 
X92590 > 1861
HIRA p ro ce  > 548
gccaccccccgcgccaacaaccccacccaagaccgaaccc
S P S V L T T P S K I E P
mbconsphas > 77685 aCgaaagcaCCCgacccccggtCcacagaacggcccaaag
X92590 > 1901 ........................................................................................
HIRA p ro ce  > 5 6 1  M K A F D S R F T E R S K
mbconsphas > 77725 ccacaccaggC gcC ccC cccccgaccagcgcgaccccaac
X92590 > 1941 ........................................................................................
HIPA p ro ce  > 574 A T P G A P S L T S V I P T
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mbconsphas > 77765 agctgccgaaag  I gcaggcggcagccactgcacccccccgg
X92590 > 1931 ................................
HIRA p ro c e  > 588 A V E R
m bconsphas > 77805 gactC caccacgcaC ccC gcccccC ttaggagagcaaggc
-------------------------------in t r o n  15, sequence 77845-88884 n o t shown--------------------
m bconsphas > 88885 tcaC agaaC gaatggctC C gcagacagag ttacagatg tc
m bconsphas > 88925 cc tg a c ttca g ig tc g a a a g a g c a g a ac c c c g tc a a g g a g c
X92590 > 1991 ......................................................................
HIRA p ro c e  > 591 R L K E Q N L V K E
mbconsphas > 88965 cgaggccccgggaaccggagagcagcagcgacagcgacga
X92590 > 2022 ........................................................................................
HIRA p ro c e  > 601 L R S R E L E S S S D S D E
mbconsphas > 39005 gaaggcccacccagccaagcccC cC C cactgcccaagcgc
X92590 > 2062 ........................................................................................
HIRA p ro c e  > 615 K V H L A K P S S L S K R
mbconsphas > 89045 aaacccgagcccgaggcagagacggcggaaaagaagaaga
X92590 > 2102 ........................................................................................
HIRA p ro c e  > 628 K L E L E V E T V E K K K
L (a. a. according to
genomic sequence)
m bconsphas > 89085 aaggccgcccCaggaaggaCCcacgccttCCacccaCgCc
X92590 > 2142 ......................................................... t ............................
HIRA p ro c e  > 641 K G R P R K D S R P L P M S
(a. a. in mouse cONA 
X92590)
m bconsphas > 89125 cc tgC ccg tccag  1 gCgaggcctacggacCgtcCCgcctgc
X92590 > 2182 ...........................
HIRA p ro c e  > 655 L S V Q
mbconsphas > 89165 cccacccCgccCccCCgggaggcccCCgcgcgcggagggc
-------------------------------in c ro n  16, s i z e  noc a v a i la b le  --------------------------------
Note: Not all sequences are shown. indicates the identity. "I" indicates the splice 
site. Capitalized sequence is exon 10 which Powerblast program failed to find 
as mouse HIRA gene. Sequence from 39174 to 39350 and sequence from 
66933 to 67039 are alternatively spliced exon 3a and 11a.
195
3 .7 .2  Comparison of the human and mouse HIRA gene
As discussed above, the human and mouse cDNA have an identity of 87.53% 
as determined by Cross_match and identity in the coding region of 89.80%. The 
identity at the amino acid level is 97.60%. Alignment of the amino acid sequences of 
the human (X89887) and mouse (X92590) HIRA gene products is provided in Rgure
41. According to the mouse genomic sequence, amino acid 650 in the mouse HIRA 
protein is a Leucine which agrees with that in the human HIRA protein.
Figure 41 : CLUSTAL W( 1.60) sequence alignment between human (X89887) and
mouse (X92590) HIRA gene products.
CLUSTAL W(1.60) m u ltip le  sequence a lig n m en t
hshira(X 89887) 
m m hira(X92590)
MKLLKPTWVNHNGKPIFSVDXHPDGTKFATGGQGQDSGKWIWNMSPVLQEDDEKDENIP
MKLLKPTWVNHNGKPIFSVDXHPDGTKFATGGQGQDSGKWIWNMSPVLQEDDEKDENIP
hshira(X 89887) 
mmhira(X92590)
KMLC^ŒMiLACVNCVHWSNSGMyLASGGDDKLIMVWKRATYIGPSTVFGSSGKLANVEQ
KMLCQtŒMUACVNCVBWSNSGMÏLASGGDDKLIMVWKRATYIGPSTVFGSSGKLANVEQ
hshira(X 89887) 
mmhira(X92590)
WRCVSILRNHSGDVMDVAWSPHDAWLASCSVI»nWIWNAVKFPEILATLRGHSGLVKGL
WRCVSILRSHSGDVMDVAWSPHnAWLASCSVDNrWIVlNAVKFPEILATLRGHSGLVKGL
hshira(X 89887) 
mmhira(X92590)
TWDPVGKYIASQADDRSLKVWRTLDWaLETSITKPFDECGGTTHVLRLSWSPDGHÏLVSA
TODPVGKYIASQADDRSLKVWRTLEWQLETSITKPCDECGGTTHVLRLSWSPDGHYLVSA
hshira(X 89887) 
mmhira(X92590)
HAMNNSGPTAQIIEREGWKTNMDFVGHRKAVTWKFNPKIFKKKQKNGSSAKPSCFirCCC
HAMNNSGPTAQIIEREGWKTNMDFVC3»KAVTWKFNPKIFKKKQKNGSSTKPSCPYCCC
hshira(X 89887) 
mmhira(X92590 >
AVGSKDRSLSVWLTCLKRPLWIHELFDKSIMDISWrLNGLGILVCSMDGSVAFLDFSQD
AVGSKDRSLSVWLTCLKRPLWIHKLFDKSIMDISWrLNGLGILVCSMDGSVAFLDFSQD
hshira(X 89887) 
mmhira(X92590)
ELGDPLSEEEKSRIHQSTYGKSLAIHrEAQLSTAVIENPEMLKYQRRQQC3QQLDQKSAAT
ELGDPLSEEEKSmHQSTYGKSLAIMrEAQLSTAVIENPEMLKYQRRQQQQQLDQKNATT
hshira(X 89887) 
mmhira(X92590)
REMGSATSVAGWNGESLEDIRKNLLKKQVETRTADGRRRITPLCIAQLOTGDFSTAFFN
RETSSASSVTGWNGESLEDIRKNLLKKQVETRTADGRSRITPLCIAQLDTGDFSTAFFN
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hshira(X S9887) 
mmhira(X92590)
SI PLSGSLAGTMLSSHSSPQLLPLDSSTPNSFGASKPCTEPWaASARPAGDSVNKDSMN 
SIPLSSSLAGTMLSSPSGQQLLPLDSSTP-SFGftSKPCTEPV3\ATSARPTGESVSKDSMN
hshira(X 89887)
itinhira(X92590)
ATSTPAALSPSVLTTPSKIEPMKAFDSRFTERSKATPGAPALTSMTPTAVERLKE01LVK
ATSTPAASSPSVLTTPSKIEEMKAFDSRFTERSKarPGAPSLTSVIPTAVERLKE®lLVK
hshira(X 89887) 
mmhira(X92590)
hshira(X 89887) 
mmhira(X92590)
ELRPRDLLESSSDSDEKVPLAKASSLSKRKLELEVETVEKKKKGRPRKDSRLMPVSLSVQ
ELRSR-ELESSSDSDEKVHLAKPSSLSKRKLELEVETVEKKKKGRPHKDSRfLPMSLSVQ
The "f* i n  mouse (X92590) 
p r o te in  d is a g r e e s  w ith  
th e  human (X89887) 
p r o te in ,  and a c c o rd in g  to  
th e  mouse genom ic 
seq u en ce , i t  i s  an  *L" 
w hich a g re e s  w ith  th e  
human p r o t e i n .
SPAALTAEKEAMCLSAPALALKLPIPSPQRAFTLQVSSDPSMÏIEVENEVTWGGVKLSR
SPAALSTEKEAMCLSAPALALKLPIPGPQRAFTLQVSSDPSMÏIEVENEVTTVGGIRLSR
hshira(X 89887) 
mmhira(X92590)
LKCNRBGKEWETVLTSRILTAAGSCDWCVACEKRMLSVFSTCGRRLLSPILLPSPISTL
LKCNHBGKEWETVLSSRVLTAAGSCDWCVACEKRMLSVFSTCGRKLLPPILLPSPISTL
hshira(X 89887)
mmhira(X92590)
HCTGSYVMALTAAATLSVWDVHRQVWVKEESLHSILAGSIMrVSQILLTQHGIPVMNLS
HCTGPYVMRLTAAATLSVWDVHRQWWKEESLHSILSGSEMrVSQILLTQHGIPVMNLS
hshira(X 89887) 
mmhira(X92590)
DGKAÏCFNPSLSTWNLVSDKQDSLAaCADFRSSLPSQDAMLCSGPLAINQGRTSNSGRQA
DGKAirCFNPSLSTVJNLVSDKQDSLAQCADFRNSLPSQDftMLCSGPLAIIQGRTSNSGRQA
hshira(X 89887)
mmhira(X92590)
ARLFSVPHWQQETTLAXLENQVAAALTLQSSHEÏRHWLLVYARYLVNEGFEYRLREICK
ARLFSVPHWQQETTLAYLENQVAAALTLQSSHEyRHWLLLYARYLVNEGFEYRLREICK
hshira{X89887) 
mmhira(X92590)
DLLGPVHYSTGSQWESTWGLRKRELLKELLPVIGQNLRFQRLFTECQEQLDILRDK
DIXGPVHCSTGSQWESTWGLRKRELLKELLPVIGÇyiLRFQRLFTECQGQLDrLWGK
Note: indicates identity, indicates similarity, " " (space) indicates dissimilarity,
and indicates deletion/insertion. Mouse amino acid sequence does not 
include alternative spliced exons.
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Human HIRA gene (from exon I to 16)
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Figure 42; Dotplot comparison of the human and mouse HIRA genomic DNA.
The human sequence is on X-axis and the mouse sequence is on 
Y-axis.
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Comparison of the genomic sequences of the human and mouse HIRA genes 
determined as part of this dissertation research were studied in detail. The nucleotide 
sequences were compared by the GCG Bestfît program and the Cross_match program. 
The similarity between the genomic sequences in the introns of these two genes is so 
low that both programs cannot find any similarity except in the coding regions. The 
Dotplot comparison program of GCG package gives the comparison shown in Figure
42. From the Dotplot results, it can be seen that the similariQf in genomic sequence 
level between the human and mouse HIRA gene is definitely clear but very low. The 
sizes of introns of the human and mouse HIRA gene are listed and compared in Table
19. Although the sizes of all introns are different, the relative distances from each exon 
to neighboring exons are clearly proportional in the human and mouse HIRA gene, i. 
e., larger introns in the human HIRA gene also are larger in the mouse gene and vice 
versa. This result indicates that the genomic organizations of the human and the mouse 
HIRA gene are similar and interestingly conserved during at least human and mouse 
evolution. A graphical version of the comparison of the size and position of introns of 
the human and mouse HIRA gene is given in Figure 43.
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Table 19: S iz e  o f  in trons o f  th e  hum an and m o u se  H IR A  g e n e s .
intron number
human
size
mouse
1 20662 17033
2 2122 1617
3 1208 1133
4 1303 1574
5 7699 11198
6 1044 1302
7 2277 4213
8 2127 2368
9 3545 3227
10 666 466
11 1974 2688
12 1814 1574
13 5552 5344
14 2075 1956
15 13697 11159
Note: Only known introns are compared.
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Figure 43: Comparison of size and position of introns of the human and mouse HIRA
genes. The green lines are the genomic sequences of the human and mouse 
HIRA genes. The filled vertical arrows are exons. The numbers above the 
arrows are the numbers of the exons. The sequence of the rest of the mouse 
HIRA gene is not available.
The promoter regions of the human and mouse HIRA genes were compared by 
Dotplot program (see Figure 44). From this initial comparison, it can be seen that 
several regions 5’ to the first exon are highly similar. A more detailed comparison of 
these two regions was performed by the GCG Bestfit program and the highly similar 
regions are displayed in Figure 45. The 5' region of the mouse HIRA gene was 
analyzed by the SIGNALSCAN program that uses the TRANSFAC database to 
identify the potential transcription factor binding sites. As found above with the human 
HIRA gene promoter region, the mouse HIRA gene promoter region lacks a TATA box 
but does contain several GC boxes (GGGCGG). The GC boxes bind the Spl 
transcription factor and have been shown to be required for interaction of transcription 
factor HD (TFHD) when TATA promoters 1264.266] absenL There also are two 
putative histone H4 gene-specific transcription factors present in the mouse HIRA gene 
promoter region. Thus, in the highly similar promoter regions of both the human and 
mouse HIRA gene, potential transcription factor binding sites can be found for the:
C AC-binding protein, H4TF-2 (histone H4 gene-specific transcription factor), LF-Al 
(liver specific trans-acting factor), NF-l (nuclear factor 1), NF-l/L (nuclear factor 1- 
like), NF-E (erythroid specific nuclear factor), Pit-1 (pituitary transcription factor-1), 
Spl, and SRF (serum response factor) as shown in Figure 45.
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Figure 44: Dotplot comparison of promoter regions of human
and mouse HIRA gene. Human sequence is 
horizontal and mouse sequence is vertical.
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F igu re 4 5  : Prom oter reg ion  o f  the m o u se  H IR A  gen e
g c a c g a c tta g g c t tc a c a c t tg t ta g g c a a a c a g c c tg t ta a g ts a g c a  -1151
IRF-2
c a c t£ £ c a g ttc g g a ttttc a C c c g c a a c a g a tg c g g ta g g c c c a tg c c c  -1101
NF-l
agaaacaatc tgcgagcaccagcgagcagc tacggggcaaagcccgcgca  -1051
LF-Al
CQCQCcctaaacaCtctQccacccQcxrQ ctacactcaccaactccoaoac -1001
N F-l/CA C-binding p r o te in
cq caaaacccocqcaacacacaacaccacccca o ta a cca t a a t t t t t c a  -951
S p l CACCC-binding N F-l
f a c to r
********* * ******* * *****
ca c c a cc c a c t aacq aacaq c ttc c a a q a a cacqcccc t aqqcqq tccaa  -901
NF-l/CAC- S p l/S p l  Spl Spl/H4TF-2
b in d in g
p r o te in
* *  *  * * *  * * *
cc tg ag g tacccg g tcg g g tcL g g sag g cc tcg g cccg g aac tcg cg g g t -851
N F-l/L
c ta a a a t tc c a a a aaacqqacc c q c a a c tqqccccqcccccqacacaqcc -801
Spl Spl
cco ccccqaacaaacaaca q ta a c t t c a c c a c a c c c t t t t a caqqcq tcc  -751
Spl LF-Al CAC-binding p r o te in  Spl
c g c c t tc tg tg g a tg c tg c g g tg t t t tc c tg c tc tc tg c tc c g c c tg g c c  -701
t a t q t q t t t a c a t c t a tq aaaacq ccccqc tc t tc ta a ta a a tq c q c c cq -651
P i t - 1  Spl GR P i t - 1  Spl
tc tq q c c c c c ta tc c t tc a c c a q c c ta a t t c t t t ta tq c a tq c a a tc q a q  -601
NF-E GR
c tc a q q q c c c q c tq c c q tc tq c c q c ta a a tq c a tq c tq q cqcccqcccgq  -551
P it-1  Spl
c tg g c g c tc g cg a g a tg c c c â à ta g c g cg a a ttg a tg g a tg g c g g a a g c t -501
SRF
* * * * *  * * * *  * * * * * *  * *
ag ttac taag c tg g ac tcg g ag ccg cg g ag g tag aac tag ag a tc taC âC  -451
Spl
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accaccctaatccCQcatcoccoaqcqaaatcccaaaactticaccaQccc -401
CAC-binding p ro c e in  Spl NF-1
gcccacaccgacccC caccggcgaccacaC cagtggcagcggagtatccc -351
N F-l/L
c a tc c c c c c c c c c c t a t c t accoaacraaccqaqqcaaccc a a tc c a c a ta  -301
NF-E S p l H4TF-2
qqaaacaa t t t c c c q c caaao caa ttccrqcaaatCTCxrcac c a tq a c t tc c  -251
S p l N F -l/L  S p l
******************** ********* s c a re  o f  exon 1 
ggcgttgcccgggagccgccggaggaggag  I cggcgcaggggatgcggctg  -201
tggcggcggcggcggcggccgagcgcaggaggcggctgtggcggcggctg  -151
ggggcacgggccggcgacggcgcggcggcgctgagggcaagggCgggcgg -101
cggccggagggcgggcggcgcgggaggaagctgcggcagctccatggccc -51
aggcg tgc tgagggacacggccctggcctcagcccggcagcggccgaaca  -1
sc a re  o f  co d ing  re g io n  
IATGAAGCTCTTGAAGCCAACCTGGGTCAACCACAATG
Note: Position 1 is defined as starting position of coding region. Potential
transcription factor binding sites are underlined. above the sequence 
indicates identity to human sequence.
205
Chapter IV 
Conclusion
The results presented in this dissertation provide support for ±e notion that a 
pUC plasmid-based double stranded random shotgun sequencing strategy employing 
genetically engineered thermally stable Taq DNA polymerase and dye-labeled 
terminator chemistry is feasible for large-scale genomic DNA sequencing. Through 
continuous improvements in the overall random shotgun sequencing strategy, this 
approach yields a highly accurate final sequence that could be generated in a reasonable 
amount of time and with a cost within the range of 50 to 60 cents per base as targeted 
by the NIH Human Genome Project. Specifically, as part of this dissertation research, 
efforts to improve the methods of DNA shearing, DNA template isolation, subcloning 
and sequencing were carried out. Also, by employing various different computer 
assembly programs, such as XGAP, FAK2, CAPII, and Phred/Phrap, and collecting 
new data until all gave identical assemblies, one gains confidence that the final sequence 
assembly is accurate. Once the sequence of a region was accurately defined, 
approaches that include database searches (Powerblast) and computer based exon and 
feature prediction (Xgrail) programs were implemented to determine the genomic 
organization, by locating the presence of known genes by their homology with the 
same or similar genes already in the database, and to predict possible new genes.
When this dissertation research began, it was questionable if the random 
shotgun sequencing approach was feasible to determine the sequence of large regions 
of the human genome. It also was not known how many shotgun sequencing reactions 
should be generated during the random phase and when one should switch to a more 
directed sequencing approach to finish a large scale DNA sequencing project more
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efficiently. It was however accepted that the accuracy of a determined DNA sequence 
depends largely on the level of sequence redundancy, i. e., the number of times an 
individual base in the final DNA sequence has been determined, and confidence that a 
sequence is accurate also is strengthened by determining the sequence of each base 
from both strands, i. e., both orientations or directions. Thus, for regions where 
shotgun sequencing yields only reach in one orientation, directed sequencing methods 
could be used to sequence the opposite strand with a custom synthesized primer. 
However, because the approach of random shotgun sequencing is sophisticated, it is 
relatively easy and quick to generate a high number of random sequences once one is 
trained in the techniques. Considering the expenses of large scale DNA sequencing, it 
also is less expensive to generate random sequences rather than synthesize custom 
primers until the redundancy reaches a level of 5 to 6 fold and the number of gaps is 
small. This level has been practically determined during the course of this research to 
be sufficient to maintain a highly accurate sequence because most of the gel readings, 
which were collected after redundancy reaches a high level and most of the project is 
defined, will fall into the already sequenced regions and will not help to cover the gaps 
between the known regions and the regions with less accuracy based on probability 
rules. Furthermore, some of the gaps and less accurate regions exist because they are 
regions that, for either known or unknown reasons, are difficult to sequence. In this 
case, directed sequencing using different approaches is the only viable choice to obtain 
these sequences. Because the bottleneck of the large scale DNA sequencing is the stage 
of directed sequencing, much of the work in this dissertation was concentrated on 
reducing the expense and time needed to select and synthesize the oligonucleotides, that 
could be used as the primers for PCR and subsequent sequencing by primer walking.
In addition, because other difficulties are encountered in the gap closure stage, this 
stage is considered as the most challenging and time consuming step in large scale DNA 
sequencing. Therefore a sophisticated, systematic strategy for gap closure is crucial for
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economical and efficient large scale DNA sequencing. In the course of this 
dissertation, a feasible and effective gap closure strategy has been developed. This 
strategy entails resequencing the ends of each contig using long gels followed by 
primer walking at the ends of contigs with custom primers, PCR amplification to 
estimate the size of the gap, sequencing directly off the PCR product, and if necessary 
nebulizing, subcloning and sequencing the shotgun cloned PCR product.
In summary, with the recently available technology and expensive and time- 
consuming methods of oligonucleotide synthesis, large scale DNA sequencing can be 
completed after only 5 to 6-fold redundancy, followed by custom primer synthesis and 
directed sequencing to obtain the final 15% to 20%. This timely and cost effective 
approach results in a final accuracy of at least 99.99%.
During this dissertation work, the above strategy was employed to sequence 
four segments of human DiGeorge syndrome critical region genomic DNA covering 
43,995, 211,386, 157,885, and 67,378 base pairs in contigs 1, 2, 3, and 4 
respectively, and 89,500 base pairs of a mouse genomic BAG containing DNA that is 
syntenic to the human HIRA gene region. These studies revealed the presence of a 
clathrin heavy chain-like gene (CLTCL), a repressor of histone gene transcription 
(HIRA), a ubiquitin fusion-degradation protein 1-like gene (UFDIL), a putative gene 
with unknown function, and a gene homologous to the mouse TIO gene. A ribosomal 
L34 pseudogene and a human Tigger 1-like transposon also were found in these 
regions. These human genomic DNA segments have a gene density of slightly more 
than one gene per 100 kb and approximately 32% of repeated sequences. In addition, 
the mouse BAG was shown to contain 16 of the 25 exons of the mouse HIRA gene. 
Functionally, all of the genes in these regions are involved in various biochemical 
pathways, with the GLTGL most likely involved in endocytosis, the HIRA being a
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negative regulator of core histone gene transcription, and the UFDIL probably involved 
in protein degradation. A predicted putative gene distal to the UFDIL gene encodes 
four putative transmembrane domains but the function of this gene is unknown, as is 
that of the TIO gene. The presence of different families of interspersed repetitive 
elements, such as Alu, LI, Mer, Mir, Mit, and Thelb also was observed. There also 
are countless simple sequence repeats (including di- or tri-oligonucleotides repeats or 
other simple combinations of tandem repeats) within these regions, 2851
During the course of this research, a team effort was employed to sequence the 
entire 1.25 mb DiGeorge syndrome critical region. Initially, the team consisted of Dr. 
Zhili Wang, Dr. Guozhong Zhang, the author, and more recently Axin Hua and 
Lingzhi Chu joined the team. Drs. Nientung Ma and Steve Toth also contributed 
during the early stage of this project. To date, approximately 1.25 mb of sequence 
covering the entire DiGeorge syndrome critical region has been completed. There are a 
total of 27 genes in this region, although two are ribosomal protein pseudogenes that 
most likely are non-functional. The minimum DiGeorge syndrome region, which is 
about 300 kb in size and located at the proximal end of DiGeorge syndrome region, 
contains 12 genes. The gene density of this minimum region is relatively high but the 
genes in the minimum region contain various numbers of exons. Among these 12 
genes, CLTCL (CHC2) has 34 exons, the LAN, DGS-I, and CTP genes have 10 
exons, 9 exons and 9 exons, respectively, the DGCR-5, Gscl, and DGS-D genes have 
only 5, 3, and 2 exons, respectively, and the remaining 5 genes only have one exon.
In the entire DiGeorge syndrome region, there is only one single exon gene located 
outside of the minimum region, and it is a putative transmembrane protein that is 
deleted in Velocardiofacial syndrome, named TMVCF. Interestingly, TMVCF is distal 
to another predicted putative transmembrane protein gene that is transcribed on the 
opposite strand. In total of the 27 genes, 15 are transcribed in the direction from distal
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to proximal and 12 are transcribed from proximal to distal. A list of all the genes in this 
1.3 mb region showing their transcription direction, number of exons and relevant 
references, as well as a diagram showing their relative positions in this region of human 
chromosome 22, are provided at the end of this chapter.
Approximately 36 kb of genomic sequences &om two individuals also were 
sequenced from overlapping clones. When compared, these sequences differed by 
approximately 0.2%. Surprisingly, these regions of microheterogeneity between the 
two individuals are not distributed evenly but are clustered into two places. One of 
these two regions is within an Alu element and the other is within an LI repeat In the 
Alu region, a total of 8 variations occur within a region of 67 bp and all 8 variations are 
transitions (6 "t" <-> "c" and 2 "a" <-> "g"). In the LI region, 8 variations occur 
within a 120 bp region, but six of these 8 variations are indel (6 "a" and 1 "g"), one is 
transition ("a" <-> "g") and one is transversion ("c" <-> "a").
The genomic sequences of the human and mouse HERA genes also were 
determined and compared. Although the cDNAs of these two genes are highly similar, 
with an identity of 87.53%, and the similarity of the translated amino acid sequences is 
even higher, with an identity o f97.60%, the similarity of the genomic sequences is 
much lower. Even so, the genomic organizations of these two genes are extremely 
similar and conserved since the sizes of their respective introns are similar. Thus, even 
though these introns contain very little if any identical sequences, the large introns in 
the mouse HIRA gene also are large in human and vice versa. This raises the 
possibility of conservation of intron length and distribution in other syntenic regions of 
the human and mouse genome. Thus, additional comparative sequencing studies for 
other human and mouse genes would give support for the hypothesis that the size and 
organization of these introns are conserved throughout evolution. This possibility
210
raises the question, if they are conserved, how did this conservation occur while the 
sequences in these syntenic introns differ? It is hypothesized here that the intronic 
regions evolved by a mechanism of random insertion over the millennium, after the 
exons first were split from each other by some unknown events, as the human and 
mouse genomes further evolved, the intron length of each species increased as a 
function of the length of the primordial initial intron by random insertions. Thus, based 
on probability, given a sufficient number of insertion events, each intron would be 
expanded in proportion to its original size. The fact that noncoding region conservation 
at the nucleotide level is rare, any small regions conserved in the noncoding segments 
most likely were maintained by functional selection. In addition, it also is likely that the 
proportional spacing of these regions is selected, since this spacing most likely is 
required for proper gene expression. The similarity of promoter regions of these two 
genes also is strikingly similar as both genes lack the TATA promoter element but 
instead contain the typical GC rich promoters of the housekeeping gene family 
members. The nucleotide sequence conservation observed in the regions adjacent to the 
transcription sites indicates that proper expression of these genes most likely requires 
that these sequences be conserved and that the spacing between these region may be 
needed to maintain their function. In conclusion, at present, large scale sequencing of 
genomic DNA is both robust and efficient, and through such studies, a greater 
understanding of the function of coding and noncoding sequences of a large complex 
gene region can be obtained and additional insight into previously unknown events that 
occurred during evolution also can be gained.
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L i s e  o f  G e n e s  i n  c h e  D iG e o r g e  S y n d rc sn e  C r i t i c a l  R e g io n
* ot 
gene
Abb. Name Full Name Orientation # of 
exons
reference
1. DGCR-5 C -> T 5 57
2. DGS-A. DiGeorge Syndrome G^ie A C -> T 1 57
3. DGS-B DiGeorge Syndrome Gene B C -> T 1 56
4. LAN DiGeorge Syndrome LAN Gene T -> C 10 57. 58. 59
5. DGS-D DiGeorge Syndrome Gene 0 T -> C 2 57
6. DGS-E DiGeorge Syndrome Gene F T -> C 1 57
7. TSK-1 Threonine/Serine Kinase Gene C -> T 1 57
3. DGS-H DiGeorge Syndrome Gene H T -> C 1 57
9. DGS-I DiGeorge Syndrome Gene I T -> C 9 57
10. Gscl Goosecoid-Like Gene T -> C 3 283
11. CTP Citrate Transport Protein Gene T -> C 9 57
12. CHC2 Clathrin Heavy Chain 2 Gene T -> C 34 61
13. Ribosomal Protein L34 
Pseudogene
T -> C 1 251
14. HIRA/TOPLE Histone Gene Transcription 
Repressor Gene
T -> C 25 62. 63
15. UFDIL Ubiquitin Fusion-Degradation 
Protein 1-like Gene
T -> C 12 268
16. Putative Transmembrane protein 
Gene
C -> T 20 predicted
17. TMVCF Transmembrane Protein 
Deleted in VCFS
T -> C 1 234
18. H5-Iike H5 Like Gene C -> T 6 285
19. Platelet Glycoprotein 
lb beta Gene
C -> T 5 285
20. TEXl T-faox 1 Gene C -> T 9 286
21. Ribosomal Protein L7A 
Pseudogene
C -> T 1 287
22. Glutathione Reductase-like 
Gene
T -> C 12 predicted
23. CCMT Catechol 0-methyl 
Transferase Gene
C -> T 6/4 59, 70. 71
24. ARVCF Armadillo Repeat Protein Gene T -> C 16 288
25. TIO Mouse TXO-like Gene C -> T 9 65
26. Htf9C T -> C 10 289
27. RanBPl Ran-Binding Protein 1 Gene C -> T 5 290
Note: Predicted - Gene model built based on the EST matches from Genbank, )%rail predicted exons and
pocencial promocer.
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Hgure 46: Human and the Syntenic Mouse Sequences in the Mb DiGeorge
Critical Region
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